[
  {
    "section": "Content",
    "content": "KDIGO2024CLINICALPRACTICEGUIDELINE\nFORTHEMANAGEMENTOFLUPUSNEPHRITIS\nKidneyInternational\nS1\n(2024)105(Suppl1S),S1–S69\ncontents\nwww.kidney-international.org\nVOL105|ISSUE1S|JANUARY2024\nKDIGO2024ClinicalPracticeGuidelinefortheManagement\nofLupusNephritis\nS3Tables,gures,andSupplementaryMaterials\nS6KDIGOExecutiveCommittee\nS7Referencekeys\nS8CKDnomenclature\nS9Conversionfactors\nS10Abbreviationsandacronyms\nS11Notice\nS12Foreword\nS13WorkGroupmembership\nS14Abstract\nS15Summaryofrecommendationstatementsandpracticepoints\nS23Lupusnephritis\nS52Methodsforguidelinedevelopment\nS57Biographicanddisclosureinformation\nS61Acknowledgments\nS62References\nThisarticleispublishedaspartofasupplementsponsoredbyKidneyDisease:ImprovingGlobalOutcomes(KDIGO).The\nopinionsorviewsexpressedinthissupplementarethoseoftheauthorsanddonotnecessarilyreecttheopinionsorrec-\nommendationsoftheInternationalSocietyofNephrologyorElsevier.Dosages,indications,andmethodsofuseforproducts\nthatarereferredtointhesupplementbytheauthorsmayreecttheirclinicalexperienceormaybederivedfromthepro-\nfessionalliteratureorotherclinicalsources.Becauseofthedifferencesbetweeninvitroandinvivosystemsandbetween\nlaboratoryanimalmodelsandclinicaldatainhumans,invitroandanimaldatadonotnecessarilycorrelatewithclinicalresults.\nKidneyInternational\nS2\n(2024)105(Suppl1S),S1–S69",
    "page": 1,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "TABLES",
    "content": "S52Table1.Hierarchyofoutcomes\nS53Table2.ClinicalquestionsandsystematicreviewtopicsinPICODformat\nS55Table3.Gradingthecertaintyoftheevidence\nS55Table4.GRADEsystemforgradingcertaintyofevidence\nS56Table5.KDIGOnomenclatureanddescriptionforgradingrecommendations\nS56Table6.Determinantsofthestrengthofrecommendation",
    "page": 4,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "FIGURES",
    "content": "S15Figure1.Diagnosisofkidneyinvolvementinsystemiclupuserythematosus\nS24Figure2.Activityandchronicityitemsincludedinlupusnephritiskidneybiopsyreport\nS16Figure3.Measurestominimizetheriskofcomplicationsrelatedtolupusnephritisoritstreatment\nS17Figure4.ImmunosuppressivetreatmentforpatientswithClassIorClassIIlupusnephritis\nS30Figure5.RecommendedapproachforinitialtherapyofactiveClassIII/IVlupusnephritis\nS31Figure6.Cyclophosphamidedosingregimens,combinedwithglucocorticoids,ininitialtreatmentforactive\nClassIII/IVlupusnephritis\nS18Figure7.Examplesofglucocorticoidregimensforlupusnephritis\nS39Figure8.RecommendedoptionsofmaintenancetherapyforClassIIIandClassIVlupusnephritis\nS19Figure9.Maintenanceimmunosuppressiveregimensinpatientswithlupusnephritis\nS19Figure10.ManagementofpatientswithpureClassVlupusnephritis\nS20Figure11.Denitionsofresponsecommonlyusedinclinicaltrialsoflupusnephritis\nS20Figure12.Managementofpatientswhoshowunsatisfactoryresponsetoinitialtherapyforactivelupusnephritis\nS21Figure13.Managementofpatientswithlupusnephritisandthromboticmicroangiopathy(TMA)\nS54Figure14.Searchyieldandstudyowdiagram",
    "page": 4,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "SUPPLEMENTARYMATERIAL",
    "content": "SupplementaryFile(PDF)\nAppendixA.Searchstrategies\nTableS1.Searchstrategiesforsystematicreviewtopics\nAppendixB.ConcurrencewithInstituteofMedicine(IOM)standardsforguidelinedevelopment\nTableS2.GuidelinedevelopmentchecklistIOMstandardsfordevelopmentoftrustworthyclinical\npracticeguidelines\nTableS3.AdaptedsystematicreviewreportingstandardschecklistIOMstandardsforsystematicreviews\n—ﬁ\nAppendixC.Datasupplementsummaryofndings(SoF)tablescitedintheguidelinetext\nTableS4.Patientswithlupusnephritisantimalarialsversusstandardofcare\nTableS5.Patientswithproliferativelupusnephritisinduction:intravenouscyclophosphamideversus\ninduction:glucocorticoidsalone\nTableS6.Patientswithproliferativelupusnephritisinduction:high-dosecyclophosphamideversus\ninduction:low-dosecyclophosphamide\nTableS7.Patientswithproliferativelupusnephritisinduction:mycophenolatemofetilversusinduction:\nintravenouscyclophosphamide\nTableS8.Patientswithproliferativelupusnephritisinduction:mycophenolatemofetilplustacrolimus\nversusinduction:intravenouscyclophosphamide\nTableS9.Patientswithproliferativelupusnephritisinduction:voclosporinversusinduction:placebo\nTableS10.Patientswithproliferativelupusnephritisinduction:CNI-includedtripletherapyversusinduction:\nstandardofcare\nKidneyInternational\nS3\n(2024)105(Suppl1S),S1–S69",
    "page": 4,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "contents (Part 1)",
    "content": "www.kidney-international.org\nTableS11.Patientswithproliferativelupusnephritis(ClassIII/IV)orpureClassVlupusnephritisinduction:\ninduction:belimumabversusinduction:placebo\nTableS12.Patientswithproliferativelupusnephritisinduction:reduced-doseoralglucocorticoidsversus\ninduction:standard-doseoralglucocorticoids\nTableS13.Patientswithproliferativelupusnephritisinduction:intravenouscyclophosphamideversusinduction:\noralcyclophosphamide\nTableS14.Patientswithproliferativelupusnephritisinduction:mycophenolatemofetilversusinduction:\ntacrolimus\nTableS15.Patientswithproliferativelupusnephritisinduction:tacrolimusversusinduction:cyclophosphamide\nTableS16.Patientswithproliferativelupusnephritisinduction:cyclophosphamideversusinduction:\nazathioprine\nTableS17.Patientswithproliferativelupusnephritisinduction:plasmaexchangeplusimmunosuppression\nversusinduction:immunosuppressionalone\nTableS18.Patientswithproliferativelupusnephritisinduction:sirukumabplusotherimmunosuppressiveagent\nversusinduction:placeboplusotherimmunosuppressiveagent\nTableS19.Patientswithproliferativelupusnephritisinduction:laquinimodplusotherimmunosuppressiveagent\nversusinduction:placeboplusotherimmunosuppressiveagent\nTableS20.Patientswithproliferativelupusnephritisinduction:rituximabplusmycophenolatemofetilversus\ninduction:placeboplusmycophenolatemofetil\nTableS21.Patientswithproliferativelupusnephritisinduction:rituximabpluscyclophosphamideversus\ninduction:rituximab\nTableS22.Patientswithproliferativelupusnephritisinduction:abataceptplusotherimmunosuppressiveagent\nversusinduction:placeboplusotherimmunosuppressiveagent\nTableS23.Patientswithproliferativelupusnephritisinduction:ocrelizumabplusotherimmunosuppressive\nagentversusinduction:placeboplusotherimmunosuppressiveagent\nTableS24.Patientswithproliferativelupusnephritismaintenance:azathioprineversusmaintenance:\nmycophenolatemofetil\nTableS25.Patientswithproliferativelupusnephritisinduction:longduration(18months)cyclophosphamide\nversusinduction:short-duration(6months)cyclophosphamide\nTableS26.Patientswithproliferativelupusnephritismaintenance:azathioprineversusmaintenance:\ncyclosporine\nTableS27.Patientswithproliferativelupusnephritismaintenance:immunosuppressivetherapy(IST)\n(mycophenolatemofetilorazathioprine)continuationversusmaintenanceIST(mycophenolatemofetil\norazathioprine)taper\n—ﬂ\nTableS28.Patientswithproliferativelupusnephritismaintenance:leunomideversusmaintenance:\nazathioprine\nAppendixD.DatasupplementAdditionalSoFtablesdevelopedaspartoftheevidencereview\nTableS29.Patientswithproliferativelupusnephritisinduction:calcineurininhibitorsversusinduction:\ncyclophosphamide\nTableS30.Patientswithnonproliferativelupusnephritis(ClassV)induction:intravenouscyclophosphamide\nversusinduction:cyclosporine\nTableS31.Childrenwithproliferativelupusnephritisinduction:intravenousglucocorticoidsversusinduction:\noralglucocorticoids\nTableS32.Patientswithnonproliferativelupusnephritis(ClassV)induction:cyclosporineversusinduction:\nprednisone\nTableS33.Patientswithnonproliferativelupusnephritis(ClassV)induction:intravenouscyclophosphamide\nversusinduction:prednisone\nTableS34.Patientswithproliferativelupusnephritisinduction:azathioprineplusglucocorticoidsversus\ninduction:glucocorticoidsalone\nTableS35.Patientswithproliferativelupusnephritisinduction:mycophenolatemofetilversusinduction:oral\ncyclophosphamide\nTableS36.Patientswithproliferativelupusnephritisinduction:mycophenolatemofetilplusintravenous\ncyclophosphamideversusinduction:intravenouscyclophosphamide\nKidneyInternational\nS4\n(2024)105(Suppl1S),S1–S69",
    "page": 5,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "contents",
    "content": "www.kidney-international.org\nTableS37.Patientswithproliferativelupusnephritisinduction:cyclophosphamideplusazathioprineplus\nglucocorticoidsversusinduction:glucocorticoidsalone\nTableS38.Patientswithproliferativelupusnephritisinduction:cyclophosphamideplusglucocorticoidsversus\ninduction:glucocorticoidsalone\nTableS39.Patientswithproliferativelupusnephritisinduction:misoprostolplusglucocorticoidsversus\ninduction:glucocorticoidsalone\nTableS40.Patientswithproliferativelupusnephritisinduction:plasmaexchangeversusinduction:\nimmunosuppression\nTableS41.Patientswithproliferativelupusnephritismaintenance:azathioprineversusmaintenance:\ncyclosporine\nTableS42.Patientswithproliferativelupusnephritismaintenance:azathioprineversusmaintenance:tacrolimus\nTableS43.Patientswithproliferativelupusnephritismaintenance:prednisonewithdrawalversusmaintenance:\nprednisonecontinuation\nTableS44.Patientswithproliferativelupusnephritismaintenance:intravenousimmunoglobulinversus\nmaintenance:intravenouscyclophosphamide\nTableS45.Patientswithproliferativelupusnephritisinduction:anifrolumab900mgor300mgversusinduction:\nplacebo\nTableS46.Patientswithproliferativelupusnephritisinduction:anifrolumab900mgversusinduction:\nanifrolumab300mg\nTableS47.Patientswithproliferativelupusnephritisinduction:obinutuzumabversusinduction:placebo\nTableS48.Patientswithproliferativelupusnephritisinduction:dapirolizumabversusinduction:placebo\n—–\nTableS49.Patientswithproliferativelupusnephritismaintenance:hydroxychloroquine,lowdose(23mg/kg/d)\nversusmaintenancehydroxychloroquine,highdose(45.5g/kg/d)\nKidneyInternational\nS5\n(2024)105(Suppl1S),S1–S69\nKDIGOexecutivecommittee\nwww.kidney-international.org\nKDIGOEXECUTIVECOMMITTEE\nGarabedEknoyan,MD\nNorbertLameire,MD,PhD\nFoundingKDIGOCo-Chairs\nWolfgangC.Winkelmayer,MD,MPH,ScD\nImmediatePastCo-Chair\nMichelJadoul,MDMorganE.Grams,MD,PhD,MHS\nKDIGOCo-ChairKDIGOCo-Chair\nGloriaE.Ashuntantang,MDMichelleM.OShaughnessy,MB,BCh,BAO,MS,MD\nSunitaBavanandan,MBBSPatrickRossignol,MD,PhD\nIrenedeLourdesNoronha,MD,PhDPaulE.Stevens,MB,FRCP\nMichelleR.Denburg,MD,MSCERitaS.Suri,MD,MSc\nJenniferE.Flythe,MD,MPHSydneyC.W.Tang,MD,PhD,FRCP,FACP,FHKCP,FHKAM\nMasafumiFukagawa,MD,PhDIrmaTchokhonelidze,MD\nJoachimH.Ix,MD,MASMarcelloA.Tonelli,MD,SM,MSc,FRCPC\nMegJ.Jardine,MBBS,PhDWolfgangC.Winkelmayer,MD,MPH,ScD\nMarkusKetteler,MD,FERA\nKDIGOStaff\nJohnDavis,ChiefExecutiveOfcer\nDanielleGreen,ExecutiveDirector\nMelissaThompson,ChiefOperatingOfcer\nﬁﬁ\nMichaelCheung,ChiefScienticOfcer\nAmyEarley,GuidelineDevelopmentDirector\nJenniferKing,DirectorofMedicalWriting\nTanyaGreen,EventsDirector\nCoralCyzewski,EventsCoordinator\nKathleenConn,DirectorofCommunications\nKidneyInternational\nS6\n(2024)105(Suppl1S),S1–S69",
    "page": 6,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Referencekeys",
    "content": "NOMENCLATUREANDDESCRIPTIONFORRATINGGUIDELINERECOMMENDATIONS\nWithineachrecommendation,thestrengthofrecommendationisindicatedasLevel1orLevel2,andthecertaintyofthesupporting\nevidenceisshownasA,B,C,orD.\nImplications\nGradePatientsCliniciansPolicy\nLevel1MostpeopleinyoursituationwouldMostpatientsshouldreceivetheTherecommendationcanbeevaluated\n“”\nWerecommendwanttherecommendedcourseofrecommendedcourseofaction.asacandidatefordevelopingapolicy\naction,andonlyasmallproportionoraperformancemeasure.\nwouldnot.\nLevel2ThemajorityofpeopleinyoursituationDifferentchoiceswillbeappropriateforTherecommendationislikelytorequire\n“”\nWesuggestwouldwanttherecommendedcoursedifferentpatients.Eachpatientneedssubstantialdebateandinvolvementof\nofaction,butmanywouldnot.helptoarriveatamanagementstakeholdersbeforepolicycanbe\ndecisionconsistentwithherorhisdetermined.\nvaluesandpreferences.\nGradeCertaintyofevidenceMeaning\nAHighWearecondentthatthetrueeffectisclosetotheestimateoftheeffect.\nBModerateThetrueeffectislikelytobeclosetotheestimateoftheeffect,butthereisapossibilitythatitissubstantiallydifferent.\nCLowThetrueeffectmaybesubstantiallydifferentfromtheestimateoftheeffect.\nDVerylowTheestimateoftheeffectisveryuncertain,andoftenitwillbefarfromthetrueeffect.\nKidneyInternational\nS7\n(2024)105(Suppl1S),S1–S69",
    "page": 8,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "CKDnomenclature",
    "content": "www.kidney-international.org\nCURRENTCHRONICKIDNEYDISEASE(CKD)NOMENCLATUREUSEDBYKDIGO\nﬁ>ﬁ\nCKDisdenedasabnormalitiesofkidneystructureorfunction,presentfor3months,withimplicationsforhealth.CKDisclassied\n––\nbasedonCause,GFRcategory(G1G5),andAlbuminuriacategory(A1A3),abbreviatedasCGA.",
    "page": 9,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "and albuminuria categories",
    "content": "<30 mg/g30–300 mg/g>300 mg/g\n<3 mg/mmol3–30 mg/mmol>30 mg/mmol",
    "page": 9,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "G5",
    "content": "Green: low risk (if no other markers of kidney disease, no CKD); Yellow: moderately increased risk; Orange: high\nrisk; Red: very high risk. GFR, glomerular filtration rate.\nKidneyInternational\nS8\n(2024)105(Suppl1S),S1–S69\n[Table 1]\n |  |  |  | Persistent albuminuria categories\nDescription and range |  | \n------------------------------------------------------------\n |  |  |  | A1 | A2 | A3\n |  |  |  | Normal to mildly\nincreased | Moderately\nincreased | Severely\nincreased\n |  |  |  | <30 mg/g\n<3 mg/mmol | 30–300 mg/g\n3–30 mg/mmol | >300 mg/g\n>30 mg/mmol\n)2m\n37.1/nim/lm(\negnar\ndna\nseirogetac noitpircseD\nRFG | G1 | Normal or high | ≥90 |  |  | \n | G2 | Mildly decreased | 60–89 |  |  | \n | G3a | Mildly to\nmoderately decreased | 45–59 |  |  | \n | G3b | Moderately to\nseverely decreased | 30–44 |  |  | \n | G4 | Severely decreased | 15–29 |  |  | \n | G5 | Kidney failure | <15 |  |  |",
    "page": 9,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "CONVERSIONFACTORSOFCONVENTIONALUNITSTOSIUNITS",
    "content": "ConventionalunitConversionfactorSIunit\nAlbuming/dl10g/l\nCreatininemg/dl88.4mol/l\nCreatinineclearanceml/min0.01667ml/s\nCyclosporineng/ml0.832nmol/l",
    "page": 10,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "mm",
    "content": "Mycophenolicacidg/ml3.12mol/l\nProtein-creatinineratio(PCR)mg/g0.113mg/mmol\nTacrolimusng/ml1.24nmol/l\nPCR,protein-creatinineratio;SI,InternationalSystemofUnits.\n(cid:1)¼\nNote:ConventionalunitconversionfactorSIunit.",
    "page": 10,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "RELATIONSHIPAMONGCATEGORIESFORALBUMINURIAANDPROTEINURIA",
    "content": "Categories\nMeasureNormaltomildlyincreased(A1)Moderatelyincreased(A2)Severelyincreased(A3)\n<–>\nAER(mg/d)3030300300\n<–>\nPER(mg/d)150150500500\nACR\n<–>\n(mg/mmol)\n333030\n<–>\n(mg/g)\n3030300300\nPCR\n<–>\n(mg/mmol)\n15155050\n<–>\n(mg/g)\n150150500500\nProteinreagentstripNegativetotraceTraceto++orgreater\nACR,albumin-to-creatinineratio;AER,albuminexcretionrate;PCR,proteincreatinineratio;PER,proteinexcretionrate.\nRelationshipsamongmeasurementmethodswithinacategoryarenotexact.Forexample,therelationshipsbetweenAERandACRandbetweenPERandPCRarebasedon\ntheassumptionthataveragecreatinineexcretionrateisapproximately1.0g/dor10mmol/d.Theconversionsareroundedforpragmaticreasons.(Foranexactconversion\nfrommg/gofcreatininetomg/mmolofcreatinine,multiplyby0.113.)Creatinineexcretionvarieswithage,sex,race,anddiet;therefore,therelationshipamongthese\ncategoriesisapproximateonly.Therelationshipbetweenurinereagentstripresultsandothermeasuresdependsonurineconcentration.\nKidneyInternational\nS9\n(2024)105(Suppl1S),S1–S69\nabbreviationsandacronyms\nwww.kidney-international.org",
    "page": 10,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Abbreviationsandacronyms",
    "content": "LNlupusnephritis\naPLAantiphospholipidantibodies\nMCDminimalchangedisease\nAPSantiphospholipidsyndrome\nMPAmycophenolicacid\nCFHComplementFactorH\nMPAAmycophenolicacidanalogs\nCFHRComplementFactorHrelated\nMMFmycophenolatemofetil\nCIcondenceinterval\nNIHNationalInstitutesofHealth,USA\nCKDchronickidneydisease\nORoddsratio\nCNIcalcineurininhibitor\nPCRproteincreatinineratio\nCVcardiovascular\nPERRprimaryefcacyrenalresponse\ndsDNAdouble-strandeddeoxyribonucleicacid\np.o.oral\neGFRestimatedglomerularltrationrate\nRAS(i)reninangiotensinsystem(inhibitor[s])\nFDAFoodandDrugAdministration\nRCTrandomizedcontrolledtrial\nFSGSfocalsegmentalglomerulosclerosis\ns.c.subcutaneous\nG6PDglucose-6-phosphatedehydrogenase\nSCrserumcreatinine\nGNglomerulonephritis\nSLEsystemiclupuserythematosus\nHBVhepatitisBvirus\nTGATherapeuticsGoodsAdministration\nHCVhepatitisCvirus\nTMAthromboticmicroangiopathy\nHIVhumanimmunodeciencyvirus\nTMP-SMXtrimethoprim-sulfamethoxazole\nHRhazardratio\nU.S.UnitedStates\ni.v.intravenous\nKDIGOKidneyDisease:ImprovingGlobalOutcomes\nKidneyInternational\nS10\n(2024)105(Suppl1S),S1–S69\nnotice\nwww.kidney-international.org",
    "page": 11,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Notice",
    "content": "SECTIONI:USEOFTHECLINICALPRACTICEGUIDELINE\nThisClinicalPracticeGuidelinedocumentisbaseduponliteraturesearcheslastconductedinJuly2022andupdatedinApril\n2023.Itisdesignedtoassistdecision-making.Itisnotintendedtodeneastandardofcareandshouldnotbeinterpretedas\nprescribinganexclusivecourseofmanagement.Variationsinpracticewillinevitablyandappropriatelyoccurwhenclinicians\nconsidertheneedsofindividualpatients,availableresources,andlimitationsuniquetoaninstitutionortypeofpractice.\nHealthcareprofessionalsusingtheserecommendationsshoulddecidehowtoapplythemtotheirownclinicalpractice.\nSECTIONII:DISCLOSURE\nKidneyDisease:ImprovingGlobalOutcomes(KDIGO)makeseveryefforttoavoidanyactualorreasonablyperceivedconicts\nofinterestthatmayarisefromanoutsiderelationshiporapersonal,professional,orbusinessinterestofamemberoftheWork\nGroup.AllmembersoftheWorkGrouparerequiredtocomplete,sign,andsubmitadisclosureandattestationformshowing\nallsuchrelationshipsthatmightbeperceivedasorareactualconictsofinterest.Thisdocumentisupdatedannually,and\ninformationisadjustedaccordingly.Allreportedinformationispublishedinitsentiretyattheendofthisdocumentinthe\n’ﬁ\nWorkGroupmembersDisclosuresectionandiskeptonleatKDIGO.\n(cid:1)\nCopyright2023,KidneyDisease:ImprovingGlobalOutcomes(KDIGO).PublishedbyElsevierInc.onbehalfofthe\nInternationalSocietyofNephrology.ThisisanopenaccessarticleundertheCCBY-NC-NDlicense(http://creativecommons.\norg/licenses/by-nc-nd/4.0/).Singlecopiesmaybemadeforpersonaluseasallowedbynationalcopyrightlaws.Specialrates\nareavailableforeducationalinstitutionsthatwishtomakephotocopiesfornonproteducationaluse.Nopartofthispub-\nlicationmaybereproduced,amended,ortransmittedinanyformorbyanymeans,electronicormechanical,including\nphotocopying,recording,oranyinformationstorageandretrievalsystem,withoutexplicitpermissioninwritingfromKDIGO.\nDetailsonhowtoseekreprints,permissionforreproductionortranslation,andfurtherinformationaboutKDIGOsper-\nmissionspoliciescanbeobtainedbycontactingMelissaThompson,ChiefOperatingOfcer,atmelissa.thompson@kdigo.org.\nNeitherKDIGO,KidneyInternational,thePublisher,northeauthors,contributors,oreditorsshallhaveorassumeany\nliabilityforanydirect,indirect,incidental,special,exemplary,orconsequentialdamages(includingwithoutlimitationlost\nprots)oranyinjuryand/ordamagetopersonsorproperty,howevercausedandonanytheoryofliability,whetherin\ncontract,strictliability,ortort(includingproductliability,negligenceorotherwise)arisinginanywayoutoftheuseor\noperationofanymethods,products,instructions,orideascontainedinthematerialherein.\nKidneyInternational\nS11\n(2024)105(Suppl1S),S1–S69\nforeword\nwww.kidney-international.org",
    "page": 12,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Foreword (Part 1)",
    "content": "KidneyInternational\n(2024)105(Suppl1S),S1–S69;https://doi.org/10.1016/j.kint.2023.09.002\nCopyright2023,KidneyDisease:ImprovingGlobalOutcomes(KDIGO).PublishedbyElsevierInc.onbehalfoftheInternationalSocietyofNephrology.Thisisanopenaccess\narticleundertheCCBY-NC-NDlicense(http://creativecommons.org/licenses/by-nc-nd/4.0/). “”\nThemissionofKidneyDisease:ImprovingGlobalOutcomesexpertguidanceorgoodpracticestatementsandusethem\n“ﬁ\n(KDIGO)istoimprovethecareandoutcomesofpeopleastheyseettoinformthecareofpatients. withkidneydiseaseworldwidethroughpromotingcoordi-WeonceagainthankJürgenFloege,MD,andBradH. nation,collaboration,andintegrationofinitiativestodevelopRovin,MD,forleadingthisimportantinitiative,andwevery\nandimplementclinicalpracticeguidelines.Sinceitsincep-muchappreciatethecontinueddedicationoftheWork\ntionin2003,KDIGOhaspublishedcomprehensiveguidelinesGroupmembers,TakMao(T.M.)Chan,MD,DSc;Isabelle\nonmanydistincttopics,includingtheClinicalPracticeAyoub,MD;Zhi-HongLiu,MD;andJuanMejía-Vilet,MD,\nGuidelinesfortheManagementofGlomerulonephritisinPhD.Eachofthesevolunteersprovidedaconsiderable\n2012andGlomerularDiseasesin2021.ThelatterguidelineamountoftimeandexpertisetothecurrentLupusnephritis\nsummarizedrecommendationsfor11diseasesbasedonevi-guideline.TheindependentEvidenceReviewTeam(ERT)\ndenceavailablethroughJune2020.Thecurrentupdate,just2fromBrownUniversitySchoolofPublicHealthledbyEthan\nﬂﬁ\nyearslater,reectstheunprecedentedpaceofscienticdis-Balk,MD,MPH,andCraigGordon,MD,MS,updatedthe\ncoveryintheeld,andcentersonguidanceregardingtheevidencereviewsthatinformedthislatestversionofthe\ndiagnosis,treatment,andmonitoringofkidneyinvolvementguideline. insystemiclupuserythematosus.Toensuretransparencyandrigorouspublicreviewduring\nKDIGOstrivestomaintainthehigheststandardsofguidelinedevelopment,thedraftguidelineupdatewasmade\nexcellenceandprovideclinicianswiththemostrelevant,publiclyavailableforcommentinMarch2023,perKDIGO\nevidence-basedguidance,incorporatingbothrecentad-policy.Weverymuchappreciatethefeedbackreceivedfrom\nvancementsaswellaswidelyacceptedclinicalstandards.Asthescienticcommunity.AllWorkGroupmembershave\nrevisedandapprovedtheupdateforformalrelease. such,thisLupusnephritisguidelineupdatefeaturesacom-\nbinationofbothgradedrecommendationsandpracticeInsummary,wearepleasedtopresentthisrevisedClinical\npoints.GradedrecommendationsarebasedonasystematicPracticeGuidelinefortheManagementofLupusNephritis,\nreviewoftheevidenceandaregradedforstrengthofthereectingthemostrecentandup-to-dateglobalevidencefor\n“”“\nrecommendation(level1,werecommendorlevel2,wethecareofpeoplewithlupusnephritisthroughouttheworld. ”“”“ﬁ\nsuggest)andcertaintyoftheevidence(A,high;B,mod-Wearethrilledatthepaceofscienticadvancementandare\n”“”“”\nerate;C,low;orD,verylow).Practicepointsareun-exceptionallygratefultotheWorkGroupCo-Chairs,Work\ngraded,consensus-basedstatementsrepresentingtheexpertGroupmembers,andothercontributorstothisveryimpor-\njudgmentoftheWorkGroup.ThesepracticepointsareissuedtantKDIGOactivity.",
    "page": 13,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Foreword (Part 2)",
    "content": "whentherehasnotbeenasystematicreview.Somepractice\npointsaimathelpingthereaderintheimplementationofMorganE.Grams,MD,PhD,MHS\ngradedrecommendationsandweoftenprovidetheseinaMichelJadoul,MD\ngraphicalformat.ReadersshouldconsiderpracticepointsasKDIGOCo-Chairs\nKidneyInternational\nS12\n(2024)105(Suppl1S),S1–S69\nWorkGroupmembership\nwww.kidney-international.org",
    "page": 13,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "WorkGroupmembership",
    "content": "WORKGROUPCO-CHAIRS\nJürgenFloege,MDBradH.Rovin,MD,FACP,FASN\nUniversityHospital,RWTHAachenTheOhioStateUniversityCollegeofMedicine\nAachen,GermanyColumbus,OH,USA\nWORKGROUP\nIsabelleM.Ayoub,MDZhi-HongLiu,MD\nTheOhioStateUniversityCollegeofMedicineNationalClinicalResearchCenterofKidneyDiseases,\nColumbus,OH,USANanjingUniversitySchoolofMedicine\nNanjing,China\nTakMaoChan,MBBS,MD,DSc,MRCP,FHKCP,FHKAM,JuanManuelMejía-Vilet,MD,PhD\nFRCP,FASNInstitutoNacionaldeCienciasMédicasy\nUniversityofHongKongNutrición,SalvadorZubirán\nHongKong,ChinaMexicoCity,Mexico\nMETHODSCHAIR\nMarcelloA.Tonelli,MD,SM,MSc,FRCPC\nUniversityofCalgary\nCalgary,Alberta,Canada\nEVIDENCEREVIEWTEAM\nCenterforEvidenceSynthesisinHealth,BrownUniversitySchoolofPublicHealthProvidence,RI,USA\nEthanM.Balk,MD,MPH,ProjectDirector,EvidenceReviewTeamDirector\nCraigE.Gordon,MD,MS,AssociateProfessorofMedicine,TuftsUniversitySchoolofMedicine,DivisionofNephrology,\nTuftsMedicalCenter;AssistantProjectDirector,EvidenceReviewTeamAssociateDirector\nGaelenAdam,MLIS,MPH,InformationSpecialistandResearchAssociate\nKidneyInternational\nS13\n(2024)105(Suppl1S),S1–S69\nabstract\nwww.kidney-international.org",
    "page": 14,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Abstract",
    "content": "TheKidneyDisease:ImprovingGlobalOutcomes(KDIGO)2024ClinicalPracticeGuidelinefor\ntheManagementofLupusNephritisrepresentsafocusedupdateoftheLupusnephritischapter\nfromtheKDIGO2021ClinicalPracticeGuidelinefortheManagementofGlomerularDiseases.\nTheaimistoassistclinicianscaringforindividualswithlupusnephritis.Theupdatetakesinto\nconsiderationevidencefromrandomizedcontrolledtrialspublishedsinceFebruary2022.Asin\n2021,thechapterfollowsthesametemplate,providingguidancerelatedtodiagnosis,treatment,\nandspecialsituations.Basedontheevidence,thisupdateisfocusedonguidancerelatedto\ntreatmentoflupusnephritis.Thisguidelineupdatefollowedanexplicitprocessofevidence\nreviewandappraisal.Treatmentapproachesandguidelinerecommendationsarebasedonsys-\ntematicreviewsofrelevantstudies,andappraisalofthestrengthofrecommendationsandcer-\ntaintyoftheevidencefollowingtheGradingofRecommendationsAssessment,Development\nandEvaluation(GRADE)approach.Limitationsoftheevidencearediscussedandareasof\nfutureresearcharepresented.\nKeywords:evidence-based;glomerulardiseases;glomerulonephritis;guideline;KDIGO;lupus\nnephritis;nephroticsyndrome;systematicreview\nCITATION\nIncitingthisdocument,thefollowingformatshouldbeused:KidneyDisease:Improving\nGlobalOutcomes(KDIGO)LupusNephritisWorkGroup.KDIGO2024ClinicalPractice\nGuidelinefortheManagementofLupusNephritis.KidneyInt.2024;105(1S):S1S69.\nKidneyInternational\nS14\n(2024)105(Suppl1S),S1–S69",
    "page": 15,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "PracticePoint10.1.1:Approachtothediagnosisofkidneyinvolvementinsystemiclupuserythematosus(SLE)(Figure1)",
    "content": "Patient with systemic lupus erythematosus\nTesting indicated when:\n• Systemic lupus erythematosus presentation\n• As regular surveillance\nTesting panel:\n• Serum creatinine and eGFR\n• Urinalysis (dipstick and sediment)\n• Spot protein–creatinine ratio (PCR)\n• Serology (anti-dsDNA and complement)\nIs there evidence of abnormal proteinuria or urine sediment:Is there evidence of decreased or decreasing GFR:\n• Abnormal proteinuria assessed by dipstick protein ≥2+• For example, abnormal eGFR that is below the\nexpected level based on age and clinical history,\nor decreasing eGFR, with no attributable\n• Urine sediment positive for acanthocytescause other than systemic lupus erythematosus\n(≥5%), red blood cell casts or white blood cell casts\nNoseYoNYes\nRepeat testingQuantify proteinuria\nNo further urineNo further kidney function\ntesting at this timetesting at this time\nIs 24-hour proteinuria\n≥500 mg/d?\nYesYesNo\nRepeat testing and\nfollow the progress\nNo\nNo further urine\nConsider kidney biopsy\ntesting at this time\nFigure1|Diagnosisofkidneyinvolvementinsystemiclupuserythematosus.anti-dsDNA,anti-double-strandeddeoxyribonucleicacid;\neGFR,estimatedglomerularltrationrate.\nKidneyInternational\nS15\n(2024)105(Suppl1S),S1–S69",
    "page": 16,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "summaryofrecommendationstatementsandpracticepoints (Part 1)",
    "content": "www.kidney-international.org\n10.2Treatment\n10.2.1Generalmanagementofpatientswithlupusnephritis\nRecommendation10.2.1.1:WerecommendthatpatientswithSLE,includingthosewithlupusnephritis(LN),be\ntreatedwithhydroxychloroquineoranequivalentantimalarialunlesscontra-\n(1C)\nindicated. RiskRisk attenuation\nCardiovascular risk\n• Dyslipidemia management\n• Low-dose aspirin during pregnancy\n• Blood pressure control\n• Avoid high-sodium diet\nProteinuria and\n• Optimize blood pressure\nCKD progression\n• Renoprotective medications, such as RAAS blockade, SGLT2 inhibitor, etc., in\n(refer to Chapter 1)\nstable patients without AKI\n• Avoid nephrotoxic insult\n• Prevent AKI\n• Assess medical history of herpes zoster and tuberculosis\nInfection risk\n• Screening for HBV, HCV, HIV, and HBV vaccination\nPneumocystis jirovecii\n•  prophylaxis (issue of potential adverse drug reaction\ndiscussed below)\n• Individualized consideration for recombinant zoster vaccine\n• Individualized consideration for other infectious organisms as dictated by\npublic health concerns at the time of treatment\n• Bone mineral density and fracture risk assessment\nBone injury\n• Calcium and vitamin D supplementation\n• Bisphosphonates when appropriate\n• Broad-spectrum sunscreen\nUltraviolet light\n• Limit ultraviolet light exposure\nexposure\n• Gonadotropin-releasing hormone agonists (i.e. leuprolide)\nPremature ovarian\n• Sperm/oocyte cryopreservation\nfailure\n• Individual evaluation and counselling for contraception type\nUnplanned pregnancy\n(preference, thrombosis risk, age)\n• Evaluate individual risk factors for malignancies\nCancer\n• Minimize lifetime cyclophosphamide exposure to <36 g\nFigure3|Measurestominimizetheriskofcomplicationsrelatedtolupusnephritisoritstreatment.Note:Chapter1referstoChapter1\noftheKDIGOGuidelineonGlomerularDiseases.AKI,acutekidneyinjury;CKD,chronickidneydisease;HBV,hepatitisBvirus;HCV,hepatitisC\nﬁ–\nvirus;HIV,humanimmunodeciencyvirus;RAAS,reninangiotensin-aldosteronesystem;SGLT2,sodium-glucosecotransporter-2.",
    "page": 17,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "summaryofrecommendationstatementsandpracticepoints (Part 2)",
    "content": "KidneyInternational\nS16\n(2024)105(Suppl1S),S1–S69\n[Table 1]\nRisk | Risk attenuation\n------------------------------------------------------------\nCardiovascular risk | • Dyslipidemia management\n• Low-dose aspirin during pregnancy\n• Blood pressure control\nProteinuria and\nCKD progression\n(refer to Chapter 1) | • Avoid high-sodium diet\n• Optimize blood pressure\n• Renoprotective medications, such as RAAS blockade, SGLT2 inhibitor, etc., in\nstable patients without AKI\n• Avoid nephrotoxic insult\n• Prevent AKI\nInfection risk | • Assess medical history of herpes zoster and tuberculosis\n• Screening for HBV, HCV, HIV, and HBV vaccination\n• Pneumocystis jirovecii prophylaxis (issue of potential adverse drug reaction\ndiscussed below)\n• Individualized consideration for recombinant zoster vaccine\n• Individualized consideration for other infectious organisms as dictated by\npublic health concerns at the time of treatment\nBone injury | • Bone mineral density and fracture risk assessment\n• Calcium and vitamin D supplementation\n• Bisphosphonates when appropriate\nUltraviolet light\nexposure | • Broad-spectrum sunscreen\n• Limit ultraviolet light exposure\nPremature ovarian\nfailure | • Gonadotropin-releasing hormone agonists (i.e. leuprolide)\n• Sperm/oocyte cryopreservation\nUnplanned pregnancy | • Individual evaluation and counselling for contraception type\n(preference, thrombosis risk, age)\nCancer | • Evaluate individual risk factors for malignancies\n• Minimize lifetime cyclophosphamide exposure to <36 g\n\nsummaryofrecommendationstatementsandpracticepoints\nwww.kidney-international.org\nPracticePoint10.2.1.1:AdjunctivetherapiestomanageLNandattenuatecomplicationsofthediseaseoritstreatments\nshouldbeconsideredforallpatients,asoutlinedinFigure3. 10.2.2ClassIorClassIIlupusnephritis\nKidney biopsy showing\nClass I/II lupus nephritis\nemordnys citorhpeNairunietorp level-woL\nEvaluate for lupus podocytopathy\n(electron microscopy would be useful)\nTreat as minimal change disease\n(Chapter 5)\nImmunosuppressive treatment\nConsider maintenance combination\nguided by extrarenal manifestations\ntherapy with low-dose glucocorticoid\nof systemic lupus erythematosus\nand another immunosuppressive agent\nFigure4|ImmunosuppressivetreatmentforpatientswithClassIorClassIIlupusnephritis.Note:Chapter5referstoChapter5ofthe\nKDIGOGuidelineonGlomerularDiseases.",
    "page": 17,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "summaryofrecommendationstatementsandpracticepoints (Part 3)",
    "content": "PracticePoint10.2.2.1:ApproachtoimmunosuppressivetreatmentforpatientswithClassIorClassIILN(Figure4)\n10.2.3ClassIIIorClassIVlupusnephritis\n10.2.3.1InitialtherapyofactiveClassIII/IVlupusnephritis\nRecommendation10.2.3.1.1:WerecommendthatpatientswithactiveClassIIIorIVLN,withorwithouta\none\nmembranouscomponent,betreatedinitiallywithglucocorticoidsplusanyof\nthefollowing:\n1B\ni.mycophenolicacidanalogs(MPAA)();or\n1B\nii.low-doseintravenouscyclophosphamide();or\n1B\niii.belimumabandeitherMPAAorlow-doseintravenouscyclophosphamide();or\niv.MPAAandacalcineurininhibitor(CNI)whenkidneyfunctionisnot\nﬁ£\nseverelyimpaired(i.e.,estimatedglomerularltrationrate[eGFR]45\n1B\nml/minper1.73m)(). KidneyInternational\nS17\n(2024)105(Suppl1S),S1–S69\nsummaryofrecommendationstatementsandpracticepoints\nwww.kidney-international.org\nPracticePoint10.2.3.1.1:Aregimenofreduced-doseglucocorticoidsfollowingashortcourseofmethylprednisolonepulses\nmaybeconsideredduringtheinitialtreatmentofactiveLNwhenboththekidneyandextrarenal\ndiseasemanifestationsshowsatisfactoryimprovement(Figure7). High-dose schemeModerate-dose schemeReduced-dose scheme\nNil or 0.25–0.5 g/day up to 3 days0.25–0.5 g/day up to 3 days often0.25–0.5 g/day up to 3 days usually\nMethylprednisolone\nas initial treatmentincluded as initial treatmentincluded as initial treatment\nintravenous pulses\nOral prednisone\nequivalent (/day)\nWeek 0–20.8–1.0 mg/kg (max 80 mg)0.6–0.7 mg/kg (max 50 mg)0.5–0.6 mg/kg (max 40 mg)\nWeek 3–40.6–0.7 mg/kg0.5–0.6 mg/kg0.3–0.4 mg/kg\nWeek 5–630 mg20 mg15 mg\nWeek 7–825 mg15 mg10 mg\nWeek 9–1020 mg12.5 mg7.5 mg\nWeek 11–1215 mg10 mg5 mg\nWeek 13–1412.5 mg7.5 mg2.5 mg\nWeek 15–1610 mg7.5 mg2.5 mg\nWeek 17–187.5 mg5 mg2.5 mg\nWeek 19–207.5 mg5 mg2.5 mg\nWeek 21–245 mg<5 mg2.5 mg\nWeek >25<5 mg<5 mg<2.5 mg\nFigure7|Examplesofglucocorticoidregimensforlupusnephritis.max,maximum. PracticePoint10.2.3.1.2:IntravenouscyclophosphamidecanbeusedastheinitialtherapyforactiveClassIIIandClass\nIVLNinpatientswhomayhavedifcultyadheringtoanoralregimen. PracticePoint10.2.3.1.3:AnMPAA-basedregimenisthepreferredinitialtherapyofproliferativeLNforpatientsathighrisk\nofinfertility,suchaspatientswhohaveamoderate-to-highpriorcyclophosphamideexposure. PracticePoint10.2.3.1.4:InitialtherapywithanimmunosuppressiveregimenthatincludesaCNI(voclosporin,tacrolimus,or\ncyclosporine)maybepreferredinpatientswithrelativelypreservedkidneyfunctionandnephrotic-\nrangeproteinurialikelyduetoextensivepodocyteinjury,aswellaspatientswhocannottolerate\nstandard-doseMPAAorareuntfororwillnotusecyclophosphamide-basedregimens. PracticePoint10.2.3.1.5:AtripleimmunosuppressiveregimenofbelimumabwithglucocorticoidsandeitherMPAAor\nreduced-dosecyclophosphamidemaybepreferredinpatientswithrepeatedkidneyaresorat\nhigh-riskforprogressiontokidneyfailureduetoseverechronickidneydisease.",
    "page": 17,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "summaryofrecommendationstatementsandpracticepoints (Part 4)",
    "content": "PracticePoint10.2.3.1.6:Othertherapies,suchasazathioprineorleunomidecombinedwithglucocorticoids,maybe\ninlieu\nconsideredoftherecommendedinitialdrugsforproliferativeLNinsituationsof\npatientintolerance,lackofavailability,and/orexcessivecostofstandarddrugs,butthese\nﬁﬂ\nalternativesmaybeassociatedwithinferiorefcacy,includingincreasedrateofdiseaseares\nand/orincreasedincidenceofdrugtoxicities. PracticePoint10.2.3.1.7:Newerbiologicandnon-biologictherapiesareunderdevelopmentandmayofferfutureoptions\nforthetreatmentofactiveLN.Rituximabmaybeconsideredforpatientswithpersistentdisease\nactivityorinadequateresponsetoinitialstandard-of-caretherapy. 10.2.3.2MaintenancetherapyforClassIIIandClassIVlupusnephritis\nRecommendation10.2.3.2.1:Werecommendthataftercompletionofinitialtherapy,patientsshouldbeplaced\n(1B)\nonMPAAformaintenance. PracticePoint10.2.3.2.1:AzathioprineisanalternativetoMPAAaftercompletionofinitialtherapyinpatientswhodonot\ntolerateMPAA,whodonothaveaccesstoMPAA,orwhoareconsideringpregnancy. PracticePoint10.2.3.2.2:Glucocorticoidsshouldbetaperedtothelowestpossibledoseduringmaintenance,exceptwhen\nglucocorticoidsarerequiredforextrarenallupusmanifestations;discontinuationofglucocor-\nticoidscanbeconsideredafterpatientshavemaintainedacompleteclinicalrenalresponse\nfor12months. KidneyInternational\nS18\n(2024)105(Suppl1S),S1–S69\n[Table 1]\n | High-dose scheme | Moderate-dose scheme | Reduced-dose scheme\n------------------------------------------------------------\nMethylprednisolone\nintravenous pulses | Nil or 0.25–0.5 g/day up to 3 days\nas initial treatment | 0.25–0.5 g/day up to 3 days often\nincluded as initial treatment | 0.25–0.5 g/day up to 3 days usually\nincluded as initial treatment\nOral prednisone\nequivalent (/day)\nWeek 0–2\nWeek 3–4\nWeek 5–6\nWeek 7–8\nWeek 9–10\nWeek 11–12\nWeek 13–14\nWeek 15–16\nWeek 17–18\nWeek 19–20\nWeek 21–24\nWeek >25 | 0.8–1.0 mg/kg (max 80 mg)\n0.6–0.7 mg/kg\n30 mg\n25 mg\n20 mg\n15 mg\n12.5 mg\n10 mg\n7.5 mg\n7.5 mg\n5 mg\n<5 mg | 0.6–0.7 mg/kg (max 50 mg)\n0.5–0.6 mg/kg\n20 mg\n15 mg\n12.5 mg\n10 mg\n7.5 mg\n7.5 mg\n5 mg\n5 mg\n<5 mg\n<5 mg | 0.5–0.6 mg/kg (max 40 mg)\n0.3–0.4 mg/kg\n15 mg\n10 mg\n7.5 mg\n5 mg\n2.5 mg\n2.5 mg\n2.5 mg\n2.5 mg\n2.5 mg\n<2.5 mg",
    "page": 17,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "canbeconsidered(Figure9).",
    "content": "MaintenanceLow-dose glucocorticoids AND\nimmuno-\nMycophenolicMizoribineCNI (such asCNI and mycophenolicBelimumab andAzathioprine\nsuppressive\nacid analogsvoclosporin, tacrolimusacid analogsmycophenolic acid\nregimens\nor cyclosporine)analogs or azathioprine\nExperienceTacrolimus andLow medicationPreferred treatment\nComments\nmostly incyclosporine safe incost; safe inbelimumab demonstratedvoclosporin demonstratedbased on high-\nJapanesepregnancyin BLISS-LN (104-wk) andin AURORA 1 (52-wk) andcertainty evidence;\npatientspregnancy data onopen-label extensionAURORA 2 continuation trials\nvoclosporintrials (28-wk)than azathioprine\n[Practice Point 10.2.3.2.5]tacrolimus demonstrated inmaintenance\n‘Multitarget Therapy’ trial in\nChinese patients in which\ntacrolimus and reduced-dose\nMPAA were given for\n24 months\n[Practice Point 10.2.3.2.5]\nFigure9|Maintenanceimmunosuppressiveregimensinpatientswithlupusnephritis.AURORA,AuriniaRenalResponseinActiveLupus\nwithVoclosporin;BLISS-LN,EfcacyandSafetyofBelimumabinPatientswithActiveLupusNephritis;CNI,calcineurininhibitor;MPAA,\nmycophenolateacidanalogs.",
    "page": 20,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "inFigure10. (Part 1)",
    "content": "Kidney biopsy\nshowing Class V lupus nephritis\nairunietorp egnar-citorhpeNairunietorp level-woL\nMonitor the level of proteinuria and prevent or treat\ncomplications (e.g., thrombosis, dyslipidemia, edema)\n1  Renin-angiotensin system blockade and1  Renin-angiotensin system blockade and blood pressure control\nblood pressure control2  Combined immunosuppressive treatment with glucocorticoid and\n2  Immunosuppressive treatment guided    one other agent (e.g., mycophenolic acid analogs, cyclophosphamide,\nby extrarenal manifestations of systemic\nlupus erythematosus    recommendation of glucocorticoid regimen, but moderate or reduced\n3  Hydroxychloroquine    dose preferred. Please refer to Practice Point 10.2.3.1.1. 3  Hydroxychloroquine\nIf proteinuria worsens and/or complications\nof proteinuria develop (e.g., thrombosis,\ndyslipidemia, edema), consider\nimmunosuppressive therapy\nFigure10|ManagementofpatientswithpureClassVlupusnephritis. KidneyInternational\nS19\n(2024)105(Suppl1S),S1–S69\n[Table 1]\nMaintenance\nimmuno-\nsuppressive\nregimens | Low-dose glucocorticoids AND |  |  |  |  | \n------------------------------------------------------------\n | Mycophenolic\nacid analogs | Azathioprine | Belimumab and\nmycophenolic acid\nanalogs or azathioprine | CNI and mycophenolic\nacid analogs | CNI (such as\nvoclosporin, tacrolimus\nor cyclosporine) | Mizoribine\n\nsummaryofrecommendationstatementsandpracticepoints\nwww.kidney-international.org\n10.2.5Responseandrelapseconsiderations\n10.2.5.1AssessingtreatmentresponseinLN\nPracticePoint10.2.5.1.1:DenitionsofresponsetotherapyinLNusedinclinicaltrialsareprovidedinFigure11. • Reduction in proteinuria <0.5 g/g (50 mg/mmol) measured as the PCR from\nComplete response*\na 24-h urine collection\n• Stabilization or improvement in kidney function (±10%–15% of baseline)\n• Within 6–12 mo of starting therapy, but could take more than 12 mo\n• PCR ≤0.7 g/g (70 mg/mmol)\nrenal response\nper 1.73 m\n• No use of rescue therapy for treatment failure\n• Reduction in proteinuria by at least 50% and to <3 g/g (300 mg/mmol)\nPartial response\nmeasured as the PCR from a 24-h urine collection\n• Stabilization or improvement in kidney function (±10%–15% of baseline)\n• Within 6–12 mo of starting therapy\n• Failure to achieve a partial or complete response within 6–12 mo of starting\nNo kidney response\ntherapy\nﬁ<\nFigure11|Denitionsofresponsecommonlyusedinclinicaltrialsoflupusnephritis.*Forchildren18yearsold,completeresponseis\nﬁ<<\n22\ndenedasproteinuria0.5g/1.73mperdayor300mg/mperdaybasedona24-hoururinespecimen.eGFR,estimatedglomerular\nﬁ–\nltrationrate;PCR,proteincreatinineratio. 10.2.5.2Managementofunsatisfactoryresponsetotreatment\nPracticePoint10.2.5.2.1:Analgorithmicapproachtopatientswhoseresponsetotherapyisdeemedunsatisfactoryis\nprovidedinFigure12.",
    "page": 20,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "inFigure10. (Part 2)",
    "content": "Verify adherence to treatment\nEnsure adequate dosing of immunosuppressive medications by measuring\nplasma drug levels if applicable or available (check mycophenolic acid level\nif on mycophenolic acid analogs/check infusion records if on cyclophosphamide)\nRepeat biopsy if concern for chronicity or other diagnosis\n(e.g., thrombotic microangiopathy)\nConsider switching to an alternative recommended treatment regimen when\nthere is persistent active disease\nConsider the following in patients refractory\n• Addition of rituximab or other biologic therapies\n• Extended course of i.v. pulse cyclophosphamide\n• Enrollment in clinical trials if eligible\nFigure12|Managementofpatientswhoshowunsatisfactoryresponsetoinitialtherapyforactivelupusnephritis.i.v.,intravenous. 10.2.5.3TreatmentofLNrelapse\nPracticePoint10.2.5.3.1:Afteracompleteorpartialremissionhasbeenachieved,LNrelapseshouldbetreatedwiththe\nsameinitialtherapyusedtoachievetheoriginalresponse,oranalternativerecommended\ntherapy. KidneyInternational\nS20\n(2024)105(Suppl1S),S1–S69\n[Table 1]\nComplete response* | • Reduction in proteinuria <0.5 g/g (50 mg/mmol) measured as the PCR from\na 24-h urine collection\n• Stabilization or improvement in kidney function (±10%–15% of baseline)\n• Within 6–12 mo of starting therapy, but could take more than 12 mo\n------------------------------------------------------------\nrenal response | • PCR ≤0.7 g/g (70 mg/mmol)\nper 1.73 m2\n• No use of rescue therapy for treatment failure\nPartial response | • Reduction in proteinuria by at least 50% and to <3 g/g (300 mg/mmol)\nmeasured as the PCR from a 24-h urine collection\n• Stabilization or improvement in kidney function (±10%–15% of baseline)\n• Within 6–12 mo of starting therapy\nNo kidney response | • Failure to achieve a partial or complete response within 6–12 mo of starting\ntherapy\n\n[Table 2]\nVerify adherence to treatment\n------------------------------------------------------------\nEnsure adequate dosing of immunosuppressive medications by measuring\nplasma drug levels if applicable or available (check mycophenolic acid level\nif on mycophenolic acid analogs/check infusion records if on cyclophosphamide)\nRepeat biopsy if concern for chronicity or other diagnosis\n(e.g., thrombotic microangiopathy)\nConsider switching to an alternative recommended treatment regimen when\nthere is persistent active disease\nConsider the following in patients refractory\n• Addition of rituximab or other biologic therapies\n• Extended course of i.v. pulse cyclophosphamide\n• Enrollment in clinical trials if eligible",
    "page": 20,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "summaryofrecommendationstatementsandpracticepoints",
    "content": "www.kidney-international.org\n10.3Specialsituations\n10.3.1Lupusnephritisandthromboticmicroangiopathy\nPracticePoint10.3.1.1:PatientswithLNandthromboticmicroangiopathy(TMA)shouldbemanagedaccordingtothe\nunderlyingetiologyofTMA,asshowninFigure13.\nLupus nephritis AND\nsuspected thrombotic microangiopathy\nTest for ADAMTS13 activity and antibodies to ADAMTS13\nTest for antiphospholipid antibodies\nStart plasma exchange\nModerate/high riskand glucocorticoid\n(>5 points)while awaiting test\nThrombotic thrombocytopenic\nresults (adults)\npurpura\n(PLASMIC score)\nLow risk\n(0–4 points)\nLow ADAMTS13Normal ADAMTS13Normal ADAMTS13\nactivity (<10%)activity and negativeactivity and positive\nantiphospholipidantiphospholipid\nantibodiesantibodies\nSystemic lupusEvaluate forAntiphospholipid\nerythematosus-thromboticsyndrome nephropathy\nassociated thromboticmicroangiopathy\nthrombocytopenic purpuraetiologies\nPrimary or secondary\ncomplement-mediated\nthrombotic\nmicroangiopathy\nConsiderOtherPlasma exchangeAnticoagulation\neculizumabetiology\n+ glucocorticoid+/– plasma exchange\n+ rituximab\n+/– caplacizumab\nFigure13|Managementofpatientswithlupusnephritisandthromboticmicroangiopathy(TMA).BendapudiPK,HurwitzS,FryA,etal.\nDerivationandexternalvalidationofthePLASMICscoreforrapidassessmentofadultswiththromboticmicroangiopathies:acohortstudy.\nLancetHaematol.2017;4:e157e164.ADAMTS13,adisintegrinandmetalloproteinasewithathrombospondintype1motif,member13;\nPLASMIC,Plateletcount,combinedhemoLysisvariable,absenceofActivecancer,absenceofStem-cellorsolid-organtransplant,mean\ncorpuscularvolume(MCV),internationalnormalizedratio(INR),Creatinine.\nKidneyInternational\nS21\n(2024)105(Suppl1S),S1–S69\nsummaryofrecommendationstatementsandpracticepoints\nwww.kidney-international.org\n10.3.2Pregnancyinpatientswithlupusnephritis\nPracticePoint10.3.2.1:PatientswithactiveLNshouldbecounseledtoavoidpregnancywhilethediseaseisactiveorwhen\ntreatmentwithpotentiallyteratogenicdrugsisongoing,andfor6monthsafterLNbecomes\ninactive.\nPracticePoint10.3.2.2:Toreducetheriskofpregnancycomplications,hydroxychloroquineshouldbecontinuedduring\npregnancy,andlow-doseaspirinshouldbestartedbefore16weeksofgestation.\nPracticePoint10.3.2.3:Glucocorticoids,hydroxychloroquine,azathioprine,tacrolimus,andcyclosporineareconsideredsafe\nimmunosuppressivetreatmentsduringpregnancy.\n10.3.3Treatmentoflupusnephritisinchildren\nPracticePoint10.3.3.1:TreatpediatricpatientswithLNusingimmunosuppressionregimenssimilartothoseusedinadults,\nbutconsiderissuesrelevanttothispopulation,suchasdoseadjustment,growth,fertility,and\npsychosocialfactors,whendevisingthetherapyplan.\n10.3.4Managementoflupuspatientswithkidneyfailure\nPracticePoint10.3.4.1:PatientswithLNwhodevelopkidneyfailuremaybetreatedwithhemodialysis,peritonealdialysis,\norkidneytransplantation;andkidneytransplantationispreferredtolong-termdialysis.\nKidneyInternational\nS22\n(2024)105(Suppl1S),S1–S69",
    "page": 22,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "failure,whileminimizingmedication-associatedtoxicities. (Part 1)",
    "content": "Patient with systemic lupus erythematosus\nTesting indicated when:\n• Systemic lupus erythematosus presentation\n• As regular surveillance\nTesting panel:\n• Serum creatinine and eGFR\n• Urinalysis (dipstick and sediment)\n• Spot protein–creatinine ratio (PCR)\n• Serology (anti-dsDNA and complement)\nIs there evidence of abnormal proteinuria or urine sediment:Is there evidence of decreased or decreasing GFR:\n• Abnormal proteinuria assessed by dipstick protein ≥2+• For example, abnormal eGFR that is below the\nexpected level based on age and clinical history,\nor decreasing eGFR, with no attributable\n• Urine sediment positive for acanthocytescause other than systemic lupus erythematosus\n(≥5%), red blood cell casts or white blood cell casts\nNoseYoNYes\nRepeat testingQuantify proteinuria\nNo further urineNo further kidney function\ntesting at this timetesting at this time\nIs 24-hour proteinuria\n≥500 mg/d? YesYesNo\nRepeat testing and\nfollow the progress\nNo\nNo further urine\nConsider kidney biopsy\ntesting at this time\nFigure1|Diagnosisofkidneyinvolvementinsystemiclupuserythematosus.anti-dsDNA,anti-double-strandeddeoxyribonucleicacid;\neGFR,estimatedglomerularltrationrate. KidneyInternational\nS23\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\n10.1Diagnosis\nincludingclinical,urinary,andlaboratoryparameters,and\nrepeatedinvestigationstonotetheprogressionofabnormal\nPracticePoint10.1.1:Approachtothediagnosisofkidney\nndingsovertime,areimportantininformingclinical\ninvolvementinsystemiclupuserythematosus(SLE)\nmanagementdecisions.Becauseclinicalndingsdonotal-\n(Figure1)\nwayscorrelatewiththeextentorseverityofkidney\n10,11\nPatientswithSLEshouldbeactivelyandregularly\ninvolvement,akidneybiopsyisusefultoconrmthe\nmonitored,astheclinicalpresentationofkidneyinvolve-\ndiagnosisandfortheassessmentofactivityandchronicity\n1020\nmentcanremainsilentorasymptomaticforasignicant\nfeaturesthatinformtreatmentdecisionsandprognosis.",
    "page": 24,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "failure,whileminimizingmedication-associatedtoxicities. (Part 2)",
    "content": "periodoftime.AstheincidenceofLNvariesbyrace/\nKidneybiopsiesshouldbereadbyanexperiencedkidney\nethnicityandage,ahighindexofsuspicionshouldbe\npathologistandclassiedaccordingtotheInternational\nmaintainedforpatientsofAsian,African/Caribbean,and\nSocietyofNephrology(ISN)/RenalPathologySociety(RPS)\n25\n2123\nHispanicdescent.Childhood-onsetSLEisassociatedwith\nscheme.Electronmicroscopy,whereavailable,ishelpful\nahigherincidenceofLNandmoreseverediseasethanadult-\ninascertainingultrastructuraldetailsofhistopathologysuch\nonsetSLE.Althoughaproteinurialevelof500mg/dis\nastheextentandseverityofpodocyteinjuryandthelocation\nsuggestedasathresholdforfurtherinvestigations,taking\nofimmunedeposits.Cliniciansshouldpayattentiontothe\nintoconsiderationphysiologicalcausesoflow-levelpro-\ndetaileddescriptionofbothactiveandchronichistopatho-\nteinuriaandtoavoidunnecessarykidneybiopsies,itis\nlogicfeaturesaffectingdifferentelementsofthekidneypa-\nimportanttonotethattheseverityofproteinuriavaries\nrenchyma,especiallyregardingpotentiallyreversibleactive\nconsiderablyinsevereactivenephritisandcanappearrela-\nlesionsversuschronicdamagenotreversiblebyimmuno-\n“ﬁ”\ntivelyinsignicantattimes.Aholisticassessment\nsuppressivemedications(Figure2). Calculating the activity score\nComponents of the activity indexScore\nPointsExtent of lesion\n0–30Not present• Endocapillary hypercellularity\n0–31Present in <25%• Neutrophils and/or karyorrhexis\n(0–3) × 22Present in 25%–50%• Fibrinoid necrosis\n0–33Present in >50%• Hyaline deposits (wire loop and/or hyaline thrombi)\n(0–3) × 2\n0–3\n0–24Total:\nCalculating the chronicity score\nItems included in the NIH chronicity scoreScore\nPointsExtent of lesion\n0–3Present in <10%• Total glomerulosclerosis (global + segmental) 0\n0–3Present in 10%–25%• Fibrous crescents1\n0–3Present in 25%–50%2\n0–3Present in >50%• Tubular atrophy3\n0–12Total:\n• Collapsing lupus glomerulopathy\nFigure2|Activityandchronicityitemsincludedinlupusnephritiskidneybiopsyreport.NIH,NationalInstitutesofHealth,USA.",
    "page": 24,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "failure,whileminimizingmedication-associatedtoxicities. (Part 3)",
    "content": "KidneyInternational\nS24\n(2024)105(Suppl1S),S1–S69\n[Table 1]\nComponents of the activity index Sco | re | Calculating the activity score\nExtent of lesion Points\n------------------------------------------------------------\n• Endocapillary hypercellularity 0–3\n• Neutrophils and/or karyorrhexis 0–3\n• Fibrinoid necrosis (0–\n• Hyaline deposits (wire loop and/or hyaline thrombi) 0–3\n(0–\n0–3\nTot | 3) × 2\n3) × 2\nal:0–24 | Not present 0\nPresent in <25% 1\nPresent in 25%–50% 2\nPresent in >50% 3\nItems included in the NIH chronicity score Sco | re | Calculating the chronicity score\nExtent of lesion Points\n• Total glomerulosclerosis (global + segmental) 0–3\n• Fibrous crescents 0–3\n0–3\n• Tubular atrophy 0–3\nTot | al:0–12 | Present in <10% 0\nPresent in 10%–25% 1\nPresent in 25%–50% 2\nPresent in >50% 3\n• Collapsing lupus glomerulopathy |  | \n\nlupusnephritis\nwww.kidney-international.org\n10.2Treatment\ninfection,andmayincreasecompleteremissionratein\npatientswithLN.Althoughthecertaintyoftheevidenceislow\nduetostudylimitations,indirectness,orimprecision,this\n10.2.1Generalmanagementofpatientswithlupusnephritis\nisstatedasarecommendationbecauseoftherelativelylarge\nRecommendation10.2.1.1:Werecommendthatpa-\neffectsizesreportedandthegenerallysatisfactorysafetydata\n––\n2628,3650\ntientswithSLE,includingthosewithlupusnephritis\n(SupplementaryTableS4).Twoobservationalstudies\n(LN),betreatedwithhydroxychloroquineoran\nreportedanassociationbetweenhydroxychloroquinetreatment\n(1C)\nequivalentantimalarialunlesscontraindicated. andreducedmortalityinpatientswithLN,butthecertainty\nofevidenceforthisoutcomeisverylow(Supplementary\n28,50\nTableS4). Thisrecommendationplacesarelativelyhighervalueonthe\nThepotentialbenetsofpreventing\nValuesandpreferences. variousbenetsassociatedwithhydroxychloroquineusereported\norgandamageandvascularcomplicationswerejudgedas\ninobservationalstudies(includinglowerratesofdiseaseares,\nbeingimportanttopatients.TheWorkGroupalsojudged\nprogressivekidneydamage,andvascularcomplications)andon\nthattherelativelylowriskofadverseeventsassociatedwith\nthegenerallyfavorablesafetyproleofhydroxychloroquine\nhydroxychloroquinewouldalsobeimportanttopatients. treatment.Itplacesarelativelylowervalueonthelackoflarge-\nTherefore,theWorkGroupfeltthatnearlyallwell-informed\nscaleprospectiverandomizedcontrolledtrial(RCT)data. patientsinthetargetpopulationwouldchoosetoreceive\nhydroxychloroquinetreatmentincomparisontono\ntreatment. Keyinformation\nHydroxychloroquinecanbean\nThereportedbenetsof\nResourceuseandcosts. Balanceofbenetsandharms. expensivedruginsomecountries.Inlow-resourcesettings,\nantimalarialuseinSLEincludelowerarerates(including\n24,252427\nonemightconsidersubstitutingitwithstructurallysimilar\nkidney),higherresponseratestotherapy,slower\n28,29\ndrugssuchaschloroquinethathaveasimilarmechanismof\nprogressionofkidneydisease,lowerincidenceofcar-\nactionandarelessexpensive,buttheincreasedriskoftoxicity\ndiovascular(CV)andthromboticeventsinpatientswith\n––\n303328,3438\nofthelattershouldbenoted.",
    "page": 24,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "failure,whileminimizingmedication-associatedtoxicities. (Part 4)",
    "content": "antiphospholipidantibodies,lessorgandamage,\n39,40\nimprovedlipidprole,andbetterpreservationofboneBecauseoftheriskof\nConsiderationsforimplementation. 41\nhemolysisinpatientswhohaveglucose-6-phosphatedehy-\nmass. Hydroxychloroquineuseinpregnancyhasbeenassociateddrogenase(G6PD)deciency,measurementofG6PDlevels\nispreferredinmen,especiallythoseofAfrican,Asian,or\nwithadecreaseinlupusactivityandasatisfactorysafety\nﬁﬁ\n4244\nMiddleEasternorigin,beforestartinghydroxychloroquine. proleinboththemotherandthefetus.Signicantside\nHowever,thisriskappearedlow,accordingtothendings\neffectsareuncommonbutincludeskinrash,increaseinskin\n51\npigmentation,muscleweakness,andvisualchangeorlossofofarecentreport.UpdatedguidelinesfromtheRoyal\nCollegeofOphthalmologistsintheUnitedKingdompub-\nvision.Hydroxychloroquinemayaccumulateinlysosomes\nlishedin2020donotrecommendbaselineexamination\nandcauseaformofphospholipidosiswithaccumulationof\nmultilamellarzebrabodiesinpodocytesthatcanmimicthepriortoinitiatingtreatment(https://www.rcophth.ac.uk/\n45,46\nresources-listing/2609/),andyearlymonitoringshould\nappearanceofFabrydisease. beginafter1yearoftherapyinpatientswithadditionalrisk\nModerate-certaintydatasupport\nCertaintyofevidence. factors(concomitanttamoxifenuse;estimatedglomerular\nthebenetofhydroxychloroquineuseinpatientswithSLE,\nﬁ<\nltrationrate(eGFR)60ml/minper1.73m;doseof\nbutinLN,theavailableevidenceisfromobservational\nhydroxychloroquine5mg/kg/d;useofchloroquine)or\nstudiesandposthocanalyses.Ina24-weekRCTthat\n52\nincluded47patients,theCanadianHydroxychloroquineafter5yearsoftherapyotherwise.Nevertheless,recent\ndatashowedthathydroxychloroquineretinopathyinlong-\nStudyGroupreportedahigherincidenceofSLEaresin\ntermusersismorecommonthanpreviouslyperceived,\npatientswhostoppedhydroxychloroquinecomparedto\nthosewhocontinuedtreatment,withahazardratio(HR)affecting0.5%after6yearsoftreatment,increasingto\n7.5%oflong-termusersingeneral,andcouldbe20%\nof2.50(95%CI:1.085.58).ThefrequencyofsevereLN\nwhentreatmentdurationisover20years.Therecom-\nareswasalsoincreasedbutdidnotreachstatisticalsig-\n47\nmendedstartingdoseofhydroxychloroquineisaround\nnicance.Asystematicreviewthatincluded95reports\npublishedbetween1982and2007,5ofwhichwereRCTs,5mg/kg/d(2.3mg/kg/dforchloroquine).Dosesof\n23mg/kg/dmaynotachieveadequatebloodlevelsand\nconcludedthathydroxychloroquineusecouldpreventSLE\nﬂﬂ\n53,54\naresandincreaselong-termpatientsurvival,whiletoxicitycouldbeassociatedwithhigherarerates.Recentdata\nsuggestedthatabloodhydroxychloroquinelevelabove0.6\nwasinfrequent,mild,andusuallyreversible;andhydroxy-\n55\nmg/lmaybeassociatedwithalowerriskofLNare.In\nchloroquineuseinpregnancywasassociatedwithadecreasein\n48\npatientswitheGFR30ml/minper1.73m,thedoseof\nlupusactivitywithoutharmtothefetus.Low-certainty\nhydroxychloroquineshouldbereducedby25%.Also,\nobservationalstudieshaveindicatedthathydroxychloroquine\nantimalarialsmayrarelybecardiotoxic,manifestingas\nmayhavekidneybenets,mayhaveprotectiveeffectsagainst\nKidneyInternational\nS25\n(2024)105(Suppl1S),S1–S69",
    "page": 24,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 1)",
    "content": "www.kidney-international.org\ncardiomyopathyorconductionabnormalitiesinpatientsAlthoughmanyoftheaboverecommendationsalsoapply\nwithahighcumulativeexposure.topatientswithproteinurickidneydiseasestreatedwith\nimmunosuppressioningeneral(KDIGO2021GDGuideline\nChapter1),somerisksareespeciallyrelevanttopatients\nRationale\nDatafrommultipleobservationalcohortstudiesshowvariouswithSLEandLN.PatientswithSLEshowincreasedmortality\nbenetsofhydroxychloroquinetreatmentinSLE,notablyarateswhencomparedtoage-andsex-matchedcontrolsinthe\n56,57\nreducedincidenceofareandorgandamageaccrual,andageneralpopulation.Infections,cardiovascular(CV)\nrelativelylowrateofdrug-relatedadverseeffects,includingcomplications,andCKD,especiallykidneyfailure,aremajor\n68,58\noculartoxicity.Despitetherelativelylow-certaintyevidence,causesofdeath.Earlydeathsarerelatedtoinfectionsor\ntheoverallbalancebetweenbenetsandpotentialriskspro-lupusactivity,whileCVandmalignantcomplicationsand\n59\nvidesthebasisforrecommendingitsuseaspartofgeneraldeathsrelatedtokidneyfailureaccountforlatemortalities. managementinpatientswithSLE.Patients\nCardiovascularcomplicationsinpatientswithLN. withSLEhavebothtraditional(dyslipidemia,smoking,\nPracticePoint10.2.1.1:AdjunctivetherapiestomanageLNobesity,etc.)andnon-traditional(proteinuria,inammation,\nandattenuatecomplicationsofthediseaseoritstreatmentsetc.)CVriskfactors.Apatientoftenhasmultipleriskfactors,\nshouldbeconsideredforallpatients,asoutlinedinFigure3.whichcanbesecondarytodisease-relatedorgandamage\nRiskRisk attenuation\nCardiovascular risk\n• Dyslipidemia management\n• Low-dose aspirin during pregnancy\n• Blood pressure control\n• Avoid high-sodium diet\nProteinuria and\n• Optimize blood pressure\nCKD progression\n• Renoprotective medications, such as RAAS blockade, SGLT2 inhibitor, etc., in\n(refer to Chapter 1)\nstable patients without AKI\n• Avoid nephrotoxic insult\n• Prevent AKI\n• Assess medical history of herpes zoster and tuberculosis\nInfection risk\n• Screening for HBV, HCV, HIV, and HBV vaccination\nPneumocystis jirovecii\n•  prophylaxis (issue of potential adverse drug reaction\ndiscussed below)\n• Individualized consideration for recombinant zoster vaccine\n• Individualized consideration for other infectious organisms as dictated by\npublic health concerns at the time of treatment\n• Bone mineral density and fracture risk assessment\nBone injury\n• Calcium and vitamin D supplementation\n• Bisphosphonates when appropriate\n• Broad-spectrum sunscreen\nUltraviolet light\n• Limit ultraviolet light exposure\nexposure\n• Gonadotropin-releasing hormone agonists (i.e.",
    "page": 27,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 2)",
    "content": "leuprolide)\nPremature ovarian\n• Sperm/oocyte cryopreservation\nfailure\n• Individual evaluation and counselling for contraception type\nUnplanned pregnancy\n(preference, thrombosis risk, age)\n• Evaluate individual risk factors for malignancies\nCancer\n• Minimize lifetime cyclophosphamide exposure to <36 g\nFigure3|Measurestominimizetheriskofcomplicationsrelatedtolupusnephritisoritstreatment.Note:Chapter1referstoChapter1\noftheKDIGOGuidelineonGlomerularDiseases.AKI,acutekidneyinjury;CKD,chronickidneydisease;HBV,hepatitisBvirus;HCV,hepatitisC\nﬁ–\nvirus;HIV,humanimmunodeciencyvirus;RAAS,reninangiotensin-aldosteronesystem;SGLT2,sodium-glucosecotransporter-2. KidneyInternational\nS26\n(2024)105(Suppl1S),S1–S69\n[Table 1]\nRisk | Risk attenuation\n------------------------------------------------------------\nCardiovascular risk | • Dyslipidemia management\n• Low-dose aspirin during pregnancy\n• Blood pressure control\nProteinuria and\nCKD progression\n(refer to Chapter 1) | • Avoid high-sodium diet\n• Optimize blood pressure\n• Renoprotective medications, such as RAAS blockade, SGLT2 inhibitor, etc., in\nstable patients without AKI\n• Avoid nephrotoxic insult\n• Prevent AKI\nInfection risk | • Assess medical history of herpes zoster and tuberculosis\n• Screening for HBV, HCV, HIV, and HBV vaccination\n• Pneumocystis jirovecii prophylaxis (issue of potential adverse drug reaction\ndiscussed below)\n• Individualized consideration for recombinant zoster vaccine\n• Individualized consideration for other infectious organisms as dictated by\npublic health concerns at the time of treatment\nBone injury | • Bone mineral density and fracture risk assessment\n• Calcium and vitamin D supplementation\n• Bisphosphonates when appropriate\nUltraviolet light\nexposure | • Broad-spectrum sunscreen\n• Limit ultraviolet light exposure\nPremature ovarian\nfailure | • Gonadotropin-releasing hormone agonists (i.e. leuprolide)\n• Sperm/oocyte cryopreservation\nUnplanned pregnancy | • Individual evaluation and counselling for contraception type\n(preference, thrombosis risk, age)\nCancer | • Evaluate individual risk factors for malignancies\n• Minimize lifetime cyclophosphamide exposure to <36 g\n\nlupusnephritis\nwww.kidney-international.org\n(especiallyCKD,hypertension,proteinuria)ortreatmentconicting.VaccinationagainstSARS-CoV-2isrecommended\n(suchasglucocorticoidsandcalcineurininhibitors[CNIs]).ingeneral,althoughtherehavebeenanecdotalreportsofnew\nRegularevaluationofvariousriskfactorsandtimelytreat-onsetoraresofimmune-mediateddiseasesfollowing\n6067\nmentareessentialtopreventprematureCVcomplications.exposuretomRNACOVID-19vaccines. InfectionisaleadingcauseofCKDiscommoninpatientswithLNdue\nInfectionsinpatientswithLN.CKDprogression.",
    "page": 27,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 3)",
    "content": "68,69\ndeathinpatientswithLN,andinfection-relateddeathsaretothekidneyaresthatreducenephronmass.Inaddition\nmorecommonduringtheinitialphaseofmanagementtotreatmentandpreventionofactiveLN,itisimportantthat\nfollowingexposuretointensiveimmunosuppressivether-measurestoreducetherateofkidneyfunctiondeterioration\n49,56,61\napy.Therearedatatosuggestahigherincidenceofbeincludedaspartofholisticmanagement,suchasoptimal\nadverseoutcomesrelatedtoinfectionsinAsia,whichmaybebloodpressurecontrol,theuseofrenoprotectivemedications,\n61\nrelatedtodelayedpresentationandtheaccesstocare.avoidanceofnephrotoxicinsults,andpreventionofcircum-\nAvoidanceofoverimmunosuppressionisanimportantmea-stancesthatmayresultinacutekidneyinjury(AKI). suretoreducetheriskofinfectionsandadverseoutcomes.Pregnancyinpatientswith\nContraceptionandpregnancy.",
    "page": 27,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 4)",
    "content": "Pneumocystispneumoniaisaseriouscomplicationinpa-LNisassociatedwithincreasedmaternalcomplicationsand\ntientswhoareimmunosuppressedandcanresultinfatality.inferiorfetaloutcomescomparedwiththeoccurrencein\nProphylaxisshouldbeactivelyconsidered,takingintohealthyindividuals,andtherisksarehigherwhenLNis\nconsiderationapatientsallergicdiathesisandavailableal-active.Someofthefrequentlyusedmedicationsinpatients\nternatives.ProphylaxisforPneumocystisisstandardpracticeinwithlupusarecontraindicatedduringpregnancy,suchas\norgantransplantrecipients,butitsroleinpatientsonhigh-mycophenolatemofetil(MMF),cyclophosphamide,and\ndoseglucocorticoidtherapywithouthumanimmunode-warfarin.Counselingwithregardtocontraceptionand\nciencyvirus(HIV)infectionremainscontroversial,andtherepregnancyshouldbedoneearlyinpatientsofchildbearing\n2,62\narefewdatafrompatientswithSLE.Antibiotic-relatedage.Thechoiceofmethodsforcontraceptionshouldbe\nadversedrugreactionsarenotinfrequentinpatientswithdiscussed,andifnecessary,theopinionofagynecologist\nlupus,andinanearlysurvey,31%reportedallergytosul-shouldbesought.Forpatientswhopreferoralhormonal\nﬁ–\nfonamide,withone-fthofthesepatientsalsoreportingcontraception,estrogenprogestincontraceptiveswithethinyl\n63\nworseningofSLEwiththedrugintolerance.Inaretro-estradioldosenothigherthan30gmaybeusedinpatients\nspectivestudyfromThailandthatincluded132patientswithwhoarenegativeforantiphospholipidantibodiesandwith\nvariousconnectivetissuediseases,trimethoprim-sulfameth-stablelowdiseaseactivity,whereasprogestin-onlycontra-\noxazole(TMP-SMX)waseffectiveinpreventingpneumo-ceptivesarepreferableinpatientswithamoderateorhigh\ncystispneumonia,andadversedrugreactionoccurredinonlylevelofdiseaseactivity.Estrogen-containingcontraceptives\n64\n9.4%ofpatientswithSLEgivenprophylaxis.However,ashouldbeavoidedinpatientswithantiphospholipidanti-\nrecentretrospectivestudyfromJapanreportedanadversebodiesorahistoryofthrombosis,inviewoftheriskof\n70\ndrugreactionrateof41.9%inpatientswithlupusgivenTMP-thromboembolism.Datafromwomenexposedtochemo-\nSMXprophylaxiswithconventionaldosing,butonly10.7%therapyshowedefcacyofgonadotrophin-releasinghormone\ninthosewithgradualintroductionofthedrugovera9-day(GnRH)analogsinreducingtherateofprematureovarian\n65\nperiod.Pentamidineinhalationcanbeusedinpatientsfailure,whereastheputativegonadalprotectiveeffectoforal\n71\nwhoarenotsuitableforTMP-SMX.Alternativesecond-linecontraceptivepillsappearedvariable.Fertilityprotection\nagentsincludedapsoneandatovaquone.withGnRHagonists,orspermandoocytecryopreservation,\nResponsetovaccinationisreducedfollowingexposuretoshouldbeconsideredinpatientstreatedwithcyclophospha-\nhigh-doseimmunosuppressionwithglucocorticoid,myco-mide,especiallyinpatientswithhighcumulativeexposure. 66\nphenolate,orrituximab.VaccinationforthepreventionofGlucocorticoidtherapy,especiallywhenhigh\nBonehealth.",
    "page": 27,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 5)",
    "content": "72,73\nhepatitisBinfectionisrecommended,especiallyinendemicdosesareusedforlongdurations,increasesboneloss.In\nregions.TherateofHerpeszosteris210timeshigherinchildren,glucocorticoidcumulativedoseaffectspeakbone\n74\npatientswithSLEthaninhealthycontrols.Availablezostermassandgrowth.Individualevaluationoffractureriskcan\nvaccinepreparationsincludethelive-attenuatedvaccinebeestimatedusingpatientdemographicsandclinicalhistory,\n(cid:3)\nZostavaxandtheadjuvantedrecombinantvaccineShingrix.glucocorticoiddose,andtheFractureRiskAssessmentTool\n75,76\nIngeneral,livevaccinesshouldbeavoidedinimmunosup-(FRAX)score.Calcium(optimalintake10001200mg/d)\npressedsubjects.WhilesomeguidelinesrecommendtheuseandvitaminDsupplementationarerecommendedforpa-\nofrecombinantzostervaccineinimmunodecientortientswithLN,aswellasconsiderationfororalbisphosph-\n77,78\nimmunosuppressedpatients,includingpatientswithSLE,onatesaccordingtoindividualriskassessment. therearecontroversialdataonwhetherthevaccinemightPatientswithSLEhave\nMalignanciesinpatientswithLN. ﬂ’\nprecipitateaareofimmune-mediateddiseasesinasmallincreasedriskofmalignanttumors,includingnon-Hodgkins\nnumberofpatients,andastudyinvestigatingitsefcacyandlymphoma,lung,liver,vulvar/vaginal,thyroid,nonmelanoma\nsafetyinpatientswithSLEisongoing.Thereisalsoconcernskincancer,andtherisk(especiallywithbladdercancer)is\nthatthepoliovaccinationhasbeenassociatedwithlupusincreasedinpatientswithahistoryofexposuretocyclophos-\nﬂﬂ\n79,80\nares,whereasthedataoninuenzavaccinationarephamide.Ingeneral,thesurveillanceformalignanciesin\nKidneyInternational\nS27\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\npatientswithLNfollowsthecancer-screeningpoliciesforthemorelimited,butthereappearstobeasignicantriskof\n93\ngeneralpopulationinthelocalcommunity,andspecicma-relapseafterglucocorticoidsaretapered.Althoughoptimal\nlignancyscreeningguidelinesforpatientswithSLEareeitherdurationisnotknown,maintenancewithlow-dosegluco-\n81\nlackingorlargelyopinion-based.Althoughthereisevidencecorticoidplusanadditionalagentsuchasmycophenolicacid\nshowingefcacyandsafetyofhumanpapillomavirusvaccinesanalogs(MPAA),azathioprine,oraCNIissuggested,espe-\ninpatientswithSLE,thedevelopmentofSLEorlupus-likeciallyinpatientswithahistoryofrelapse. 82,83\ndiseasefollowingvaccinationhasbeenreported.",
    "page": 27,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 6)",
    "content": "10.2.3ClassIIIorClassIVlupusnephritis\n10.2.2ClassIorClassIIlupusnephritis\n10.2.3.1InitialtherapyofactiveClassIII/IVlupusnephritis\nPracticePoint10.2.2.1:Approachtoimmunosuppressive\nRecommendation10.2.3.1.1:Werecommendthat\ntreatmentforpatientswithClassIorClassIILN(Figure4)\npatientswithactiveClassIIIorIVLN,withor\nPatientswithClassIorClassIILNgenerallyhavenormal\nwithoutamembranouscomponent,betreated\nkidneyfunction,oratmost,low-gradeproteinuriathatiswell\none\ninitiallywithglucocorticoidsplusanyofthe\nbelowthenephroticrange,andsometimesmicroscopiche-\nfollowing:\nmaturia.Forthesepatients,nospecicimmunosuppressive\n(1B)\ni.mycophenolicacidanalogs(MPAAs);or\ntherapybeyondwhatisbeinggivenfornonrenallupusis\n(1B)\nii.low-doseintravenouscyclophosphamide;or\n84\nneeded. iii.belimumabandeitherMPAAorlow-dose\nPatientswithClassIorIIhistologybutwithnephrotic-\n(1B)\nintravenouscyclophosphamide;or\nrangeproteinuriaornephroticsyndrome(NS)areconsid-\niv.MPAAandacalcineurininhibitor(CNI)when\neredtohavelupuspodocytopathy.Thisdiagnosismaybe\nkidneyfunctionisnotseverelyimpaired(i.e.,\nﬁ£\nconrmedbydemonstratingdiffusepodocyteeffacementon\nestimatedglomerularltrationrate[eGFR]45\n(1B). ml/minper1.73m)\nelectronmicroscopy.Clinicalandhistologicmanifestationsof\npatientswithpodocytopathyaresimilartothosewithmini-\nmalchangedisease(MCD)orfocalsegmentalglomerulo-\nThisrecommendationplacesahighvalueonresultsfromclinical\nsclerosis(FSGS),andtheyoftenshowagoodresponseto\ntrialsdemonstratingclinicalefcacywithcombinedimmuno-\n8587\nglucocorticoidtreatment.Althoughtherehavebeenno\nsuppressiveregimensthatincludeglucocorticoidsandeitherlow-\nRCTs,observationaldatashowedthatover90%ofpatients\ndoseintravenouscyclophosphamideorMPAA(dualimmuno-\ngivenglucocorticoidmonotherapyachievedremissionwithin\nsuppressivetherapy),aswellastripleimmunosuppressiveregi-\n85,8892\namediantimeof4weeks.Dataonrelapseareeven\nmensthatincludebelimumaborvoclosporin(ortacrolimus)\nKidney biopsy showing\nClass I/II lupus nephritis\nemordnys citorhpeNairunietorp level-woL\nEvaluate for lupus podocytopathy\n(electron microscopy would be useful)\nTreat as minimal change disease\n(Chapter 5)\nImmunosuppressive treatment\nConsider maintenance combination\nguided by extrarenal manifestations\ntherapy with low-dose glucocorticoid\nof systemic lupus erythematosus\nand another immunosuppressive agent\nFigure4|ImmunosuppressivetreatmentforpatientswithClassIorClassIIlupusnephritis.Note:Chapter5referstoChapter5ofthe\nKDIGOGuidelineonGlomerularDiseases.",
    "page": 27,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 7)",
    "content": "KidneyInternational\nS28\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\naddedtotheabovedualimmunosuppression.InthecaseofCNI,intolerabilityofMPAA.Also,concomitanthigh-dosegluco-\ntheimprovedclinicalresponsewasdrivenbygreaterreductionofcorticoidscontributedtomanytreatment-associatedadverse\n12,14,100102\nproteinuriacomparedwithplacebo,andinthecaseofbelimumab,events.Basedongenerallyfavorablereal-world\nareducedincidencerateofadversekidneyoutcomeswasalsoclinicalexperience,combinedimmunosuppressionwithglu-\nobservedinposthocanalysis.AsummaryofoptionsofinitialcocorticoidsandMPAAiswidelyusedasinitialtreatmentof\ntherapythatcanberecommendedforactiveproliferativeLNisproliferativeLN. showninFigure5.TheWorkGroupacknowledgestheconsider-CNIsreduceIL-2transcriptionandTlymphocyteprolif-\nablevariationofcharacteristicsamongpatients.Readersareerationandhaveadirectmodulatoryeffectonpodocyte\nadvisedtorefertothepracticepointsfordiscussionsonthecytoskeleton,therebyreducingproteinuriaduetopodocyte\npreferredchoiceoftherapyaccordingtopatientcharacteristics.injury.Theadditionofxed-dosetacrolimustolow-dose\nAlso,regardingthechoiceoftherapyandthedoseofspecicMPAAandglucocorticoidsinatripleimmunosuppressive\n“”\nmedications,theWorkGroupemphasizestheimportanceofregimen(termedmultitargetedtherapy)wasinvestigatedin\n19,103105\npreventingpotentialadverseeffectsthatcouldresultfromhigh-Chinesepatients.Aprospectivestudyincluding40\n(cid:3)\ndoseglucocorticoid,high-dosecyclophosphamide,andCNILN(ClassIVV)patientsfromChinademonstratedhigher\n–“\nnephrotoxicity.Inthisregard,patientswithCKDG3bG5were24-weekresponseratesinpatientstreatedwiththemulti-\noftenexcludedfromtherespectiveclinicaltrials.targetregimencomparedwithhigh-dosecyclophosphamide\n103\nandglucocorticoids.Thesendingswerelatercorroborated\ninatrialof368ChinesepatientswithactiveLNandbaseline\nKeyinformation\nTheshort-termprognosisofserumcreatinine(SCr)3mg/dl(265mol/l;translatingto\nBalanceofbenetsandharms. patientswithproliferativeLNimproveddramaticallywhenaneGFRlevelofaround25ml/minper1.73m),showinga\ntreatmentwithhigh-doseglucocorticoidswasstartedinthe\nhighercompleteresponserateat6monthsinthetriple\n94\n1960s.However,thelong-termkidneyprognosiscontinuedimmunosuppressiveschemethanwithcyclophosphamide,\n19\ntobepoor,asmanypatientsprogressedtokidneyfailurethoughwithnumericallyhighernumbersofadverseevents. despitetreatment.Inlandmarkstudiesduringthe1980s,theYet,continuedfollow-updatashowedsimilarcumulative\nadditionofcyclophosphamidetoglucocorticoidswasshowntoresponseratesat24monthsbetweenpatientswhocontinued\nbesuperiortotreatmentwithglucocorticoidsaloneinpre-tripletherapyandcontrolstreatedwithsequentialcyclo-\n13,9598\nservinglong-termkidneysurvivalinactivesevereLN.phosphamideinductionfollowedbyazathioprine\n106\nDualimmunosuppressiveregimenscomprisingglucocorti-maintenance.",
    "page": 27,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 8)",
    "content": "coidsandcyclophosphamidewerestandard-of-careinitialAtripleimmunosuppressiveregimenofvoclosporinadded\ntherapyforactiveproliferativeLNfordecades.Butthesignif-tostandard-doseMPAAandarapid-taperingregimenof\nicantincidenceofadverseeffects,duetothehighglucocorti-glucocorticoidswastestedinphase2(AuriniaUrinaryPro-\ncoiddoseandthetoxicitiesofcyclophosphamide,promptedteinReductionActive-LupuswithVoclosporin[AURA-LV])\ninvestigationofalternativeinductionregimens.andphase3(AuriniaRenalResponseinActiveLupuswith\nSubsequentinvestigationsaimedtoimprovetheriskVoclosporin[AURORA1])multinationalstudiesthat\nﬁ>\nbenetratiooftreatment.Astudyof90patientsofEuro-includedpatientswithbaselineeGFR45ml/minper1.73\n2107,108\npeandescentwithactiveLNshowedthat,whencomparedtom.Theresponseratesat24and52weekswerehigher\nhigh-dosecyclophosphamide,areduced-dosecyclophospha-invoclosporin-treatedgroupscomparedwithplacebo,with\nmideregimenwasassociatedwithnostatisticallysignicantallpatientsreceivingMPAAplusrapid-taperingglucocorti-\ndifferenceinefcacybothshort-andlong-termandancoids.Anexcessivenumberofsevereadverseevents,\n17,99\nimprovedside-effectprole.Inashort-termtrialthatincludingdeaths,wasnotedinvoclosporin-treatedpatients\nincluded100patientsfromIndia,reduced-dosecyclophos-onlyinthephase2trialandwasthoughttobeacentereffect. phamideshowedsimilarefcacytothatofMPAAwhenbothPooledphase2andphase3datashowednostatisticallysig-\n100109\nwerecombinedwithglucocorticoids.Inviewofthescarcitynicantdifferenceintheincidenceofadverseevents.Pa-\nofdataonreduced-dosecyclophosphamideinpatientsoftientswhocompletedthephase3trialwereeligibleto\nAfricanorHispanicdescent,thereisconcernastowhethercontinueonthesameblindedtherapyina2-yearcontinua-\nthisregimeniseffectiveinthesepatientgroups.Figure6tionstudy(AURORA2;116of179patientsinthevoclosporin\n110\nshowsthedetailsofcyclophosphamide-dosingregimens.armand100of178patientsinthecontrolarm).Results\nFollowingestablishmentofefcacyinpreventingfromthecompletedAURORA2ContinuationStudyshowed\norgantransplantrejection,MPAAwereinvestigatedinLNsustainedreductionofproteinuriawithvoclosporintreat-\nandwasshowntohaveefcacysimilartothatofcyclo-ment,andstablekidneyfunctioninbothgroups,withno\n100,101\nphosphamideintreatingactiveLN.Thedoseistypicallysafetysignal.Theimprovedtreatmentresponserateinpa-\nMMF23g/d(orequivalentforMPAA).TherateofadversetientstreatedwithCNIswasmainlydrivenbyearlierand\neventsinpatientstreatedwithglucocorticoidsandMPAAmoreeffectivesuppressionofproteinuria,whilethefollow-up\nappearednotsignicantlyreducedcomparedwiththatofdatatodateshowedsimilarkidneyfunctionintheCNI-\ncyclophosphamideinclinicaltrialswithMMFdoseof3g/d,treatedgroupversuscontrols.Theimpactoftheadditionof\nsuggestingadoseeffectandpossibleracialorethnicvariationaCNIonlong-termkidneysurvivalremainsunclear.",
    "page": 27,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 9)",
    "content": "KidneyInternational\nS29\n(2024)105(Suppl1S),S1–S69\nlS\nKidney biopsy showing\nClass III/IV ± V lupus nephritis\nConcomitant thromboticAssess activity and\nmicroangiopathychronicity items\n(Section 10.3.1)\nChronic Class III/IV ± V lupus nephritis\nActive Class III/IV ± V lupus nephritis\nwithout activity\nSupportive treatmentIf concomitant Class V\nfor chronic kidney diseasemanage as Class V\n(Section 10.2.4)\nGlucocorticoids\nMethylprednisolone i.v. 0.25–0.50 g/d for 1–3 days as appropriate\ndepending on disease severity and rate of progression, then\nprednisone p.o. at approximately 0.35–1.0 mg/kg/d\n(not to exceed 80 mg/d) and taper over a few months to\nmaintenance dose (the lower steroid dosing option referring\nto the reduced-dose regimen in the voclosporin trials)\n(Practice Point 10.2.3.1.1)\nand one of the\nfollowing options\nCNI + MPAAMycophenolic acidCyclophosphamide Belimumab + MPAA or\nVoclosporin 23.7 mg b.i.d. and MPAA in patients\nanalogs (MPAA)for up to 6 monthsreduced-dose cyclophosphamide\nwith eGFR >45 ml/min per 1.73 mi.v. 500 mg q2wk × 6 orBelimumab (i.v., 10 mg/kg q2wk for\n2for at least 6 months\nMMF p.o. 1.0–1.5 g b.i.d. or0.5–1.0 g/m monthly × 6;3 doses then q4wk) and MPAA or i.v. Tacrolimus (trough level approximately 5.5 ng/ml\nmycophenolic acid sodiumor p.o. 1.0-1.5 mg/kg/dcyclophosphamide 500 mg q2wk × 6\n[6.8 nmol/l], data mainly from Chinese patients)\n0.72–1.08 g b.i.d.for 3 months(Practice Point 10.2.3.1.5)\nand reduced-dose MPAA in patients with SCr\n(Practice Point 10.2.3.1.3)(Practice Point 10.2.3.1.2)\n<3.0 mg/dl (265 μmol/l) as initial andBelimumab duration up to 2.5 years\nmaintenance therapy\nConsider cyclosporine when voclosporin\nand tacrolimus are not available\n(Practice Point 10.2.3.1.4)\nCNI duration up to 3 years\n‡(",
    "page": 27,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Figure5|RecommendedapproachforinitialtherapyofactiveClassIII/IVlupusnephritis.Cautioniswarrantedwhencalcineurininhibitors(CNI)areusedinpatientswithsignicantly",
    "content": "impairedkidneyfunction,inviewofincreasedsusceptibilityforsevereconsequencesduetoCNInephrotoxicity.Theestimatedglomerularltrationrate(eGFR)andserumcreatinine(SCr)5\n†‡",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 1)",
    "content": "lupusnephritis\nwww.kidney-international.org\nHigh-dose intravenousLow-dose intravenousOral cyclophosphamide\ncyclophosphamidecyclophosphamide\n(NIH regimen)(Euro-Lupus regimen)\ni.v. 0.5–1 g/m monthly forp.o. 1.0–1.5 mg/kg/d (maxi.v. 500 mg every 2 weeks\nCyclophosphamide2\n6 months150 mg/d) for 2–6 monthsfor 3 months\nComments\nCaucasian patients, with\nethnicitiessome data from patients\nof African or Caribbean\ndescent, Hispanic descent,\nIndian patients, and other\nAsian countries\nFigure6|Cyclophosphamidedosingregimens,combinedwithglucocorticoids,ininitialtreatmentforactiveClassIII/IVlupus\nnephritis.i.v.,intravenous;max,maximum;NIH,NationalInstitutesofHealth,USA;p.o.,oral. AbnormalBlymphocytehyperreactivityisacharacteristicobservationalstudiessuggestedthathigherratesofresponse\nfeatureinthepathogenesisofSLE.B-cellactivatingfactortoinductiontherapymaytranslateintobetterlong-term\n(BAFF,alsoknownasBlymphocytestimulatororBLyS)isakidneysurvival,butthedatawerefromtreatmentregimens\n15,99,115118\ncytokineexpressedincellswithB-celllineageandactsasathatdidnotincludeaCNI. potentBcellactivator.Belimumab,ahumanmonoclonalInsummary,ClassIIIandClassIVLNareseverediseases\nantibodythatinhibitsBAFF,wasapprovedbytheUnitedthatresultinAKIthatleadstopermanentnephronlossifnot\nStates(U.S.)FoodandDrugAdministration(FDA)forthetreatedpromptlywitheffectivetherapeuticregimens.SevereLN\ntreatmentofSLEin2011basedonefcacydemonstratedinisanimportant,buttreatable,causeofpatientmorbidityand\nclinicaltrials.Theadditionofbelimumabtoglucocorticoidsmortalityinmanypartsoftheworld.Advancesintherapyhave\npluseitherstandard-doseMPAAorlow-dosecyclophospha-resultedinincreasedefcacyandreducedincidenceofadverse\nmidefollowedbyazathioprineinatripleimmunosuppressiveevents;thelattercouldbeduetodiseaseorthetoxicitiesof\nregimenwasevaluatedinamultinationalphase3trial(Ef-treatments.Attemptstoreducemedicationsideeffects,espe-\ncacyandSafetyofBelimumabinPatientswithActiveLupusciallythoseduetoglucocorticoidsandcyclophosphamide,have\nNephritis[BLISS-LN])of448patientsobservedover104beenmodestlysuccessful.Despitethepotentialofimportant\n111\nweeks.Patientstreatedwithbelimumabhadsuperiorpri-treatment-associatedtoxicities,thebenetsoftreatingprolif-\nmaryefcacyrenalresponserate(PERR,acompositeend-erativeLNclearlyoutweighthepotentialharms. pointwithproteinuria0.7g/g[70mg/mmol])comparedInthe6RCTsthatcomparedi.v. Certaintyofevidence.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 2)",
    "content": "toplacebo,whileallpatientsreceivedstandarddualimmu-cyclophosphamidewithglucocorticoids,therewasmoderate\nnosuppression.The2groupsshowedsimilarratesofadversecertaintyofevidenceforakidneybenetanddecreasein\nevents.Resultsfromasecondaryanalysisandanopen-labelkidneyrelapse.ThecertaintyoftheevidencefromtheseRCTs\nextensionstudyof28weeksshowedthattheefcacyadvan-wasdowngradedtomoderatebecauseofstudylimitations\ntagewasmaintained,andpatientstreatedwiththe(unclearblindingofparticipantsandpersonnel,unclearallo-\n13,95,96,101,119121\nbelimumab-containingtripleimmunosuppressiveregimencationconcealment;SupplementaryTableS5). 112,113\nhadlowerratesofadversekidneyoutcomes.SubgroupHigh-doseversuslow-dosecyclophosphamidehasbeen\n11417,121124\nanalysisof142EastAsianpatientsshowedsimilarndings.comparedinafewRCTs(SupplementaryTableS6). WhileintravenousbelimumabwasusedintheBLISS-LNTheresultsfromthesetrialsindicatethatlow-dosecyclo-\ntrial,theU.S.FDAapprovedboththeintravenous(i.v.)andphosphamideisassociatedwithfeweradverseevents(suchas\n121\nsubcutaneous(s.c.)routesofbelimumabtreatmentforLNininfection,malignancy,leukopenia,andbonetoxicity;\nDecember2020,thelatterbasedonpharmacokineticsalthoughinsomestudies,theefcacyalsoappearedlower\nmatchingthatshowedsimilarexposurebetweenthe2thanthatofthehigh-doseregimen),withmoderatecertainty\nadministrationrouteswithahighertroughlevelwhengivenoftheevidencebecauseofseriousimprecision(onlyafew\nsubcutaneously.events,resultinginwidecondenceintervals[CIs]indicating\nItisimportanttonotethat,whiletherewerelong-termappreciablebenetandharm). datafromcontrolledtrialsshowingthatcyclophosphamideFromtheRCTs,thereismoderatecertaintyintheevidence\ncombinedwithglucocorticoidsasinitialtherapyforactiveLNthatMMFexhibitsasimilarefcacy,andadifferentside-\nﬁﬁ\nwasmoreefcaciousthanglucocorticoidsaloneinpreservingeffectprolecomparedwithi.v.cyclophosphamide.The\nkidneyfunction,long-termdataarerelativelyscarceforthecertaintyoftheevidencewasdowngradedtomoderate\notherregimens,especiallyforthemorerecenttreatmentsbecauseofunclearreportingofallocationconcealmentin\n––\n96,9712,100102,121,125128\nsuchasCNIandbelimumab.Inthisregard,datafromtrials(SupplementaryTableS7). KidneyInternational\nS31\n(2024)105(Suppl1S),S1–S69\n[Table 1]\n | High-dose intravenous\ncyclophosphamide\n(NIH regimen) | Low-dose intravenous\ncyclophosphamide\n(Euro-Lupus regimen) | Oral cyclophosphamide\n------------------------------------------------------------\nCyclophosphamide | i.v. 0.5–1 g/m2 monthly for\n6 months | i.v. 500 mg every 2 weeks\nfor 3 months | p.o.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 3)",
    "content": "1.0–1.5 mg/kg/d (max\n150 mg/d) for 2–6 months\nComments | ethnicities | Caucasian patients, with\nsome data from patients\nof African or Caribbean\ndescent, Hispanic descent,\nIndian patients, and other\nAsian countries | \n\nlupusnephritis\nwww.kidney-international.org\nThereislow-certaintyevidencethattripleimmunosup-showedsustainedreductionofproteinuriaandstablekidney\npressiveregimensthatincludetacrolimus,reduced-dosefunctionduringfollow-up,withnoincreaseinadverseevents\n110\nMPAA,andglucocorticoidsaresuperiortostandard-of-carecomparedwithcontrols.TheoptimaldurationofCNI\nregimenswhenusedasinitialtherapy,withsimilarincidencetreatmentforLNremainsuncertain,andthereareinsufcient\n19,103,104,121\nofadverseevents(SupplementaryTableS8).Theredataonsubsequenttaperingordiscontinuation,andclinical\nishigh-certaintyevidenceshowingthattripletherapywithoutcomesthereafter. voclosporin,standard-doseMPAA,andrapid-taperinggluco-Inadditiontoincreasingthetherapeuticresponserate,post\ncorticoidsissuperiortoMPAAandrapid-taperingglucocor-hocanalysisshowedthataddingbelimumabtoMPAAor\nticoidsinachievingrenalresponse(mainlydrivenbymorecyclophosphamideandglucocorticoidsmayconferfurther\neffectivesuppressionofproteinuria)withsimilarincidenceofbenetsofreducingrenalrelapsesandtherateofadverse\n107,108,129\nadverseevents(SupplementaryTableS9andkidneyoutcomes,andtheeGFRvaluewasnumericallyhigher\n19,103,104,107,108\nSupplementaryTableS10).Thelong-termeffectinpatientstreatedwithbelimumabcomparedwithplacebo. ﬁﬁ\nofCNI-containingimmunosuppressiveregimensinLNonPosthocanalysisshowedthattheefcacybenetinLN\npreservationofkidneyfunction(50%lossofGFRorkidneyassociatedwithbelimumabtreatmentwasdrivenbypatients\nfailure)stillneedstobedemonstrated(Supplementarywithbaselineurineprotein-creatinineratio(PCR)3g/g\n19,103,104,107,108113\nTableS10).(300mg/mmol).Whetherthiscouldberelatedtothe\nThereismoderate-certaintyevidenceshowingthataddingincreasedclearanceofbelimumabinpatientswithheavy\nbelimumabtoMPAAorreduced-dosecyclophosphamideandproteinuriaremainstobeinvestigated.Resultsfromanin-\nglucocorticoidsresultsinhigherrenalresponserateswithdependentanalysisoftheBLISS-LNdatabytheU.S.FDAalso\nsimilarincidenceofadverseeventscomparedwithplacebo,showedthattheefcacyofbelimumabwasdrivenbypatients\nandlow-certaintyevidenceforaneffectofbelimumabinwithlowerlevelsofproteinuriaatbaseline,butposthoctime-\nrenalrelapsepreventionandreductionofadversekidneyto-eventanalysisofthehighproteinuriagroup(3g/g\n111,113,130\noutcomes(SupplementaryTableS11).[300mg/mmol])suggestedthattheestimatedriskofa\nWithouttreatment,theprognosiskidney-relatedeventordeathwaslowerinthebelimumab\nValuesandpreferences.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 4)",
    "content": "131\nforkidneysurvivalinpatientswithproliferativeLNispoor.group.Resultsfromthe28-weekopen-labelextensionof\nWell-informedpatientswithClassIIIandIVLNwouldtheBLISS-LNstudyshowedcontinuedincreaseinthepro-\nnormallychoosetobetreatedwithoneoftheimmunosup-portionsofpatientsachievingPERRorcompleterenal\npressiveregimenswithprovenefcacyasoutlinedpreviously,response,andnosafetysignal,associatedwithbelimumab\n112\nandpatientsshouldbeinformedofthesevereriskoftreatment. decliningornotadheringtotreatment.GiventherisksofDespitethesebeingposthocanalysisorextensionstudy\ninfertilityassociatedwithcyclophosphamideandthespectraresults,theWorkGroupattributesvaluetotheseobserva-\nofpotentialmalignancies,mostpatientsofchildbearingtions,whicharerelevanttooptimizingthechoiceoftherapies\nagewhoanticipateconceivinginthefuture,andmosttomatchdifferentpatientcharacteristics. patients,ingeneral,willlikelyoptforinitialMPAAoverManagementofactiveLNwith\nResourceuseandcosts. cyclophosphamide-basedtreatment.Low-dosei.v.cyclo-immunosuppressionisresource-andlabor-intensive\nphosphamidehaslessriskthanhigh-doseandisareasonablebecausethemedicationsandthesurveillanceforpotential\nalternativetoMPAA,butbecausethedatafavoringlow-dosecomplicationsarecostly.Accesstoappropriatetherapiesis\ncyclophosphamidehavelargelycomefromWhitepatientsessentialtopreventadverseclinicaloutcomes,includingthe\nwithmildtomoderatelysevereLN,thisalternativemaynothightreatmentcostforkidneyfailure.Intravenousadmin-\nbeappropriateforthetreatmentofsevereLNinpatientsofistrationrequiresaninfusioncenterwithsupervision,and\n17\nAfricanorHispanicancestry.patientsmustbemonitoredfrequentlyfortreatment-or\nTripleimmunosuppressiveregimensthatincludeaCNI,disease-relatedcomplicationsandrequirefrequentclinical\ntogetherwithMPAAandglucocorticoids,maybeparticularlylaboratorytesting.However,itislikelythatthesecostsare\nusefulforpatientswithhigh-gradeproteinuriaassociatedlowerovertimethanthoseassociatedwithmanagingCKD\nwithextensivepodocyteinjury.Cautionisrecommendedandkidneyfailureresultingfromnotreatment,althougha\nwiththeuseofthisregimeninpatientswithimpairedkidneydirecteconomicanalysishasnotbeendone.Furthermore,\nfunctionand/orsignicantchronicdamageinkidneybiopsy.therehavebeennocomparisonsofqualityoflifebetween\nInthevoclosporintrials,patientswithbaselineeGFR45ml/patientswithCKD,patientswithkidneyfailurereceiving\nminper1.73mwereexcluded,andthiseGFRthresholdiskidneyreplacementtherapy,andpatientsreceivingimmu-\nalsoincludedintheregulatoryapprovalforthedrug.Inthenosuppression,especiallywithhigh-doseorprolonged\n“”\nclinicaltrialonChinesepatientswiththemultitargetadministrationofglucocorticoids.MPAAregimenswere\nregimenthatincludedxed-dosetacrolimus,reduced-doseassociatedwithhighermedicationcostsbutlowerfacility\nMPAA,andglucocorticoids,patientswerecontinuedonthiscostsandasuperiorqualityoflifecomparedtoi.v.cyclo-\n132134\nregimenforupto2years.Theprimaryendpointinthephasephosphamideregimens.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 5)",
    "content": "3voclosporintrialwasassessedat1year,andresultsfromaAdditionofathirddrug(CNIorbelimumab)increasesthe\n135\nfurther2-yearextensiononthesameblindedtreatmentcostsoftherapy,whilethepotentialincreaseincomplete\nKidneyInternational\nS32\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\nresponseratesandpreventionofrenalrelapsesmaybecost-minper1.73m,andthesepatientswereexcludedfromthe\n136141\nsaving.Accesstotreatment,costbarriers,andcostoftrials.Similarly,inatrialinvestigatingthetripleimmu-\nadditionalmonitoringsuchasbloodlevelmeasurementsarenosuppressiveregimenofglucocorticoidsandreduced-dose\nadditionalfactorstoconsider.ThisWorkGroupadvocatesMMFandxed-dosetacrolimusinChinesepatients,pa-\nindividualizedchoiceoftreatmentregimen,includingtientswithabaselineSCr3mg/dl(265mol/l)were\n19\ninformeddiscussionswithpatients,tosuituniquepatientexcluded.Theoverallresultssuggestthatkidneyfunction\ncharacteristics.remainedrelativelystablewheneithervoclosporinortacro-\nInviewofthesignicantlimuswasusedatthereporteddosesintheselectedpop-\nConsiderationsforimplementation. 134,137,138\ntreatmentcosts,thechoiceoftherapyisoftenulationsforadurationof23years. region-specicanddependsondrugavailability,reimburse-Withregardtothedurationoftreatment,reduced-dose\nmentpolicies,andthenancialmeansofindividualpatients.cyclophosphamideisgivenfor12weeks,whereashigh-dose\nOtherconsiderationswhenchoosinginitialtherapyforLNcyclophosphamideisnormallygivenforupto6months,\nincludelikelihoodofadherence,age,priorimmunosuppres-andMPAAcanbecontinuedaftertheearlytreatmentphase\nsiveexposure,diseasetempoandseverity,andraceandasmaintenanceimmunosuppression.CNIscanbeusedas\nethnicity.long-termmaintenanceimmunosuppression,butvigilanceto\nPhysiciansmaychooseani.v.regimenifsuboptimalpreventnephrotoxicityiswarranted.Resultsfromthe2-year\nadherenceisanticipated.Ageisanimportantfactorwithcontinuationstudy(AURORA2)suggestedthatvoclosporin\nrespecttopreservationoffertility,assusceptibilitytogonadaltreatmentfor3yearswassafeinpatientswithLNwhose\nfailureaftercyclophosphamideuseincreaseswithageandbaselineeGFRwas45ml/minper1.73m.Resultsfromthe\ncumulativeexposure.FuturesusceptibilitytomalignanciesBLISS-LNopen-labelextensionstudysuggestedsafetyof\nincreaseswithhigherlifetimecyclophosphamideexposure,socontinuingbelimumabtreatmentforaround2.5years.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 6)",
    "content": "adetailedknowledgeofpriortherapiesisimportant.Many\nphysiciansmaystillchoosehigh-dosecyclophosphamidefor\nRationale\npatientsinwhomkidneyfunctionisrapidlydeterioratingandClassIIIorIVLNisanaggressivediseasethatrequiresprompt\nwhosebiopsyshowssevereactivity(e.g.,capillarynecrosis,anandeffectivetherapytoabateongoinginjuryanddestructionof\nabundanceofcrescents).Itshouldbenotedthattherearenormalnephrons.Immunosuppressivetreatmenttargetsthe\nsparsedataonthisgroupofpatientswhopresentwithactiveinammatorylesionsinkidneyhistopathology,incontrast\naggressivedisease,astheirclinicalcharacteristicsprecludedtothechroniclesions,whosenumberportendsthelikelihoodof\nthemfrominclusioninclinicaltrials.PhysicianscaringforCKDandlong-termkidneyprognosis. patientsofmixedethnicbackgroundorHispanicethnicityThechoiceofinitialtreatmentforClassIIIorIVLNen-\nmaychooseMPAAovercyclophosphamideastherearesometailspersonalizedconsiderationofthebalancebetween\nﬁﬁ\n139,140\nposthocanalysisdatasuggestingithashigherefcacy,benetandriskandisinformedbydataonshort-term\nwhereasphysicianscaringforChinesepatientsmaywanttoresponseandlong-termefcacyandsafety,potential\nchooseMPAAandglucocorticoids,ortripleimmunosup-adverseeffects,includinginfectionsandcumulativetoxicities,\npressionwithglucocorticoidspluslow-doseMPAApluslow-qualityoflife,andfactorsrelevanttopatientexperienceand\ndoseCNI,asopposedtoacyclophosphamide-basedadherence. 19,106\nregimen.PatientandkidneysurvivalratesinClassIIIandClassIV\nﬁﬁ\nBasedonbenet-versus-riskconsiderations,theinclusionofLNhaveimprovedsincethe1970s,rstwiththeuseofglu-\nCNIinthetreatmentregimenmaybepreferredinpatientscocorticoids,andsubsequentlyfollowingtheadoptionof\nwithhigh-levelproteinuriaduetopodocyteinjuryandwithoutcombinedimmunosuppressiveregimenswithcyclophospha-\nﬁ(cid:3)\nsignicantlyimpairedkidneyfunction,whiletheinclusionofmideorMPAACNIorbelimumabasstandardtherapy. belimumabmaybepreferredinpatientstreatedwithMPAAinGlucocorticoidsremainanintegralcomponentininitial\ncontrasttocyclophosphamide,andwhenpreventionofdiseasetherapyforClassIIIandIVLNbasedontheiranti-\nﬂﬂ\naresandadversekidneyoutcomesassumeshighprioritysuchinammatoryandimmunosuppressiveactions.Theaddition\nasinpatientswithsignicantCKD.Notethattherearenodataoftheotherimmunosuppressantswasassociatedwithlower\nonvoclosporingiventogetherwithcyclophosphamide.Also,relapseratesandimprovedlong-termkidneysurvival\nresultsfromvoclosporintrialssuggestthatinclusionofaCNIcomparedwithglucocorticoidtreatmentalone.Combined\nmightfacilitaterapidglucocorticoidtapering.Inaddition,re-immunosuppressiveregimensalsofacilitateglucocorticoid\nsultsfromposthocanalysissuggestedthatbelimumabmightminimization,therebyreducingtheiradverseeffects\nnotbeaseffectiveinpatientswhopresentwithheavypro-(Figure7). teinuriainthenephroticrange.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 7)",
    "content": "TheuseofCNIinpatientswithsevereCKDrequiresPracticePoint10.2.3.1.1:Aregimenofreduced-doseglu-\ncarefulindividualizedconsiderationofriskversuspotentialcocorticoidsfollowingashortcourseofmethylpredniso-\nbenet,andshouldbedonewithcautionandcarefulmoni-lonepulsesmaybeconsideredduringtheinitialtreatment\ntoring,andatreduceddrugexposure.VoclosporinisgenerallyofactiveLNwhenboththekidneyandextrarenaldisease\nnotrecommendedforpatientswithabaselineeGFR45ml/manifestationsshowsatisfactoryimprovement(Figure7). KidneyInternational\nS33\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\nHigh-dose schemeModerate-dose schemeReduced-dose scheme\nNil or 0.25–0.5 g/day up to 3 days0.25–0.5 g/day up to 3 days often0.25–0.5 g/day up to 3 days usually\nMethylprednisolone\nas initial treatmentincluded as initial treatmentincluded as initial treatment\nintravenous pulses\nOral prednisone\nequivalent (/day)\nWeek 0–20.8–1.0 mg/kg (max 80 mg)0.6–0.7 mg/kg (max 50 mg)0.5–0.6 mg/kg (max 40 mg)\nWeek 3–40.6–0.7 mg/kg0.5–0.6 mg/kg0.3–0.4 mg/kg\nWeek 5–630 mg20 mg15 mg\nWeek 7–825 mg15 mg10 mg\nWeek 9–1020 mg12.5 mg7.5 mg\nWeek 11–1215 mg10 mg5 mg\nWeek 13–1412.5 mg7.5 mg2.5 mg\nWeek 15–1610 mg7.5 mg2.5 mg\nWeek 17–187.5 mg5 mg2.5 mg\n2.5 mg\nWeek 19–207.5 mg5 mg\nWeek 21–245 mg<5 mg2.5 mg\nWeek >25<5 mg<5 mg<2.5 mg\nFigure7|Examplesofglucocorticoidregimensforlupusnephritis.max,maximum.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 8)",
    "content": "Glucocorticoidsareusedinallcurrenttreatmentregimensglucocorticoidpulsesfollowedbyalowerstartingdoseand/or\nforLN.Thesedrugshavebothimmunosuppressiveandanti-more-rapidtaperingoforalglucocorticoidinrecentclinical\n107\ninammatoryeffectsandprovideimmediatetreatmentfortrials.Resultsfromaretrospectivepropensityanalysisof\ntheoften-extensiveintrarenalinammationthatisseenindatafrom63patientsenrolledintheAsprevaLupusMan-\npatientswithClassIIIandClassIVLN.ThisregimenisagementStudy(ALMS)andthephase2AURA-LVtrialsug-\nnecessarybecausethereisalagbeforetheimmunosuppressivegestedthatdosesofglucocorticoidsandMPAAlowerthan\neffectsofcyclophosphamide,MPAA,CNIs,orBcelldirectedthoseadoptedinALMSmayresultinbetterlong-termsafety,\ntherapiesareseen.Thedose,taperingregimen,anddurationincludingareductioninlymphoproliferativedisorders,skin\n142\nofglucocorticoidschemesvaryconsiderablyamongclinicianscancers,andglucocorticoid-relatedsideeffects.Inchildren,\nandarelargelyopinion-based.ExamplesaregiveninFigure7.theavoidanceofexcessiveglucocorticoidexposurealsohas\nInviewoftheestablishedefcacyassociatedwithcombinedimplicationsforgrowth,psychosocialissues,anddrug\n143\nimmunosuppression,thereisamovetowardsreducingadherence.Withaccumulatingdataontheefcacyand\nglucocorticoidexposure.glucocorticoid-sparingroleofimmunosuppressivemedica-\nTheroleofi.v.methylprednisolonepulsesatthestartoftionssuchascyclophosphamide,MPAA,andtripleimmuno-\ntreatmenthasnotbeenwell-studied,buti.v.glucocorticoidis\nsuppressivedrugcombinations,thereisamovetoward\ncommonlygivenasupto3dailydosesof500mgeach(rangereducingexposuretoglucocorticoids(Supplementary\n144146\n2501000mg/d).Thereisgeneralagreementtostarttreat-TableS12).Examplesofdosingandtaperingregimens\nmentwithi.v.pulsemethylprednisoloneinpatientswhoininitialtreatmentofLN,basedonpublishedliteratureand\npresentwithaclinicalsyndromeofrapidlyprogressiverecentclinicaltrialsthatinvestigatetheefcacyandsafetyof\nglomerulonephritis(RPGN)acuteandseveredeteriorationnewtherapeuticagents,areshowninFigure7.Theyserveto\nofkidneyfunctionoftenaccompaniedbyahighproportionillustratevariationsinexposuretoglucocorticoidsovertime.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 9)",
    "content": "ofcrescentsorvascularlesionsinthekidneybiopsyorwhenThecertaintyofevidencesupportinganyoftheseregimensis\ntherearesevereextrarenalmanifestations,suchascentrallowastheyhaveonlybeencomparedinrelativelysmallclinical\n144146147\nnervoussystemorlunginvolvement.Incontrast,opinionstrialsandobservationalstudies.Theuseofreduced-\nvaryontheuseofi.v.methylprednisoloneinpatientswithdoseglucocorticoidsmaydecreasetheincidenceofmajor\nmilderdiseasemanifestations.AsshowninFigure7,high-infectionsandotheradverseeffects.Accumulatingevidence\ndoseglucocorticoidschemesinearlierclinicaltrialscouldshowsthatreducingglucocorticoidexposureincombined\nstartwithnoi.v.methylprednisolonebutwithhigh-doseoralimmunosuppressiveregimensisfeasibleinthetreatment\nprednisone,whileglucocorticoidschemesadoptedinmoreofLN,withmaintainedefcacywhilereducingtheglucocorti-\n146,148\nrecentclinicaltrialsoftenbeganwithi.v.methylprednisolonecoid-relatedtoxicities. pulsesfollowedbyoralprednisoneatarelativelylowerdose\nandmore-rapidtapering.Also,presentlyitisunusualforthePracticePoint10.2.3.1.2:Intravenouscyclophosphamide\ndailyprednisonedosetoexceed60mg.canbeusedastheinitialtherapyforactiveClassIIIand\nTominimizethesideeffectsduetohighcumulativeexpo-ClassIVLNinpatientswhomayhavedifcultyadheringto\nsuretoglucocorticoids,thereisincreasinguseofinitiali.v.anoralregimen. KidneyInternational\nS34\n(2024)105(Suppl1S),S1–S69\n[Table 1]\n | High-dose scheme | Moderate-dose scheme | Reduced-dose scheme\n------------------------------------------------------------\nMethylprednisolone\nintravenous pulses | Nil or 0.25–0.5 g/day up to 3 days\nas initial treatment | 0.25–0.5 g/day up to 3 days often\nincluded as initial treatment | 0.25–0.5 g/day up to 3 days usually\nincluded as initial treatment\nOral prednisone\nequivalent (/day)\nWeek 0–2\nWeek 3–4\nWeek 5–6\nWeek 7–8\nWeek 9–10\nWeek 11–12\nWeek 13–14\nWeek 15–16\nWeek 17–18\nWeek 19–20\nWeek 21–24\nWeek >25 | 0.8–1.0 mg/kg (max 80 mg)\n0.6–0.7 mg/kg\n30 mg\n25 mg\n20 mg\n15 mg\n12.5 mg\n10 mg\n7.5 mg\n7.5 mg\n5 mg\n<5 mg | 0.6–0.7 mg/kg (max 50 mg)\n0.5–0.6 mg/kg\n20 mg\n15 mg\n12.5 mg\n10 mg\n7.5 mg\n7.5 mg\n5 mg\n5 mg\n<5 mg\n<5 mg | 0.5–0.6 mg/kg (max 40 mg)\n0.3–0.4 mg/kg\n15 mg\n10 mg\n7.5 mg\n5 mg\n2.5 mg\n2.5 mg\n2.5 mg\n2.5 mg\n2.5 mg\n<2.5 mg\n\nlupusnephritis\nwww.kidney-international.org\n––\n1315,102,121,125128\nCyclophosphamidemaybegivenorallyorintravenously,renalresponses(SupplementaryTableS7). ﬁﬁ\nandinahighdose(alsoknownasthemodiedNationalMMFhassignicantgastrointestinaltoxicity,andat\nInstitutesofHealth[NIH]regimenorhigh-doseregimen)ormoderate-to-highdoses,somepatientsmaynottolerateit.In\nlowdose(alsoknownastheEuro-Lupusregimen).Examplespatientswithgastrointestinalintolerance,atrialofenteric-\nofdosinganddurationfortheseregimensaregivenincoatedmycophenolicacid(MPA)inadoserangeof1440\nFigure6.2160mgiswarranted,inviewofitsgreatergastrointestinal\n146\nThechoiceofwhichregimentousedependsonseveraltolerance.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 10)",
    "content": "factorsandcanbeindividualized:AlthoughuseofMPAAdoesnotpredisposepatientsto\nEfcacy:Oralandhigh-dosei.v.cyclophosphamideregimensgonadalfailureorhematologicmalignanciesasdoescyclo-\n(cid:4)\nhavebeenusedindiverseethnicpopulationsandforalllevelsphosphamide,theALMStrial(targetdose3g/d)showeda\n18,149152\nofdiseaseseverity,andshowequivalentefcacy.similarincidenceofsideeffectsbetweenpatientstreatedwith\nLowdosecyclophosphamide(Euro-Lupusregimen)showsMMFplusglucocorticoidsandpatientstreatedwithcyclo-\n12\nefcacyequivalenttothatofstandard-dosecyclophospha-phosphamideplusglucocorticoids.Inthistrial,9deaths\n17,99\nmidebutwastestedmainlyinWhitepatients.EmergingoccurredintheMMFgroup,and5inthecyclophosphamide\ndatasuggestlow-dosecyclophosphamideiseffectiveingroup.Sevenofthe9deathsintheMMFgroupweredueto\nAsians,Hispanics,andBlackpatients,butthesestudiesdidinfections,and7ofthe9deathsinMMF-treatedpatients\nnotmakedirectcomparisonstohigh-dosei.v.cyclophos-occurredinAsia.Concomitanthigh-doseglucocorticoidsand\n17,121124,153\nphamide(SupplementaryTableS6).therelativelyhighMPAexposurehavebeenproposedas\nCost:Intravenouscyclophosphamideismoreexpensivecontributoryfactorstothehigher-than-expectedinfection-\n(cid:4)\nthanoralandrequirestheavailabilityofaninfusionsuiterelatedadverseoutcomesinthistrial.Inthisregard,data\nandexperiencedstaff.fromkidneytransplantclinicaltrialsshowedthat,compared\nConvenience:Oralcyclophosphamidedoesnotrequirepa-withanMMFdoseof2g/d,anincreasedMMFdoseof3g/\n(cid:4)\ntientstocometothehealthcarefacilityforregulardrugddidnotresultinahigherefcacyinthenon-Blackpatient\n155\ninfusionsbutresultsinrapidincreaseincumulativepopulation,butwasassociatedwithmoreadverseevents. exposure.Therefore,considerationoftheraceorethnicityofapa-\nToxicity:Thetoxicitiesofcyclophosphamidemaybecons-tient,orthegeographiclocality,mayalsoberelevantwhen\n(cid:4)\nsideredimmediate(e.g.,gastrointestinal,susceptibilitytodecidingonthedoseofMPAAtobeused,inviewofthe\ninfection)ordelayed(e.g.,lossoffertility,futurepotentialdifferencesinriskprolesamongpatients. malignancies).MPApharmacokineticsvariesconsiderablyamongpatients,\nHigh-dosei.v.cyclophosphamidewasshowntobelessespeciallyinthecontextofhypoalbuminemiaandimpaired\ntoxicthanoralcyclophosphamide,butthedoseandkidneyfunction.Datafromsmall-scalestudiessuggestedthat\ndurationoforaltreatmentinthesereportsweresub-anMPAareaundertheconcentration-versus-timecurveof\n––\nstantiallyhigherandlongerthanthosecurrentlyrecom-3545mgh/loratroughlevelof3.04.5mg/lmayserveto\n13,154\nmended(SupplementaryTableS13).Theincidenceensureadequateexposureduringinitialtherapy,buttherole\nofbladdertoxicityisalsofelttobelowerwithi.v.oftherapeuticdrug-levelmonitoringremainstobeestab-\n156160\ncyclophosphamide.Reduced-dosei.v.cyclophosphamidelished. hasthemostfavorableimmediatetoxicityproleamongMMFhasbeentestedsuccessfullyindiverseethnicgroups.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 11)",
    "content": "ﬁﬁ\nthe3cyclophosphamideregimens.AmoregranularlookattheefcacyofMMFinspecicethnic\nTheriskoffuturehematologicmalignancyisrelatedtogroupswasdonethroughaposthocanalysisofdatafromthe\n>ﬁ>\ntotallifetimeexposure(36g),asismyelobrosis(80g).ALMSstudy,thelargesttrialcomparingMMFtoi.v.cyclo-\n12,139\nTotallifetimeexposureplusageconstitutesasignicantphosphamidetodate.Theanalysisshowedhigher\n>–\nriskfactorforprematureovarianfailure(7.515g/mfortreatmentresponseratesforMMFcomparedtocyclophos-\nyoungtoolderpediatricpatients,respectively;300mg/kgphamideinHispanicpatients(60.9%vs.38.8%,P0.011)\nforadults).andpatientsfromLatinAmerica(60.7%vs.32%,P0.003),\nInviewofitstoxicities,includingtheincreasedriskofwhereastheresponsetoMMFwasnumericallyhigherbutnot\nmalignancies,theexposuretocyclophosphamideshouldbestatisticallydifferentthanthattocyclophosphamideinBlack\nminimizedtotheextentpossible.patients(53.9%vs.40.0%,P0.39).Ahigherresponserate\ntoMMFthantocyclophosphamideinHispanicpatientswas\n140\nPracticePoint10.2.3.1.3:AnMPAA-basedregimenisthealsoreportedincohortstudies.Incontrast,theresponse\npreferredinitialtherapyofproliferativeLNforpatientsatratetocyclophosphamidewasnumericallyhigherbutnot\nhighriskofinfertility,suchaspatientswhohaveastatisticallydifferentthanthattoMMFinAsianpatients\n12,139\nmoderate-to-highpriorcyclophosphamideexposure.(63.9%vs.53.2%,P0.24).Notwithstandingthese\nTrialsofMMFforinitialtreatmentofproliferativeLNhaveresults,bothMPAAandcyclophosphamideareeffective\ntargeteddosingof23g/d.SeveralstudieshaveshownthattherapiesforactiveLN. ﬁﬁ\nMMFhascomparableshort-termefcacytothatoforalorCyclophosphamidehashistoricallybeentherst-choice\ni.v.cyclophosphamideforinductionofcompleteandpartialtreatmentforverysevereproliferativeLN.Ananalysisof\nKidneyInternational\nS35\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\npooleddatafromvariousclinicaltrialsofpatientswithClassOfimportance,inthelargeChinesestudy,thenumberof\nIII/IVLN,crescentsin15%ofglomeruli,andabnormalSCrinfectionswashigherinpatientswhoreceivedtripletherapy\nlevelatpresentationshowedacomparableearlyresponsetothanthatinthosewhoweretreatedwithcyclophosphamide,\n161\nglucocorticoidspluseithercyclophosphamideorMMF.althoughthisdifferencedidnotreachstatisticalsignicance. However,theanalysisalsosuggestedthatinitialtreatmentMoredataarealsorequiredontheincidenceofacuteand\nwithcyclophosphamidemightbeassociatedwithamoresus-chronicCNInephrotoxicity,themetabolicsideeffectsof\ntainedresponseandmorefavorablelong-termkidneyoutcomeCNIsandtheireffectonbloodpressurecontrol,aswellasthe\nthaninitialtreatmentwithMMF.Inthemaintenancephaseofoptimaldurationoftreatmentandwhethertheremaybea\n16163\nALMS,althoughthedifferencewasnotstatisticallydifferent,reboundofproteinuriaafterstoppingCNIs.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 12)",
    "content": "patientsinitiallytreatedwithcyclophosphamidehadnumeri-Voclosporinisananalogofcyclosporinethatexhibits\ncallylowerratesofdiseasearecomparedwiththoseinitiallyenhancedpotencyincalcineurininhibition.Voclosporinwas\ntreatedwithMMF.noninferiortotacrolimusinthepreventionofbiopsy-proven\nacuterejectionina6-monthmulticenteropen-labelphase2b\nPracticePoint10.2.3.1.4:Initialtherapywithanimmuno-trialthatinvolved334low-riskkidneytransplantre-\n164\nsuppressiveregimenthatincludesaCNI(voclosporin,cipients.Voclosporinforthetreatmentofactivebiopsy-\ntacrolimus,orcyclosporine)maybepreferredinpatientsprovenClassIII,IV,andVLNwasinvestigatedinthe\n107\nwithrelativelypreservedkidneyfunctionandnephrotic-AURA-LVtrial,aphase2RCTof265subjectsandthe\n108,165\nrangeproteinurialikelyduetoextensivepodocyteinjury,AURORA1trial,aphase3RCTof357subjects.Both\naswellaspatientswhocannottoleratestandard-dosetrialsincludedpatientsofdiverseancestry.Voclosporinwas\nMPAAorareuntfororwillnotusecyclophosphamide-comparedtoplacebo,andallpatientsreceivedglucocorticoids\nbasedregimens.andMMF(targetdose:2g/d)asbackgroundtherapy.The\nCNIsarepotentimmunosuppressivemedicationsduetorapidlytaperedcorticosteroidregimenusedwasnovel.All\ntheirinhibitionofTlymphocyteactivationandreleaseofpatientsreceived2dosesofi.v.methylprednisolone(500mg/\ninterleukin-2.Theyalsomodulatethepodocytecytoskeleton,dose)followedby2025mgprednisonethatwasrapidly\nleadingtoreductionofproteinuriainvariousglomerulartaperedto2.5mg/dby16weeks.Theprimaryendpointof\ndiseases.TheuseofaCNIinthetreatmentofLNmaythesetrialswasrenalresponse(RR),denedasurine\n#$\nthereforeleadtomoreeffectiveormorerapidreductionofPCR0.5mg/mg[50mg/mmol],eGFR60ml/minper\nproteinuria.1.73m,ornodeclineof20%frombaseline,andpredni-\n–<\nDatafromshort-termstudieswithfollow-upof612sonedoseof10mg/dforthe8weekspriortoendpoint\nmonthssuggestthataregimenofglucocorticoidscombinedmeasurement. withcyclosporineortacrolimus,withorwithoutreduced-InAURA-LV,33%ofpatientstreatedwithvoclosporin\ndoseMPAA,asinitialLNtherapyhascomparableefcacy23.7mgtwiceperdayreachedanRRat24weekscomparedto\n19,162,163\ntoglucocorticoidscombinedwithcyclophosphamide.19%ofplacebo-treatedpatients(oddsratio[OR]2.03,\n107\nUntilrecently,mostofthesetrialshadbeendoneinAsia(seeP0.05).Similarly,inAURORA,41%ofvoclosporin-\nPracticePoint10.2.3.1.5).Thelargesttrial,conductedintreatedpatientsachievedRRat52weeks,comparedto23%\nﬁ<\n108,165\nChina,combinedaxed,relativelylowdoseoftacrolimus(4ofplacebo-treatedpatients(OR2.65,P0.001).A\n––\nmg/d,achievedtroughlevelsof5.25.5ng/ml[6.46.8nmol/pooledanalysisofthe2trialsshowedthatpatientstreated\nl])withlow-doseMMF(1g/d)inpatientswithabaselineSCrwithvoclosporinaddedtostandardtherapyhadanRRrateof\n#<\nlevel3.0mg/dl(265mol/l),andreportedearlierattain-44%at1year,comparedto23%inplacebopatients(P\n166\nmentofrenalresponsethanthatincontrolstreatedwiththe0.0001).Theincidencesofadverseeventsweresimilar\nNIH-cyclophosphamideregimen,withahighercompletebetweentheplaceboandvoclosporinarms.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 13)",
    "content": "renalresponserate(46%vs.26%)after24weeksoftreat-ComparedtootherCNIs,suchascyclosporineand\n19\nment.Extendedfollow-up,however,showedcomparabletacrolimus,voclosporinhasamoreconsistent\nrenalresponseratesinbothgroupsduringthesecondyearofpharmacokineticpharmacodynamicrelationshipdueto\n106\ntreatment.Similarly,astudyfromJapanreportedacom-enhancedbindingofthevoclosporincyclophilincomplexto\npleteresponserateof80%after6monthsoftreatmentwithacalcineurinandreduceddrugandmetaboliteload.Pre-\ntripleimmunosuppressiveregimenthatincludedglucocorti-liminaryevidence,basedondatafromtheAURA-LVand\n162\ncoids,reduced-dosecyclophosphamide,andtacrolimus.AURORAtrials,suggeststhattherapeuticdrugmonitoringis\n167\nTheevidencefromthefewRCTsthatcomparedtriplenotnecessaryinthestudiedpatientpopulation.Notethat\ntherapytocyclophosphamideisjudgedashavinglowcer-therearenodataonvoclosporingiventogetherwith\ntaintybecauseofstudylimitationsandindirectnesscyclophosphamide.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 14)",
    "content": "19,103,104,121\n(SupplementaryTableS8).AstheseearlytrialsResultsfromthepivotaltrialsledtotheU.S.FDAapproval\nmainlyincludedpatientsofAsianethnicity,andsomeofvoclosporintotreatadultpatientswithLNinJanuary\nexcludedpatientswithseveredisease,thegeneralizabilityof2021.Ofnote,voclosporinisnotrecommendedforpatients\nthistherapytothebroaderLNpopulationisunclear(seealsowithabaselineeGFR45ml/minper1.73m,andthese\nPracticePoint10.2.3.1.5).patientswereexcludedfromthetrials.Similarly,signicant\nKidneyInternational\nS36\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\nimpairmentofkidneyfunctionisoftenanexclusioncriterion20%belowbaselineoratleast60ml/minper1.73m,andno\ninclinicaltrialsofCNIs.TheuseofaCNIinpatientswithuseofrescuetherapyfortreatmentfailure.Atweek104,\nsevereCKDrequirescarefulindividualizedconsiderationofsignicantlymorepatientswhoreceivedbelimumabachieved\nriskversuspotentialbenet,andshouldbedonewithcautionaPERRcomparedtothenumberofpatientswhoreceived\nandcarefulmonitoring,andatreduceddrugexposure.placebo(43%vs.32%;OR1.60;P0.03;Supplementary\n111\nThepositiveresultsofAURA-LVandAURORAcoupledTableS11).Keysecondaryendpointsincludedcomplete\nwiththoseoftheAsianstudiesoftacrolimusandcyclosporinerenalresponseandtheriskofkidneyeventordeath.These\nsuggesttripleimmunosuppressivetherapyincorporatingaalsofavoredbelimumab.Subgroupanalysisshowedthatthe\nCNIcanbeaneffectivetreatmentregimenforLN.AnoverallPERRresponsewasdrivenbytheresultsinthelarger\nadvantageofaCNI-basedregimenisthemorerapidreduc-subgroup(73.5%)ofpatientswhoreceivedMMFasback-\ntionofproteinuria.However,outstandingissuesonthegroundtherapy.Belimumabtreatmentwasnotassociated\ndurationoftheCNI,itstaperingandsuspension,andthewithexcessadverseevents.Inthiscontext,extendedfollow-\nlong-termefcacyandsafetyofCNItripletherapyregimensupdatafromopen-labelcontinuationstudiesinpatients\nremainunderstudy.withSLEshowednonewsafetyconcernswhenbelimumab\n174,175\nAdualimmunosuppressiveregimenthatincludedtacro-wasusedfor813years.Althoughnotdirectlytestedin\nlimusandglucocorticoidswascomparedwithMPAAandtheBLISS-LNtrial,subcutaneousbelimumabhasbeenshown\nglucocorticoidsinastudyconductedinHongKong.Onetoachievesimilarexposuretointravenous.Subcutaneous\n176178\nhundredftypatientswererandomizedtotacrolimus(targetbelimumabisadministeredat200mgweekly.An\n>>\ntroughlevel5ng/ml[6.2nmol/l])orMPAAplusgluco-importantobservedeffectofbelimumabtherapyinthe\n113\ncorticoids,andcompleteresponseratesat6monthswereBLISS-LNtrialwasthepreventionofdiseaseares.The\nsimilarinthetacrolimusandMPAAgroups(62%vs.59%),\nfollow-upfor2yearsandanopen-labelfollow-upforan\nwhiletheproleofadverseeventswasdifferent,withhigheradditional6monthsreportedbetterpreservationofkidney\nHerpeszosterinfectionsinMPAA-treatedpatients(18%vs.functionandreducedincidenceofadversekidneyoutcomes\n168\n3%).Thisstudyalsoshowedahighincidenceofrenalwhenbelimumabwasaddedtostandard-of-care\n111,112\nrelapseswhentheseinductionagentswerediscontinuedaftertherapy.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 15)",
    "content": "6monthsandsubstitutedwithazathioprineformaintenance.Inposthocsubgroupanalysisofthisstudy,theefcacy\nﬁﬂﬁ\nAstatisticallynonsignicanttrendofmorediseasearesandbenetofbelimumabappearedrestrictedtopatientswho\nkidneyfunctiondeclinewassuggestedinpatientstreatedwithreceivedMMFversuscyclophosphamide,andtopatientswith\ntacrolimusduringtheinductionphase.Theevidenceforef-proteinuriainthenon-nephroticrange.Also,thosewhoself-\nﬁﬁ\ncacyforthistrialisconsideredtobeoflow-to-verylowidentiedasBlackrace(63ofatotalof446patientsinthe\n101,126,168170\ncertainty(SupplementaryTableS14).Datafromtrial)appearedtohavealowertreatmentresponserate\n10-yearfollow-upreportedahigherincidenceofkidneyarescomparedwithotherracialgroups,whiletheresponseratewith\n111,113\ninpatientstreatedwithtacrolimusduringtheinductionphasebelimumabaddedwashighercomparedwithplacebo. (53%vs.34%),whilelong-termkidneyfunctionwassimilar\n170\nbetweenthe2groups.Amorerecentopen-labelclinicalPracticePoint10.2.3.1.6:Othertherapies,suchasazathi-\ntrialrandomized314patientstotacrolimus(targettroughoprineorleunomidecombinedwithglucocorticoids,may\n––inlieu\nlevel410ng/ml[512.4nmol/l])ori.v.cyclophosphamidebeconsideredoftherecommendedinitialdrugsfor\nandreportednon-inferior6-monthresponsesbetweenproliferativeLNinsituationsofpatientintolerance,lackof\ngroups,withsimilarratesofadverseevents(Supplementaryavailability,and/orexcessivecostofstandarddrugs,but\n171173173\nTableS15).thesealternativesmaybeassociatedwithinferiorefcacy,\nincludingincreasedrateofdiseasearesand/orincreased\nPracticePoint10.2.3.1.5:Atripleimmunosuppressiveincidenceofdrugtoxicities. regimenofbelimumabwithglucocorticoidsandeitherAzathioprinecombinedwithmethylprednisolonepulses\nMPAAorreduced-dosecyclophosphamidemaybeshowedacomparableshort-termrenalresponseratetothat\npreferredinpatientswithrepeatedkidneyaresorathigh-forprednisolonecombinedwithhigh-dosei.v.cyclophos-\nriskforprogressiontokidneyfailureduetoseverechronicphamideinastudythatincluded87patientsinthe\nkidneydisease.Netherlands,buttheazathioprineandpulsemethylprednis-\nAphase3RCTofbelimumab(10mg/kgi.v.ondays1,15,olonegrouphadmoreinfections,andtheirextendedfollow-\nand29,thenevery28daystoweek100)addedtostandard-of-updatashowedahigherrelapserateandgreaterprogression\n13,179,180\ncaretherapyresultedinapprovalofbelimumabforLNbytheofCKD(SupplementaryTableS16).Nonetheless,\n111\nU.S.FDAinDecember2020.Thistrial,BLISS-LN,exam-somepatientsmaynottolerateMPAA,cyclophosphamide,or\ninedthe2-yearPERRwhenbelimumaborplacebowasaddedCNIs,orthesedrugsmaybeunavailable,toocostlyinsome\ntostandard-of-caretherapy,whichwaseitherMMFortheregionsoftheworld,orcontraindicated,asinpregnant\nEuro-Lupuslow-dosecyclophosphamideregimenchosenbypatients.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 16)",
    "content": "ﬁﬂ\nthesiteinvestigator.PERRwasdenedasaratioofPCRShort-termstudiesinChinesepatientscomparedleu-\nof0.7g/g[70mg/mmol],aneGFRthatwasnoworsethannomideagainsti.v.cyclophosphamide,inbothcases\nKidneyInternational\nS37\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\ncombinedwithglucocorticoids,andreportedcomparablesteroid-sparingisattempted(SupplementaryTables\n141,153,189,191,195198\nrenalresponseratesofapproximately70%after6S20S23). 181,182\nmonths.ItshouldbenotedthatleunomidemaycauseOngoingclinicaltrialscontinuetoinvestigatetheroleof\nbirthdefectsandhasalongeliminationhalf-lifeofover2biologicsforthetreatmentofLN.Arecentphase2study\nweeks,anditsactivemetaboliteishighlyboundtoplasmashowedthatinadultpatientswithactiveproliferativeLN\nproteins,sopatientswhohavetakenleunomidemuststoptreatedwithMPAAandglucocorticoids,theadditionof\ntreatmentforatleast2yearsbeforetryingtoconceive.obinutuzumabresultedinhighercompleterenalresponse\nﬁﬁ¼\nOthertherapiesthathavenotshownsignicantbenetratesatweek76(40%vs.18%,P0.007),andatweek104\nwhenaddedtostandardtherapyincludeplasmapheresiscomparedtoplacebo(54%vs.29%,P0.005).Therateof\n18,62,183186\n(SupplementaryTableS17),andtheanti-interleukin-seriousadverseeventsandseriousinfectionsdidnotdiffer\n187192\n6antibodysirukumab(SupplementaryTableS18).However,betweenthe2groups. inaphase2atrial,laquinimodwasassociatedwithahigherrenalAnifrolumabisahumanmonoclonalantibodythatbinds\nresponserate(62.5%comparedwith33.3%intheplacebotothetypeIinterferonreceptorunit1andhasbeenrecently\ngroup)whenaddedtostandard-of-caretreatmentwithgluco-approvedbytheU.S.FDAfortreatmentofnonrenalSLE.Ina\ncorticoidsandMMFinpatientswithactiveLN(Supplementaryphase2clinicaltrialthatrandomized147patientstoabasic\n188\nTableS19).(anifrolumab300mg),intensied(anifrolumab900mg),or\nplaceboaddedtoMPAAstandard-of-caretherapy,ani-\nPracticePoint10.2.3.1.7.Newerbiologicandnon-biologicfrolumabwasassociatedwithnumericallyhigherrenal\ntherapiesareunderdevelopmentandmayofferfutureresponserate(45.5%vs.31.1%inplacebogroup).Aspo-\noptionsforthetreatmentofactiveLN.Rituximabmaybetentialbenetofanifrolumabwassuggestedbyexploratory\nconsideredforpatientswithpersistentdiseaseactivityorendpointsofresponse,aphase3trialisongoing\ninadequateresponsetoinitialstandard-of-caretherapy.(NCT02547922).",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 17)",
    "content": "Resultsfromphase2andphase3clinicaltrialsdidnotInsummary,thereareaccumulatingdataonthebiological\nﬁ–ﬁ\ndemonstratesuperiorityinefcacywhenBcelltargetingandclinicalefcacyofvariousbiologicandnon-biologic\ntherapies(rituximab,ocrelizumab),costimulatoryblockadetherapies.Althoughlong-termresultsareawaited,resultson\n(abatacept),oranti-interleukin-6monoclonalantibodywerethesenewdrugshaveexpandedthearmamentariumof\naddedtostandardinitialtherapyofglucocorticoidsandeithertherapeuticoptionsandpotentialcombinationsoftreat-\n141,189193\nMMForcyclophosphamide.Thenegativeoutcomesments.Thefavorablesafetyproleassociatedwithsomeof\ncontrastwithreportsofcaseseriesthatsuggestedefcacythenewdrugspresentsadistinctadvantage.Furtherin-\nﬁﬁ\nwhenpatientswithsuboptimalresponsetostandardtherapyvestigationsarenecessarytodenetheprolesandcharac-\n194197\nweretreatedwithrituximab.Interestingly,patientsteristicsofpatientswhowouldbenetmostfromeachofthe\ntreatedwithrituximabandabataceptintheRCTsshowedvariousnoveltherapies. moreeffectivesuppressionofanti-double-strandeddeoxy-\nribonucleicacid(dsDNA)levelsandcomplementactivation,\n10.2.3.2MaintenancetherapyforClassIIIandClassIVlupus\nbutthisbiologicalefcacydidnottranslatetoconventional\nnephritis\n141,189\nclinicalindicatorsoftreatmentresponse.Reasonsfor\ntheapparentdiscrepancybetweenbiologicalefcacyversus\nRecommendation10.2.3.2.1:Werecommendthat\nclinicalobservations,andbetweenthecaseseriesversusRCT\naftercompletionofinitialtherapy,patientsshould\nresults,includethedifferentpopulationsofpatientsstudied,\n(1B)\nbeplacedonMPAAformaintenance. theoutcomeparametersusedinthetrials,andtherelatively\nshortdurationofobservationinthetrials.Sometrialsusing\nThisrecommendationplacesahighvalueonthedatademon-\nbiologicshaveyieldedencouragingresults.Forexample,ina\nstratingthatlong-term,reduced-doseMPAAdecreasetheriskof\nprospectivesingle-centerpilotstudytoinvestigatewhether\nLNrelapsecomparedtoazathioprineornotreatmentandthat\nrituximabcouldfacilitatecorticosteroidavoidance,50pa-\n(cid:3)\nMPAAhaveeffectivenesscomparabletothatofcyclophospha-\ntientswithactiveLN(22ClassV,28ClassIII/IVV)were\nmidebutwithalowerriskofadverseevents.Therecommen-\ntreatedwithrituximab1gandmethylprednisolone500mg\ndationplacesalowervalueontheriskofadverseevents\ni.v.onday1andday15andweremaintainedonMMF\nassociatedwithlong-termMPAAtreatmentascomparedtono\n(maximumdose1.5gtwiceperday,targettroughbloodlevel\nmm\n––\ntreatment(Figure8). ofmycophenolicacid1.22.4g/ml[3.77.5mol/l])\nwithoutglucocorticoids,andby52weeks,52%ofpatients\nachievedcompleteremissionand34%achievedpartialKeyinformation\n198\nHigh-intensityimmunosup-\nremission.Balanceofbenetsandharms.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 18)",
    "content": "pressionfortheinitialtreatmentofLNisgivenfor36\nThenegativeoutcomesinpreviousclinicaltrialsdonot\nmonths,dependingontheregimen(Section10.2.3.1).Atthe\nprecludeatherapeuticroleforsomeofthesenovelagents\nendofinitialtherapy,onlyabout10%40%ofpatientsachieve\ninselectedpatients,includingthosewhohavenotresponded\n11,17,19,199\ncompleteresponseasdenedbyclinicalparameters,\nwelltoorwhodonottoleratestandardtherapy,orwhen\nKidneyInternational\nS38\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\nReduce prednisone\nto <5 mg/d\nIndividual cases or when\nIf MPAA or azathioprine\nFirst choicePatients who received triple\nno access to MPAA\nnot tolerated or available\nimmunosuppression as initial\ntherapy for active nephritis\n(refer to Recommendation\n10.2.3.1.1 and Figure 5)\nMycophenolic acid analogs:Continue with the maintenance tripleAzathioprineCNI (tacrolimus, level ≈4–6 ng/ml;\nor\noror\nmycophenolate mofetil 1–2 g/d orimmunosuppression as described1.5–2.0 mg/kg/dcyclosporine, level ≈50–100 ng/ml)\nmycophenolic acid 720–1440 mg/din Figure 5 as appropriate, Practiceor mizoribine ≈3–5 mg/kg/d\nPoint 10.2.3.2.5, and Figure 9\nFigure8|RecommendedoptionsofmaintenancetherapyforClassIIIandClassIVlupusnephritis.Thetargetrangesofcalcineurin\ninhibitors(CNIs)havebeenbasedonthetransplantliterature.TheKidneyDisease:ImprovingGlobalOutcomes(KDIGO)WorkGroup\nacknowledgesthattargetsforglomerulardiseasesarenotknown.MostclinicianschecktheselevelstoverifyadherenceandavoidCNItoxicity. Atpresent,themostreasonabledosingofaCNImaybetotitrateintheindividualpatienttoobtainthedesiredeffectonproteinuria,balancing\ndoseescalationagainstserumcreatininelevel,reducingthedoseiftheserumcreatininelevelincreasesbutdoesnotplateauorincreasesto\nover30%ofbaseline.Iftheserumcreatinineleveldoesnotfallafterdosereduction,theCNIshouldbediscontinued.MPAA,mycophenolicacid\nanalogs.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 19)",
    "content": "andapproximately20%achievecompletehistologicremission,MMFandazathioprineweredirectlycomparedasmain-\n10\ndenedasanactivityindexofzeroonrepeatkidneybiopsy.tenanceagentsin2majorclinicaltrials(Supplementary\n12,20220416,99\nAlso,LNrelapsesfrequently,andrelapsespredisposepatientstoTableS24).InanLNcohortof227ethnically\nadditionalkidneydamageandprogressiontokidneyfailure.diversepatients,themaintenancephaseofALMSshowedthat\nOngoingtreatmentisthereforeneededtoconsolidateinitialover3yearsoffollow-up,thecompositetreatmentfailure\nresponsesintomorecompleteandsustainedresponses,andtoendpointofdeath,kidneyfailure,LNare,sustained\npreventdiseaseares.Afterinitialtherapy,ongoingimmuno-doublingofSCr,orrequirementforrescuetherapywas\nsuppressionisdesignatedasmaintenancetherapy.observedin16%ofMMF-treatedpatientsandin32%of\n¼ﬂ\n16\nTheevolutionofcurrentmaintenancetherapyforprolif-azathioprine-treatedpatients(P0.003).LNares\nerativeLNisanexampleofhowinvestigatorshavetriedtooccurredin12.9%ofMMF-treatedpatientsand23.4%of\nbalancepreservationofkidneyfunctionagainstthetoxicitiesazathioprine-treatedpatients.Incontrast,theMycophenolate\noflong-termimmunosuppressivetherapy.AfteritbecameMofetilVersusAzathioprineforMaintenanceTherapyof\nclearthattheadditionofacytotoxicagenttoglucocorticoidsLupusNephritis(MAINTAIN)trialrandomized105pre-\nduringtheinitialtreatmentofLNimprovedlong-termkidneydominantlyWhitepatientstoMMForazathioprineand\nsurvival,patientswerekeptonoral,orinlaterstudiesi.v.,glucocorticoidmaintenancetherapyafterinitialtherapywith\n119\ncyclophosphamideformonthsoryears.Thisledtothelow-dosecyclophosphamideregimenandshowedno\nconsiderablelifetimecyclophosphamideexposureanddifferenceintimetokidneyarebetweenthe2groups,witha\n200,201\ntoxicity.Astudyreportingin2004comparedquarterlycumulativekidneyarerateofaround20%inbothgroups\n99\ni.v.cyclophosphamideagainstoralMMForazathioprineforafter36months.Ahigherproportionofpatientsinthe\nLNmaintenance,andtheresultsshowednotonlyasignicantazathioprinegrouphadadverseeventsleadingtowithdrawal\nreductioninsideeffectsinthosetreatedwithMMForoftherapyintheALMSmaintenancetrial(39.6%vs.25.2%),\nazathioprinebutalsoimprovedkidneyandpatientoutcomesandtherewasahigherincidenceofcytopeniaintheazathi-\n202\ncomparedtothecyclophosphamidegroup.ThisledtoaoprinegroupintheMAINTAINtrial.Thus,inmostLN\ndecreaseintheuseofquarterlycyclophosphamideasmain-populations,MMF(MPAA)isthemaintenancedrugof\ntenancetreatment.Favorablelong-termresultswithsequen-choice.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 20)",
    "content": "tialimmunosuppressiveregimenhavebeenpublishedbyAnRCTcomparedmaintenancetreatmentwithtriple\n115,116\nothers.Together,theyusheredinthecurrenteraofimmunosuppressionthatincludedlow-doseMPAA,low-dose\n“”\nintense,high-doseimmunosuppressionfortheinitialtreat-tacrolimus,andlow-doseglucocorticoids(multitarget\nmentofproliferativeLNfollowedbyprolongedimmuno-regimen)againstazathioprineinrespondersfollowinga\n“”\nsuppressionwithaless-intenseregimentoreduceadversemultitargetregimenortheNIHi.v.cyclophosphamide\neventswhileensuringthecontinuedsuppressionofimmune-regimenasinitialtreatmentfor6monthsinthe2groups\nmediatedpathogenicprocessessothattheresponsefollowingrespectively,andtheresultsshowedsimilarefcacyinpre-\ninitialtherapyisconsolidated,thediseaseremainsquiescent,ventingaresinthe2groupsandahigherincidenceof\naresareprevented,andfurtherdamagetothekidneyoradverseeventsduetotransaminitisintheazathioprine\n106\notherorgansisavoided.group.However,thefollow-updurationof18monthswas\nKidneyInternational\nS39\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\nMaintenanceLow-dose glucocorticoids AND\nimmuno-\nMycophenolicMizoribineCNI (such asCNI and mycophenolicBelimumab andAzathioprine\nsuppressive\nacid analogsvoclosporin, tacrolimusacid analogsmycophenolic acid\nregimens\nor cyclosporine)analogs or azathioprine\nExperienceTacrolimus andLow medicationPreferred treatmentComments\nmostly incyclosporine safe incost; safe inbelimumab demonstratedvoclosporin demonstratedbased on high-\nJapanesepregnancyin BLISS-LN (104-wk) andin AURORA 1 (52-wk) andcertainty evidence;\npatientspregnancy data onopen-label extensionAURORA 2 continuation trials\nvoclosporintrials (28-wk)than azathioprine\n[Practice Point 10.2.3.2.5]tacrolimus demonstrated inmaintenance\n‘Multitarget Therapy’ trial in\nChinese patients in which\ntacrolimus and reduced-dose\nMPAA were given for\n24 months\n[Practice Point 10.2.3.2.5]\nFigure9|Maintenanceimmunosuppressiveregimensinpatientswithlupusnephritis.AURORA,AuriniaRenalResponseinActiveLupus\nwithVoclosporin;BLISS-LN,EfcacyandSafetyofBelimumabinPatientswithActiveLupusNephritis;CNI,calcineurininhibitor;MPAA,\nmycophenolateacidanalogs. relativelyshort,andthegeneralizabilityofdataneedsfurtherveryseriousimprecision(only1study,andverywideCIs,\nﬁﬁ\ninvestigation.Also,althoughtheresponseratewassigni-indicatingappreciablebenetandharm),thecertaintyofthe\n“”\ncantlyhigherinthemultitargetgroupafter6monthsofevidenceforthistrialisverylow;thus,noconclusionswere\n119\ninitialtreatment,thecumulativeresponseratewassimilarabletobedrawn(SupplementaryTableS25).",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 21)",
    "content": "betweenthe2groupsduringthesecondyearoftherapy,Similarly,only1RCT(n39)comparedazathioprinewith\nincreasingtoapproximately90%bytheendof24months.quarterlypulsecyclophosphamideasmaintenancetreatment,\nRelativelyfavorableresultsdemonstratingsustainedbenetindicatingverylowcertaintyoftheevidencebecauseofstudy\nhavebeenreportedforcontinuedmaintenanceimmuno-limitationsandveryseriousimprecision(only1study,wide\n202\nsuppressionwithtripleimmunosuppressivetreatmentregi-CIs)(SupplementaryTableS26).Thus,thendingsofthis\nmensthatincludedlow-doseglucocorticoidsandMPAAorreviewareinconclusive. azathioprineplusbelimumab;low-doseglucocorticoidsandTheALMStrialcomparedazathioprinewithMMFas\nMPAAplusvoclosporin;orlow-doseglucocorticoidsandmaintenancetherapyinpatientswithproliferativeLNand\n“”\nMPAAorazathioprinepluscyclosporineortacrolimusshowedanincreasedrateofacompositetreatmentfailure\n108,110,113,205207\n(Figures8and9).Nevertheless,theoptimalendpointandadverseeffects(e.g.,leukopenia)inpatients\n16\ndurationofsuchtreatmentremainsunclear.whoreceivedazathioprine.Despitethelargesamplesizeand\nBasedontheseconsiderationscollectively,theWorkGroupthefactthatthiswasanRCT,thecertaintyoftheevidencewas\nconcludedthatthebenetsofmaintenanceimmunosup-downgradedtomoderatebecauseofimprecision(fewevents)\npressionfaroutweighitspotentialharms,andMPAAistheorstudylimitations(unclearallocationconcealment). preferreddrugbasedonthedatatodate(PracticePointDataontheuseofCNIsormizoribineexclusivelyaddedto\n10.2.3.2.1),whilethereistheneedformoredataonhowlongthemaintenancetreatmentaregenerallyoflowcertainty\n208211\ntoextendtripleimmunosuppressiveregimenswithbelimu-(PracticePoint10.2.3.2.6),andthereisalackofin-\nmaborCNIs,andthewaytotapermaintenanceformationregardingadditionofB-celldirectedtherapiesto\n212\nimmunosuppression.themaintenancephase. InthejudgmentoftheWorkGroup,\nThreeRCTscomparedazathioprine\nValuesandpreferences. Certaintyofevidence. mostwell-informedpatientswhohaveundergoneaggressive\nwithmycophenolatemofetil.Therewasmoderatecertaintyof\nimmunosuppressiontocontroltheirLNwouldchoosemain-\nevidencethatazathioprineprobablyincreasesrenalrelapse,\ntenancetherapytotrytoattaincompleteremissionifithadnot\nrisksfordoublingofSCr,andleukopeniaduetoserious\nyetbeenachieved,andinallcasestoavoiddiseaserelapses\nimprecisionintheestimateofeffects,andloworverylow\nneedingreinstitutionofhigh-doseimmunosuppression.Inthe\ncertaintyofevidenceforotheroutcomesduetostudylimi-\njudgmentoftheWorkGroup,giventhebetterefcacyofMPAA\ntationsand/orveryseriousimprecision(Supplementary\n12,202204\nwithitsgenerallyfavorabletolerabilityprole,comparedto\nTableS24). azathioprine,mostwell-informedpatientswouldchooseMPAA\nOnly1RCTcomparedlongduration(18months)of\nastherst-linetreatment.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 22)",
    "content": "cyclophosphamidetherapy,encompassingboththeinitial\nHowever,patientswhohavehadsevereadverseeffects\ntreatmentperiodandthemaintenancephase,withshort\nwhileonMPAA,orwhoplaceahighvalueonbecoming\nduration(6months)ofcyclophosphamidetherapyasinitial\npregnant,maychooseazathioprine(oraCNI)overMPAA,as\ntreatmentfollowedbymaintenancetreatmentwithvariable\nimmunosuppressiveregimens.Duetostudylimitationsand\nKidneyInternational\nS40\n(2024)105(Suppl1S),S1–S69\n[Table 1]\nMaintenance\nimmuno-\nsuppressive\nregimens | Low-dose glucocorticoids AND |  |  |  |  | \n------------------------------------------------------------\n | Mycophenolic\nacid analogs | Azathioprine | Belimumab and\nmycophenolic acid\nanalogs or azathioprine | CNI and mycophenolic\nacid analogs | CNI (such as\nvoclosporin, tacrolimus\nor cyclosporine) | Mizoribine\n\nlupusnephritis\nwww.kidney-international.org\nmaypatientsforwhomMPAAsareunavailableoraremorerobustdatasupportingthesuperiorityofMPAA\nunaffordable.overazathioprineasmaintenancetherapyfromclinicaltrials\nIngeneral,itisreasonabletoassumethatincludedpatientsofdifferentracesandethnicities.In-\nResourceuseandcosts. thatthepersonalandsocietalcostofnotusingmaintenanceformationfromtheclinicaltrialsusingbelimumabasinitial\ntherapyandriskingdiseaserelapseafterinvestingininitialtherapyandthencontinuedfor22.5yearsasmaintenance\ntherapywouldbehigherthanthecostofmaintenancemedi-therapysuggestalowerriskfordiseaserelapsesbasedonpost\ncations.Comparedwithinitialtherapy,facilitycostsareoftenhocanalysiswithlowcertaintyofevidence. lower,asmaintenanceregimensareoral.Outsideofmedication\nexpense,majorresourceimplicationsarisefromlaboratoryPracticePoint10.2.3.2.1:Azathioprineisanalternativeto\nmonitoringoflupusactivityandimmunosuppressionandMPAAaftercompletionofinitialtherapyinpatientswho\nmanagingcomplicationsoftreatment.AlthoughthedrugcostdonottolerateMPAA,whodonothaveaccesstoMPAA,or\nofMPAAisconsiderablyhigherthanthatofazathioprine,therewhoareconsideringpregnancy. arefewcost-effectivenessanalysesofmaintenancetreatmentforAsdiscussedunderRecommendation10.2.3.2.1,thedirect\n213\nLN.Also,somedrugsmayhavelimitedaccessibilityincertaincomparisonbetweenMPAAandazathioprineasmaintenance\nregions,andthismayinuencechoices.Drug-levelmonitoringtreatmentinLN,bothcombinedwithlow-doseglucocorticoids,\nisrequiredinpatientstreatedwithsomeCNIs,butnotwhenismainlybasedondatafromALMSandtheMAINTAIN\n16,203\nazathioprineorMPAAareused,andthisalsohasimplicationstrial.Althoughtheresultsfromthelattershowednosta-\nﬁﬂ\nforaffordabilityandaccessibility.tisticallysignicantdifferenceintimetodiseaseareorlong-\nApartfromavailabilitytermclinicaloutcomesinCaucasianpatients,datafrom\nConsiderationsforimplementation.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 23)",
    "content": "andcostofMPAA,amajorconsiderationforimplementationALMSbasedonalargesamplesizefromdifferentcountrieswith\nofmaintenancetherapyissafetyduringpregnancy.ItisnotdifferentancestrydemonstratedsuperiorefcacyofMPAA\nadvisabletoattemptpregnancyuntilLNandSLEhavebeencomparedwithazathioprine.Inbothtrials,azathioprinewas\nwellcontrolledforsometime,whichwouldgiveampleop-associatedwithmoreadverseeffects,suchasleukopeniaand\nportunitytoswitchpatientsovertoaregimenthatissafeabnormalliver-enzymelevels.However,azathioprineismuch\nduringpregnancy.Pregnancydecisionsarecomplex,andcheaperthanMPAA,andnancialbarriersmaylimitaccessto\nmaintenancetherapyoftenneedstobeindividualizedonthisMPAAinmanycountries.Undersuchcircumstances,orin\nbasis(Section10.3.2.).MPAAarecontraindicatedduringpatientswhodonottolerateMPAAbecauseofsideeffects,low-\npregnancyandmustbediscontinuedwellinadvanceoftryingdoseglucocorticoidscombinedwithazathioprineareaneffec-\ntoconceive.CyclosporineisclassiedundercategoryCbybothtivemaintenanceimmunosuppressivetreatment.Observational\ntheTherapeuticGoodsAdministration(TGA)inAustraliaandcohortdatafromChinesepatientsshowedthatinpatientswho\nﬁﬂ\ntheFDAintheU.S.,whiletacrolimusisclassiedundercate-receivedMPAAasinitialtherapy,thediseaseareratewas\n15,118\ngoryCbytheTGAandisnotassignedacategorybytheFDA.increasedwhenthetotaldurationofMPAAwas2years,\nDatafromanimalstudiesshowedpotentialadverseeffectsthatandthatlong-termmaintenancetreatmentwithMPAAwas\n215\nappeareddose-related.Withregardtohumanpregnancy,associatedwithalowdiseasearerate.Overall,althoughthe\ncategoryCmeansriskcannotbeexcluded,buttheexperienceefcacyandsafetydatatodatefavorMPAAasmaintenance\ntodate,mainlyfromorgantransplantrecipients,isgenerallytreatment,azathioprineisanacceptablealternative,especiallyin\nfavorablewithbothcyclosporineandtacrolimus,showinganthelaterphaseoflong-termmanagement. increasedincidenceoflowbirthweightbutnotfetalmalfor-\nmations.PrescribinginformationfromthemanufacturerofPracticePoint10.2.3.2.2:Glucocorticoidsshouldbetapered\nvoclosporinstatestoavoiditsuseinpregnantwomenduetotothelowestpossibledoseduringmaintenance,except\nthealcoholcontentofthedrugformulation,whiletherearewhenglucocorticoidsarerequiredforextrarenallupus\ninsufcientdatatoconcludewhetherthereisadrug-associatedmanifestations;discontinuationofglucocorticoidscanbe\nriskformajorbirthdefects,miscarriage,oradversematernalorconsideredafterpatientshavemaintainedacomplete\nfetaloutcomes.Datafromanimalstudiesshowedembryo/clinicalrenalresponsefor12months.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 24)",
    "content": "feticidaleffectsbutnotreatment-relatedfetalmalformations.Prolongedglucocorticoidexposureisassociatedwith\nInthisregard,mostpreparationsofcyclosporinealsocontaincontinuedandsignicantorgandamageaccrualand\n146,148\nalcohol.Low-doseazathioprineissafeduringpregnancy.morbidity.Attheendoftheinitialphaseoftreatment,the\nThereareinsufcientdataonthesafetyofbelimumabgoalistohavereducedmostpatientstoadailydoseofpred-\nduringpregnancy,anditsusecannotberecommendedatthisnisone(orequivalent)thatis7.5mg,andpreferablyaslowas\n214\ntime.possible.Thetaperingregimenanddurationofglucocorticoid\nmaintenancetherapyvaryconsiderablyamongcliniciansand\narelargelyopinion-based,informedbyindividualizedconsid-\nRationale\n’ﬂ\nTheuseofmaintenancecombinedimmunosuppressiveerationsofapatientsriskofdevelopingdiseaseare,and\n–ﬁ\ntherapyinClassIII/IVLNtoconsolidateresponsetoinitialtheriskbenetbalanceoftheprevailingdoseofimmuno-\nimmunosuppressivetreatmentandpreventdiseasearesissuppressivemedications.Arecentopen-labelcontrolled\nsupportedbyevidenceofatleastmoderatecertainty.Theretrial(EvaluationoftheDiscontinuationofMaintenance\nKidneyInternational\nS41\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\nCorticosteroidTreatmentinQuiescentSystemicLupusproliferativeLNwhohaveachievedacompleterenalresponse\n[CORTICOLUP]trial)comparedcontinuationofprednisone5andhavenoongoingextrarenalmanifestationsbe36\nmgdailyagainstdiscontinuationin124multiethnicpatientsinmonths,basedonconsiderationofthefollowingevidence\nPariswithstableandquiescentSLE(historyofLNin34%andcollectively:\n216\n41%,respectively).TheresultsshowedasignicantlyInarecentclinicaltrial(WeaningofImmunosuppression\n(cid:4)\nincreasedarerateover52weeksoffollow-upinpatientswhoinNephritisofLupus[WIN-Lupus])fromFrance,96pa-\ndiscontinuedprednisone(HR:0.2inthosewhocontinuedtientswhorespondedtoinitialtherapyandwithprotein-\n¼–\nprednisone5mgdaily,P0.002),and45of63patientsintheuriabelow0.5g/dfor23yearswererandomizedto\ndiscontinuationgroupremainedglucocorticoid-free.Itshouldimmunosuppressiondiscontinuationover3monthsor\nbenotedthatthewithdrawalofglucocorticoidsinthisstudycontinuationandwereobservedfor24months.Thestudy\nmayhavebeentooabruptforpatientswhohadbeentakingwasunderpowered,butafter2years,thereweremorese-\n“ﬂ”ﬂ\nglucocorticoidsformanyyears,inwhichcase,thearesvereSLEaresandatrendtowardhigherrenalrelapsesin\n218\npresentedmayinfacthavebeenwithdrawalsymptoms.thediscontinuationgroup(SupplementaryTableS27). Glucocorticoiddiscontinuationinpatientswithstablequies-InChinesepatientswhoreceivedMMFasinitialtherapy,\n(cid:4)\ncentdiseasecanbeconsidered,butitshouldbeundertakendiscontinuationofMMFbefore2yearswasassociatedwith\nﬂﬂ\n15,118\nwithcautionandcarefulmonitoringfordiseaseare.Gluco-anincreasedriskofdiseaseare.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 25)",
    "content": "corticoidavoidanceinmaintenancetherapyhasbeenattemp-DuringthethirdtofourthyearofMMFmaintenance\n(cid:4)\ntedwiththeuseofrituximab,buttheevidencetosupportthistherapy,kidneyarewasassociatedwithlow12-hour\n198\napproachremainslimitedtoonecohort.troughMPAbloodlevels,whereaspatientswithtrough\nlevelsofapproximately2mg/l(6.2mol/l)remainedin\n219\nPracticePoint10.2.3.2.3:Thedoseofmycophenolateremission. mofetil(MMF)intheearlymaintenancephaseisapprox-TheALMSmaintenancephasedatademonstratedarela-\n(cid:4)\n––\nimately7501000mgtwicedaily,andformycophenolictivelyhighincidenceoftreatmentfailure(16%32%)and\n–ﬂ–\nacid(MPA),approximately540720mgtwicedaily.kidneyares(13%23%)despite36monthsofimmuno-\nThesuggesteddosagesarelargelybasedondatafromthesuppressionandmaintenancewithlow-doseglucocorti-\n16,20316\nALMSandMAINTAINtrials.Asmentionedbefore,thecoidsandeitherMMForazathioprine. WorkGrouprecommendsmaintenanceofthesedosesuntilInanItaliancohort,immunosuppressionwastaperedin\n(cid:4)\nachievementofcompleteresponse,andthentapering.Duetopatientswhowereincompleteremissionfor12months,\npharmacogeneticdifferences,thelevelofMPAexposurevariesand27%relapsed.Oneofthepredictorsofsuccessful\nconsiderablyamongpatientsreceivingthesamedoseoftreatmentdiscontinuationwasalongerduration(median\n220\nMPAA.ThedoseofMPAAmayneedtobereducedwhenof4years)ofpriorimmunosuppressivetherapy. ﬁ$$\nkidneyfunctionissignicantlyimpaired,aspatientswithDespite36monthsofimmunosuppressionand12\n(cid:4)\nCKDaremoresusceptibletotheadverseeffectsofMPA.monthsofsustainedcompleteclinicalrenalresponse,28%\nﬁﬂ\nAlthoughthereareinsufcientdatatodatetoproviderec-50%ofpatientscontinuedtoshowinammatoryhistologic\n221223\nommendationsontherapeuticdrugmonitoring,measure-activityonrepeatkidneybiopsy.Patientswith\nmentofMPAexposuremaybehelpfulinpatientswithpersistenthistologicactivityhaveanincreasedriskofLN\nunsatisfactorytreatmentresponseorpatientswhomanifestorareaftermaintenanceimmunosuppressionisdis-\nareatincreasedriskofdrugtoxicities.Therearepreliminarycontinued,comparedtopatientswhohavenoresidualin-\nﬂﬂ\n222,223\ndataassociatingdiseaseareswithlowMPAexposure,buttheammatoryactivityintheirkidneys. optimaldruglevelatdifferentphasesofclinicalmanagementPatientswhohaveachievedapartialremissiontendtobeleft\n(cid:4)\n217\nremainstobedetermined.onmaintenanceimmunosuppressionindenitely.Kidney\nbiopsystudiesofsuchpatientshaveshownthatmanyhave\nPracticePoint10.2.3.2.4:Thetotaldurationofinitialresolutionofhistologicactivitybutareclinicallyonlyin\n221223\nimmunosuppressionpluscombinationmaintenancepartialremissionduetoresidualproteinuria.Insuch\n‡ﬂ\nimmunosuppressionforproliferativeLNshouldbe36patients,proteinuriamayreectCKDasopposedtoactive\nmonths.disease,andimmunosuppressionmaybeabletobedis-\nTheoptimaldurationofmaintenanceimmunosuppressioncontinuedintheabsenceofongoingkidneyinammation.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 26)",
    "content": "inpatientswithproliferativeLNisnotknown.Ifitiswith-Insummary,despitetheunknownoptimaldurationof\ndrawntooearly,patientsmayrelapseevenafterhavinghadamaintenanceimmunosuppressionforproliferativeLN,most\ngoodresponsetotreatment.Prolongedmaintenanceincreasespatientswillrequire3yearsoftherapy.Clinicalresponse\nﬁﬁ\nexposuretoimmunosuppressionandmaynotprovidesuf-ndingsdonotcorrelatecompletelywithongoingkidney\nﬁﬂ\ncientcontinuedbenetstooutweightoxicityrisk.TheWorkinammation.Arepeatkidneybiopsycanbeconsideredto\nGrouprecommendsthatthetotaldurationofimmunosup-informthedecisiontocontinueorwithdrawmaintenance\npression(initialtherapyplusmaintenance)forpatientswithimmunosuppression. KidneyInternational\nS42\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\nPracticePoint10.2.3.2.5:Patientstreatedwithtripletherapywithtacrolimus(troughbloodleveltargetof46ng/ml\nimmunosuppressiveregimensthatincludebelimumabora[57.4nmol/l])wascomparedwithazathioprine2mg/kg/d,\nCNIinadditiontostandardimmunosuppressivetherapybothincombinationwithprednisone10mg/d.Over6months\ncancontinuewithatripleimmunosuppressiveregimenasoffollow-up,kidneyrelapseoccurredin2azathioprine-treated\n225\nmaintenancetherapy(Figure9).patientsandinnoneinthetacrolimusgroup. Inthephase3belimumabtrialinLN(BLISS-LN),patientsAddingtacrolimusorcyclosporinetomaintenancetherapy\nintheinterventionarmweretreatedwithlow-dosegluco-wasreportedincaseseriesaseffectiveinreducingproteinuria\ncorticoidsandbelimumabpluseitherMPAAorazathioprineinpatientswithunsatisfactorysuppressionofproteinuria\nasmaintenanceimmunosuppression,andtreatmentwasfollowinginitialtherapywithglucocorticoidsandMMF,\ncontinueduntil100weeksfrombaselinewiththeprimaryespeciallyinpatientswhoshowedfeaturesofClassVLNin\n111208,210,226228\nendpointassessedatweek104.Thiswasfollowedbyantheirbaselinekidneybiopsies.Cautionisrequired\nopen-labelextensionstudyof28weeksthatincluded257ofwhenconsideringaddingCNIforthepurposeofdecreasing\ntheoriginal448patientsrandomizedintheBLISS-LNtrial,proteinuria.Itisdesirablethattherebehistologicevidenceof\nduringwhichpatientsoriginallyrandomizedtoreceivepla-podocyteinjurysothattheCNIislikelytobeeffective.Also,it\n112\ncebowerechangedtobelimumab.ResultsfromthelatterisprudenttoavoidoverimmunosuppressionandchronicCNI\nﬁﬁ\nshowedthattheefcacybenetassociatedwithbelimumabnephrotoxicity,especiallyinpatientswithCKD. treatmentwasmaintainedwithnosafetyconcerns;andpostAlthoughmoststudiesweredoneinpatientsofAsian\nhocanalysisshowedthatpatientstreatedwiththebelimumab-origin,itisreasonabletoconsideraCNIformaintenance\ncontainingtripleimmunosuppressiveregimenhadlowerratestherapyinanypatientswhocannottakeMPAAorazathio-\nofadversekidneyoutcomesaswellasbetterkidneyprine.Tacrolimusandcyclosporinecanalsobeusedsafely\n112,113\nfunction.duringpregnancy(Figure9).",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 27)",
    "content": "Inthephase3voclosporintrialinLN(AURORA1),Theexperiencewithmizoribineasmaintenancetherapyin\n211,229\ntreatmentwascontinuedfor52weeksandtheprimaryLNislargelylimitedtoJapanesepatients.Resultsfroma\n141\nendpointwasassessedatweek52.Patientswhocompletedpost-marketingsurveillancestudythatincluded559\nthephase3trialwereeligibletocontinuethesameblindedmizoribine-treatedpatientsshowedthatnearlyallwere\ntherapyina2-yearcontinuationstudy(AURORA2;116ofreceivingglucocorticoids,and43.8%werereceivingtacroli-\n179patientsinthevoclosporinarmand100of178patientsinmusasconcomitanttreatment.Overall,63.3%ofpatients\n110\nthecontrolarm).Resultsfromthelattershowedsustainedachievedcompleteorpartialremission,andonly3.6%of\nreductionofproteinuriawithvoclosporintreatment,andpatientsexperiencedseriousadversedrugreactionswithin2\nstableandsimilarkidneyfunctioninbothgroups,withnoyearsofmizoribinetreatment,andtheauthorsconcludedthat\n230\nsafetysignal.mizoribinewassafeandeffective(Figure9). Inatrialof368ChinesepatientsthatcomparedtripleLeunomideisaprodrugthatoncemetabolizedinhibitsde\nimmunosuppressionwithglucocorticoidsandxed-dosenovopyrimidinenucleotidebiosynthesis.Anopen-label36-\ntacrolimusandreduced-doseMMFagainstglucocorticoidsmonthtrialfromChinarandomized270LNpatientswith\nandsequentialcyclophosphamidefollowedbyazathioprine,previousresponsetoi.v.cyclophosphamidetherapytoleu-\npatientscontinuedwiththetripleimmunosuppressivenomide20mg/dorazathioprine(targetdose100mg/d)and\n106\nregimenfor24months.Bytheendof24months,the2oralglucocorticoids.Nodifferenceinkidneyareswas\ntreatmentarmsshowedsimilarcompleteremissionratesobservedbetweengroupsby36months(15.7%vs.17.8%),\napproaching80%,andpatientstreatedwithtripleimmuno-andthekidneyfunctionwassimilarlypreservedinboth\nsuppressionshowedarelapserateof5.47%,withalowergroups.Nodifferencesinadverseeventswereobservedbe-\n231\nwithdrawalrateduetoadverseevents(1.7%)comparedwithtweengroups(SupplementaryTableS28).Thereareno\nthatofcontrols(8.9%).formalstudiescomparingleunomideandMPAA;therefore,\nTheseresultssuggestthattripleimmunosuppressiveregi-leunomideisconsideredanalternativetoMPAAinthe\nmensthatincludebelimumaboraCNIinadditiontostan-above-mentionedcircumstancesexclusively.Leunomideis\ndardmaintenanceimmunosuppressioncanbecontinuedforcontraindicatedinpregnancyandshouldbediscontinuedfor\n23years.atleast2yearsbeforepatientstrytoconceive. PracticePoint10.2.3.2.6:IfMPAAandazathioprinecannot\n10.2.4ClassVlupusnephritis\nbeusedformaintenance,CNIsormizoribineorleuno-\nmidecanbeconsidered(Figure9).PracticePoint10.2.4.1:Asuggestedapproachtotheman-\nExperienceinJapanesepatientssuggestedthatlow-doseagementofpatientswithpureClassVLNisdescribedin\ntacrolimusat3mg/dwassafeandeffectivewhengivenasFigure10.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 28)",
    "content": "long-termmaintenancetherapytogetherwithlow-doseglu-ClassVLNaccountsfor5%10%ofallLNcases.Dataon\n209,224\ncocorticoids.Inastudyof70Chinesepatientswhoach-clinicalmanagementarebasedonveryfewRCTswithsmall\nievedremissionafterinitialtherapywithglucocorticoidsandsamplesizes,analysesofpooleddata,andobservational\neitheri.v.cyclophosphamideortacrolimus,maintenancestudies.ThemanagementofClassVLNwithnoproliferation\nKidneyInternational\nS43\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\nKidney biopsy\nshowing Class V lupus nephritis\nairunietorp egnar-citorhpeNairunietorp level-woL\nMonitor the level of proteinuria and prevent or treat\ncomplications (e.g., thrombosis, dyslipidemia, edema)\n1  Renin-angiotensin system blockade and1  Renin-angiotensin system blockade and blood pressure control\nblood pressure control2  Combined immunosuppressive treatment with glucocorticoid and\n2  Immunosuppressive treatment guided    one other agent (e.g., mycophenolic acid analogs, cyclophosphamide,\nby extrarenal manifestations of systemic\nlupus erythematosus    recommendation of glucocorticoid regimen, but moderate or reduced\n3  Hydroxychloroquine    dose preferred. Please refer to Practice Point 10.2.3.1.1. 3  Hydroxychloroquine\nIf proteinuria worsens and/or complications\nof proteinuria develop (e.g., thrombosis,\ndyslipidemia, edema), consider\nimmunosuppressive therapy\nFigure10|ManagementofpatientswithpureClassVlupusnephritis.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 29)",
    "content": "inthekidneyhistologyisguidedbytheseverityofprotein-ClassVandClassIII/IVLNwhoseproteinuriaresponsewas\nuria.Long-termfollow-updatashowthat10%30%ofpa-judgedsuboptimalafterinitialtreatmentwithprednisoloneand\n210\ntientswithClassVLNprogresstokidneyfailure,andtheriskMMF.Inthephase3voclosporintrial(AURORA;seePrac-\nofprogressiveCKDisassociatedwiththeseverityofpro-ticePoint10.2.3.1.4),14%ofthepatientshadpureClassV\n165\nteinuria.Unlikeprimarymembranousnephropathy,heavyLN.Addingvoclosporintobackgroundtherapywasmore\nproteinuriainClassVLNdoesnotusuallyspontaneouslyeffectivethanbackgroundimmunosuppressionalonein\nremit.Also,heavyproteinuriaandNSincreasetheriskofachievingrenalresponse,andin31patientswithClassVLN,the\ninfectionsandCVmorbidityandpredisposepatientstomediantimetoreduceproteinuriato0.5mg/mg(50mg/\n232235\nthrombosis.mmol)was3.6monthsinpatientstreatedwithvoclosporin\nAsmallRCTdemonstratedthatremissionwassignicantlyaddedtoglucocorticoidsandMMF,comparedwith8.3months\nmorelikelywithprednisonepluscyclophosphamide(60%)orincontrolstreatedwithplaceboaddedtoglucocorticoidsand\n245\nprednisonepluscyclosporine(84%)thanwithprednisonealoneMMF(HR1.93,P0.167).IntheBLISS-LNtrial,16%of\n(27%),butcyclophosphamidemaintainedremissionlonger(nopatientshadClassVLN(36patientstreatedwithbelimumab,\nrelapseswithinayear)thanCNItreatment(40%relapsedand36patientstreatedwithplacebo).Resultsfromposthoc\n149\nwithinayearofdiscontinuingtheCNI).Pooleddatafrom2analysissuggestedthatbelimumabmightnotbeaseffectivein\nstudiesshowedthatprednisonepluseithercyclophosphamidepatientswhopresentedwithnephrotic-rangeproteinuria\norMMFhadsimilarefcacyinloweringproteinuriaafter6comparedtothosewithless-severeproteinuria,althoughit\n236\nmonthsoftreatment.Otherstudieswithrelativelysmallmightstillreducetheincidenceofadversekidneyoutcomes. samplesizesreportedtheefcacyofglucocorticoidscombinedTheoverallincreaseinPERRandcompleteresponserate(CRR)\n27,219237\nwithazathioprine,oralcyclophosphamide,i.v.cyclo-whenbelimumabwasaddedtostandardtherapywasattributed\n––\n149,23826,27,168,238240149,168,227,241243\nphosphamide,MMF,CNIs,topatientswithaproliferativehistologiccomponent,while\n198,244\nandrituximab,withresponseratesof40%60%.Tripletherewasnoobservedtreatmentdifferenceassociatedwith\nimmunosuppressionwithglucocorticoids,tacrolimus,andlow-belimumabinpatientswithClassVLN(PERR:OR:0.65;95%\n––\n113\ndoseMPAAresultedinahighercompleteremissionrateinCI:0.231.86;CRR:OR:0.83;95%CI:0.272.62).Thereisa\npatientswithClassVLNcomparedtothatincontrolstreatedlackofrobustdatainthemanagementofClassVLN,especially\nwithglucocorticoidsandhigh-dosecyclophosphamidefollowedinpatientswhopresentwithNS.Thedatatodatearemorein\n19\nbyazathioprine(33.1%vs.7.8%).Also,tacrolimuswasre-favorofcombiningglucocorticoidswithMPAA,aCNI,or\nportedaseffectivewhengiventogetherwithglucocorticoidsasshort-termcyclophosphamidethanwithotheroptions.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 30)",
    "content": "initialtherapytopatientswithClassVLNwhopresentedwithInadditiontogeneralmethodstoreduceurineprotein,\nNS,orwhengivenasadd-ontherapytopatientswithmixedsuchasrenin-angiotensinsysteminhibitorsandmeticulous\nKidneyInternational\nS44\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\n• Reduction in proteinuria <0.5 g/g (50 mg/mmol) measured as the PCR from\nComplete response*\na 24-h urine collection\n• Stabilization or improvement in kidney function (±10%–15% of baseline)\n• Within 6–12 mo of starting therapy, but could take more than 12 mo\n• PCR ≤0.7 g/g (70 mg/mmol)\nrenal response\nper 1.73 m\n• No use of rescue therapy for treatment failure\n• Reduction in proteinuria by at least 50% and to <3 g/g (300 mg/mmol)\nPartial response\nmeasured as the PCR from a 24-h urine collection\n• Stabilization or improvement in kidney function (±10%–15% of baseline)\n• Within 6–12 mo of starting therapy\n• Failure to achieve a partial or complete response within 6–12 mo of starting\nNo kidney response\ntherapy\nﬁ<\nFigure11|Denitionsofresponsecommonlyusedinclinicaltrialsoflupusnephritis.*Forchildren18yearsold,completeresponseis\nﬁ<<\n22\ndenedasproteinuria0.5g/1.73mperdayor300mg/mperdaybasedona24-hoururinespecimen.eGFR,estimatedglomerular\nﬁ–\nltrationrate;PCR,proteincreatinineratio. bloodpressurecontrol,MMFisareasonablerstchoiceformedicalrecord.Long-termdatafrom2largeEuropeanLN\ntreatingpatientswithClassVandnephrotic-rangeprotein-trialsshowedthatfavorablekidneyoutcomeswerepredicted\n#–\nuria.Ifineffective,weadvisecyclophosphamidefor6byachievingaproteinurialevelof0.70.8g/dafter12months\n117,249251\nmonthsnexttohelpinducelong-termremission,butlong-oftherapy,aconclusionsupportedbyotherreports. termCNIorrituximabmayalsobetriedifthepatienthasInthisregard,thePERRatWeek104wastheprimary\n111\nhadpriorsignicantexposuretocyclophosphamideorisendpointintheBLISS-LNtrial.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 31)",
    "content": "reluctanttotakethemedicationinviewoftheassociatedAnothercaveatisthelackofconsensusontheappropriate\ntoxicities.Decisionsonwhethertotreatwithimmunosup-timeforassessingresponse.Forlogisticandeconomicreasons,\npressivemedicationsorCNIinpatientswithproteinuriathatlargeclinicaltrialsoftenevaluateresponseat612months,but\nisnon-nephroticbutabove1g/24hneedtobeindividualized,improvementofproteinuriaandeGFRiscontinuousovertime,\ntakingintoaccounttheseverityandprogressionofprotein-andtherateofimprovementvariesconsiderablyamongpa-\nuriaandtherisksandbenetsoftreatment.Appropriatetients.Also,therearemarkeddifferencesinbaselinekidney\nmeasurestopreventvenousthrombosisshouldbeconsideredabnormalitiesatdiseasepresentation.Therefore,thetimeto\ninpatientswhoseproteinuriapersistsdespitetreatments(seereachprespeciedproteinuriaandeGFRcutoffs,eitherabso-\nChapter1oftheKDIGOGuidelineonGlomerularDiseases).luteorrelativetobaseline,variesconsiderablyamong\n12,14,15,150,227,252,253\npatients.Thetimeframesforresponse\n10.2.5Responseandrelapseconsiderations\nassessmentasstatedinthedenitionsinFigure11refertothe\ntimepointswhentheseoutcomesareassessedinclinicaltrials. Thesetimeframesdonotmeanthatonewouldneedtowaitfor\n10.2.5.1AssessingtreatmentresponseinLN\nthespeciedtimeperiodstolapsebeforemakingmanagement\nPracticePoint10.2.5.1.1:Denitionsofresponsetotherapydecisions.Instead,patientsshouldbeassessedcontinuouslyto\ninLNusedinclinicaltrialsareprovidedinFigure11.ensurethatthereiscontinuousimprovement,andinpatients\nAllresponsecriteriacurrentlyusedinclinicaltrialsofLNnotrespondingsatisfactorilytocurrenttherapy,alternative\nrequireimprovementinproteinuriaandstabilizationortreatmentsshouldbeconsideredearly. improvementinkidneyfunction.SeveralobservationalstudiesOutsideofaformalclinicaltrialsetting,theWorkGroup\nsuggestthatlong-termkidneyhealthisconsiderablymoresuggeststhatifpatientsareimproving,allowing1824\n115,246248\nfavorableinpatientswhorespondtotreatment.monthstoachieveacompleteresponseisreasonableinpa-\nHowever,therearenouniversallyacceptedcriteriaforthetientswhoshowcontinuousimprovement.Apotentialtoolto\nlevelofimprovementrequired,whichmakesdirectcompari-predictkidneyoutcomeswasderivedfromaposthocanalysis\nsonsofdifferentclinicaltrialsmoredifcult.ofthelargeALMStrial.Thisanalysissuggestedfavorable\nThedenitionsinFigure11arecommonlyused,withkidneyoutcomesarepredictedbynormalizationofcomple-\n“”$\nbaselinekidneyfunctionreferringtothelevelbeforediseasementlevelsand25%reductionofproteinuriaafter8weeks\n254\nare,whichisnotknowninpatientswithnopreviousoftreatment.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 32)",
    "content": "KidneyInternational\nS45\n(2024)105(Suppl1S),S1–S69\n[Table 1]\nComplete response* | • Reduction in proteinuria <0.5 g/g (50 mg/mmol) measured as the PCR from\na 24-h urine collection\n• Stabilization or improvement in kidney function (±10%–15% of baseline)\n• Within 6–12 mo of starting therapy, but could take more than 12 mo\n------------------------------------------------------------\nrenal response | • PCR ≤0.7 g/g (70 mg/mmol)\nper 1.73 m2\n• No use of rescue therapy for treatment failure\nPartial response | • Reduction in proteinuria by at least 50% and to <3 g/g (300 mg/mmol)\nmeasured as the PCR from a 24-h urine collection\n• Stabilization or improvement in kidney function (±10%–15% of baseline)\n• Within 6–12 mo of starting therapy\nNo kidney response | • Failure to achieve a partial or complete response within 6–12 mo of starting\ntherapy\n\nlupusnephritis\nwww.kidney-international.org\nSLEisasystemicdisease,andthekidneyshouldnotbeearlyappraisalofpotentialcausesfornonresponseandearly\nexaminedinisolationfromotherclinicalmanifestations.intervention,whereaspatientswhoshowresponsetotreatment\nSeveralotherclinicalparametershavenotbeenevaluatedincanbecloselyobservedandinvestigatedwhenthelevelof\ndetailinclinicalstudiesbutarerelevantatindividuallevels,improvementafter34monthsoftherapyissuboptimalor\nsuchassystemicactivityofSLE(e.g.,SystemicLupusEry-belowexpectation.A2-monthtimeframetoseeimprovement\nthematosusDiseaseActivityIndex[SLEDAI]score),bloodwassuggestedbasedonposthocanalysisofdatafromthe\n254\npressurecontrol,edemaresolution,urinesediment,hemoglo-ALMStrial,butdeteriorationneedstobeevaluatedonan\nbinandalbuminimprovements,andserologicparameters,individualbasisintermsofrapidityandseverity. includingdsDNAantibodiesandserumcomplements.IflupusTheroleofnonadherenceinunsatisfactorytreatment\nserologiesareabnormal,itisreasonabletoexpectimprove-responsecannotbeoveremphasized.Theprevalenceofnon-\n255258\nmentwiththerapyforLN,althoughmanypatientsremainadherenceinpatientswithSLEcouldbe60%.Itis\npositiveforanti-dsDNAand/orhavelowcomplementlevelsimperativethereforetochecktreatmentadherenceonareg-\ndespiteresolutionofproteinuria.Extrarenallupusactivityularbasis.Switchingfromoralimmunosuppressiontoi.v. requiringcontinuationorachangeintherapycouldremaincyclophosphamideshouldbeconsideredwhennonadherence\nevenifthekidneyimproves.Finally,responseiscurrentlyonlyissuspectedorknown.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 33)",
    "content": "assessedclinically.ConsiderabledatasuggestthatpersistentThecertaintyofevidenceonthemanagementofLNre-\nintrarenallupusactivitymayremain,despiteresolutionoffractorytostandardinitialtherapyismarredbyvariable\n221223\nproteinuriaandeGFR.Arepeatkidneybiopsymay,denitionsoftreatmentresponseorrefractoriness,the\ntherefore,beusefulinconrmingrenalresponse,especiallydisparitybetweenkidneyhistologyandclinicaloutcomepa-\nbeforemakingimportantmajortreatmentdecisionssuchasrameters,thelegacyeffectofpriortherapy,andtheimpactof\n10\ndiscontinuationofimmunosuppression.factorsotherthandiseaseactivityonoutcomeparameters\nAlso,holisticman-\nagementshouldincludeconsiderationsofCKDprogressionsuchasproteinuriaandkidneyfunction.Availabledataonthe\nandCVriskfactormanagement,inadditiontominimizationmanagementofrefractorydiseasearelargelyfromuncon-\nofotherlong-termadverseoutcomes.trolledobservationalcohortstudies,withvariedinclusion\ncriteriaandbasedonrelativelysmallsamplesizes. Theroleofswitchingbetweentherapeuticregimenshas\n10.2.5.2Managementofunsatisfactoryresponsetotreatment\nnotbeenformallyinvestigated.InaU.S.studythatcompared\nmycophenolatewithi.v.cyclophosphamide,patientswhodid\nPracticePoint10.2.5.2.1:Analgorithmicapproachtopa-\nﬁ$\nnotshowresponse,denedasimprovementby30%,after\ntientswhoseresponsetotherapyisdeemedunsatisfactory\n12weeksoftreatmentwereswitchedtotheothertreatment\nisprovidedinFigure12. 102\narm.AnotherstudyreportedefcacyofMMFinpatients\nJudgingtheresponsetotherapytobeunsatisfactoryis\nrefractorytoorwhohadrelapsedaftercyclophosphamide\ndifcultbecausetherearenorobustdatawithwhichto\n259\ntreatment.However,alegacyeffectofpriortherapycould\ncompareanindividualsresponsetrajectory,andthereneedsto\nnotbeexcluded.Unequivocalevidenceontheefcacyof\nbeabalancebetweengivingapatientsufcienttimetorespond\nswitchingtherapiesislacking. andminimizingthelikelihoodofongoingnephronloss. EvidencesupportingtheuseofrituximabforrefractoryLN\nNonetheless,patientsareexpectedtoshowimprovementover\nisfromopen-labelobservationalstudiesthathavereported\ntimeaftertreatment.So,noimprovementorworseningdespite\n190,215,260271\nresponseratesof50%80%andameta-analysisof\ntreatmentfor34weeksisclearlyunsatisfactoryandwarrants\nVerify adherence to treatment\nEnsure adequate dosing of immunosuppressive medications by measuring\nplasma drug levels if applicable or available (check mycophenolic acid level\nif on mycophenolic acid analogs/check infusion records if on cyclophosphamide)\nRepeat biopsy if concern for chronicity or other diagnosis\n(e.g., thrombotic microangiopathy)\nConsider switching to an alternative recommended treatment regimen when\nthere is persistent active disease\nConsider the following in patients refractory\n• Addition of rituximab or other biologic therapies\n• Extended course of i.v. pulse cyclophosphamide\n• Enrollment in clinical trials if eligible\nFigure12|Managementofpatientswhoshowunsatisfactoryresponsetoinitialtherapyforactivelupusnephritis.i.v.,intravenous.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 34)",
    "content": "KidneyInternational\nS46\n(2024)105(Suppl1S),S1–S69\n[Table 1]\nVerify adherence to treatment\n------------------------------------------------------------\nEnsure adequate dosing of immunosuppressive medications by measuring\nplasma drug levels if applicable or available (check mycophenolic acid level\nif on mycophenolic acid analogs/check infusion records if on cyclophosphamide)\nRepeat biopsy if concern for chronicity or other diagnosis\n(e.g., thrombotic microangiopathy)\nConsider switching to an alternative recommended treatment regimen when\nthere is persistent active disease\nConsider the following in patients refractory\n• Addition of rituximab or other biologic therapies\n• Extended course of i.v. pulse cyclophosphamide\n• Enrollment in clinical trials if eligible\n\nlupusnephritis\nwww.kidney-international.org\n31studieswith1112patientsthatshowedcompleteandpartialDiseaseactivityshouldbeveried,asproteinuriamaybe\n(cid:4)\nresponseratesof46%and32%,respectively,afterrituximabsecondarytoCKD. 272\nwasadded.TheroleofotherbiologicswithdemonstratedThelastpointiscriticalbutcomplex.Thesameclinical\nefcacyinrecentclinicaltrials,suchasobinutuzumaborcriteriausedtodiagnosedenovoLNareusedtodiagnoseLN\nﬂﬂ\nbelimumab,warrantsfurtherinvestigation.ares,absentakidneybiopsy.Thatis,aresaregenerally\nSimilarly,datafromobservationalcohortssuggestedefcacyconsideredwhenproteinuriaincreasesbeyondacertain\nofCNIs,combinedwitheitherglucocorticoidsand/orMMF,inthreshold,withorwithoutanactiveurinarysedimentordete-\n206,208,273277\npatientswithrefractoryorrelapsingLN.Otherriorationofkidneyfunction.Withouthistology,itissometimes\ntherapiesunderinvestigationmayofferpotentialoptionsfordifculttodeterminewhetherchangesinproteinuriaaredueto\nﬂﬂ\nrefractoryLN,suchasanti-CD19chimericantigenreceptorTactiveinammatorykidneyinjuryorreectprogressionof\n278\n(CAR-T)celltherapy.chronicdamageincurredduringprecedingepisodesofactive\nLN,becausethereisoftendiscordancebetweenclinicalndings\n10,11\nandhistologicndings.Thetempoandmagnitudeofchange\n10.2.5.3TreatmentofLNrelapse\ninproteinuriamayhelpidentifyrapidincreases,andlarge\nﬂﬂ\nRelapsesofLNarecommon,andLNareisanimportantchangesoftenreectactivedisease.SLEserologies(e.g.,com-\nﬂﬂ\n279282\npredictorofpoorlong-termkidneysurvival.LNareplement,anti-dsDNA)maysupportaarediagnosisbutneedto\nratesof10%50%havebeenreported,andrelapsesoccurbeevaluatedinthecontextofpriorserologictrends.Achange\n283\novertime.Failuretoachievecompleteremissionincreasesfromnormaltoabnormalismoreusefulthanserologicstudies\n97,115,284\ntheriskofsubsequentrelapse.Relapseratesof39%thatarealwaysnormaloralwaysabnormal.Giventherisksof\nand64%werefoundinpatientswhoachievedcompleteimmunosuppression,ifthediagnosisofareremainsuncertain,\nremissionorpartialremission,respectively,andtime-to-arepeatkidneybiopsytoassessdiseaseactivityversuschronic\n288\nrelapseaftercompleteresponsewas36months,compareddamageisimportanttoinformtreatmentdecisions.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 35)",
    "content": "97\nto18monthsafterpartialresponse.Similarly,anHRof6.2InlieuofwaitinguntilLNaresbeforetreatingit,some\nforrelapsewasreportedinChinesepatientswhodidnotinvestigatorshaveexaminedpreemptivetreatmenttoprevent\nﬂ“”\n115\nachievecompleteremissionafterinitialtherapy.are.AtrialintheNetherlandscomparedearlytreatmentof\n16patientstoconventionalmanagementof23patientswho\n289\nPracticePoint10.2.5.3.1:Afteracompleteorpartialincreasedtheiranti-dsDNAlevelsby25%.Prednisonewas\nremissionhasbeenachieved,LNrelapseshouldbetreatedincreasedby30mg/dintheearlytreatmentgroupandwas\nwiththesameinitialtherapyusedtoachievetheoriginaltaperedbacktobaselineover18weeks.Afterameanfollow-\nresponse,oranalternativerecommendedtherapy.upof2years,2majorrelapses(12.5%,bothLNrelapses)\nTherearenodatathatfocusonthetreatmentofLNaresoccurredintheearlytreatmentgroup,comparedto20re-\nalone.However,itisgenerallyagreedthatthereisnomajorlapses(87%),7ofwhichweremajor(1kidneyrelapse),inthe\ndifferencebetweenmanagementofanLNareandthatofdeconventionallymanagedpatients.Aprospectivetrialinthe\nnovoactiveLN,andinitialtherapiesarethesameasoutlinedU.S.randomized41patientswhoshowedanincreaseinboth\nabove.Althoughnotyetreadytobeappliedinclinicalman-anti-dsDNAandC3atoprednisone(30mg/dtapered4\nagement,emergingdatafromarecenttranscriptomicstudyofweeks)orplacebo.Duringashortfollow-up(90days),none\npairedserialkidneybiopsiesshowedslightdifferencesinintra-ofthepatientsgivenprednisonehadasevereare,but6\nﬂﬂ\nrenalinammatorygeneexpressionbetweentheinitialpre-placebopatientsdid,and3oftheareswerekidney-\n285290\nsentationandLNrelapse.AllLNclinicaltrialstestinginitial,related.ArecentlypublishedretrospectivestudyofChinese\ninductiontherapiesforLNincludebothtypesofpatients.patientswithLNsuggestedthatamoderateincreasein\nAlthoughtheseconsiderationsformthebasisforPracticePointimmunosuppressivetreatmentdosewaseffectiveinprevent-\n10.2.5.3.1,thereareseveralcaveatsinchoosinganapproach:ingkidneyandnonrenalareswithoutexcessivetreatment-\n217\nIfpatientshadbeentreatedwithcyclophosphamideintherelatedadverseeffects.Takentogether,allofthesedata\n(cid:4)\npast,itisimportanttocalculatelifetimeexposure.OvariansuggestthatimpendingLNaresmaybepreventable,atleast\nfailurehasbeenassociatedwithage(andoocytereserve)forsomepatients,butlargerRCTsofsufcientdurationare\nandcumulativedose,withsustainedamenorrheaoccur-neededbeforethisapproachcanbeendorsed. ringinupto50%ofpatientsaged32yearswithacu-\n10.3Specialsituations\n2286,287\nmulativeexposureof8g/m.Thechanceoffuture\nmalignancyincreasesafteratotalexposureof36g,soifa\npatientisapproachingthislevel,cyclophosphamideis\n10.3.1Lupusnephritisandthromboticmicroangiopathy\nbetteravoided. Ifpatientsrelapseduringpregnancy,treatmentchoicesarePracticePoint10.3.1.1:PatientswithLNandthrombotic\n(cid:4)\nmorelimited.ThesearediscussedinSection10.3.2.microangiopathy(TMA)shouldbemanagedaccordingto\nPatientpreferenceand/ortoleranceoftheinitialregimentheunderlyingetiologyofTMA,asshowninFigure13.",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "GlomerularDiseases;b.i.d.,twicedaily;i.v.,intravenous;MMF,mycophenolatemofetil;p.o.,oral;q2wk,every2weeks;q4wk,every4weeks;s.c.,subcutaneous. (Part 36)",
    "content": "(cid:4)\nshouldbeconsidered.Also,patientadherenceshouldbeTMAisapathologicdescriptionofvascularendothelial\n291\nconsideredinthechoiceoftreatment.injurysecondarytovariousetiologies.ThecausesofTMA\nKidneyInternational\nS47\n(2024)105(Suppl1S),S1–S69",
    "page": 31,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 1)",
    "content": "www.kidney-international.org\nLupus nephritis AND\nsuspected\nthrombotic microangiopathy\nTest for ADAMTS13 activity and antibodies to ADAMTS13\nTest for antiphospholipid antibodies\nStart plasma exchange\nModerate/high riskand glucocorticoid\n(>5 points)while awaiting test\nThrombotic thrombocytopenic\nresults (adults)\npurpura\n(PLASMIC score)\nLow risk\n(0–4 points)\nLow ADAMTS13Normal ADAMTS13Normal ADAMTS13\nactivity (<10%)activity and negativeactivity and positive\nantiphospholipidantiphospholipid\nantibodiesantibodies\nSystemic lupusEvaluate forAntiphospholipid\nerythematosus-thromboticsyndrome nephropathy\nassociated thromboticmicroangiopathy\nthrombocytopenic purpuraetiologies\nPrimary or secondary\ncomplement-mediated\nthrombotic\nmicroangiopathy\nConsiderOtherPlasma exchangeAnticoagulation\neculizumabetiology+ glucocorticoid+/– plasma exchange\n+ rituximab\n+/– caplacizumab\nFigure13|Managementofpatientswithlupusnephritisandthromboticmicroangiopathy(TMA).BendapudiPK,HurwitzS,FryA,etal. DerivationandexternalvalidationofthePLASMICscoreforrapidassessmentofadultswiththromboticmicroangiopathies:acohortstudy. LancetHaematol.2017;4:e157e164.ADAMTS13,adisintegrinandmetalloproteinasewithathrombospondintype1motif,member13;\nPLASMIC,Plateletcount,combinedhemoLysisvariable,absenceofActivecancer,absenceofStem-cellorsolid-organtransplant,mean\ncorpuscularvolume(MCV),internationalnormalizedratio(INR),Creatinine.",
    "page": 49,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 2)",
    "content": "mostrelevanttopatientswithLNarethromboticthrombo-diagnosis,suchasactivityofADAMTS13(adisintegrinand\ncytopenicpurpura(TTP),antiphospholipidsyndrome(APS),metalloproteinasewithathrombospondintype1motif,\nandcomplement-mediatedTMA.However,patientswithmember13)orthepresenceofanti-ADAMTS13antibodiesin\nlupuscanalsodevelopTMAduetoShiga-toxin-hemolyticthecaseofTTP,antiphospholipidantibodies,andcomplement\n292,293\nuremicsyndrome,infections,drugs,ormalignancies.studies,maynotbeavailable,andevenwhentheyareavailable,\nThekeytoagoodoutcomeforTMAinLNisrapiddiag-theyoftentakeconsiderabletimetocomplete(Figure13).If\nnosisandprompttreatment.WhenappropriateexpertiseisTTPissuspected,onemayconsiderusingscoringthroughthe\navailable,itispreferablethatpatientswithLNandTMAbePLASMIC(Plateletcount,combinedhemoLysisvariable,\ncomanagedwithanexperiencedhematologist.However,someabsenceofActivecancer,absenceofStem-cellorsolid-organ\nﬁﬁ\noftheserologicandgenetictestingneededforaspecictransplant,MCV,INR,Creatinine),andifthescoredenes\nKidneyInternational\nS48\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\nanintermediate-to-highriskofTTP,adultsshouldbestartedalternativecomplementpathwayduetogeneticoracquired\nonplasmaexchangeandglucocorticoidswhilewaitingforthefunctionaldefectsincomplementregulatoryproteins,resulting\ninvestigationresults.Inchildren,TTPislesscommon,andinexcessiveproductionoftheterminalcomplementcomplex\nplasmaexchangehasbeenassociatedwithconsiderableC5b-C9,triggeringendothelialcellinjurythatpredominantly\n294\nmorbidity,soitisacceptabletodeferplasmaexchangeforaffectsthekidneyvasculatureinthearteriolesandinterlobular\n–ﬁ\n2448hoursuntiltheADAMTS13resultisavailabletoconrmarteries. 295\nthattheprocedureisindicated.Complement-mediatedTMAinLNdoesnotrespondwell\nThediagnosisofTTPistoplasmaexchangeorimmunosuppressionwithglucocorti-\nTMAduetolupus-associatedTTP. mainlyreservedforpatientswithTMAandlowADAMST13coidsandcyclophosphamide,anditmaybebesttreatedwith\n#ﬁ\n291,296\nactivity(10%).ThetreatmentofconrmedTTPinacomplementinhibitorsuchaseculizumab,althoughthe\n321323\nLNisextrapolatedfromthatofacquiredTTPandincludesoptimaldoseanddurationremaincontroversial.The\n297,298299,300\nplasmaexchange,high-doseglucocorticoids,rit-limiteddatatodateshowahighresponserate,withresolution\n301304324\nuximab,and/orcaplacizumab(vonWillebrandfactorofTMAin68%ofpatientswithsecondaryaHUS.Data\n305,306\ninhibitor;Figure13).from31adultpatients(26treatedwithplasmatherapyand5\nAntiphospholipidantibodies(aPLA)areplasma-resistantpatientstreatedwitheculizumab)showed\nTMAduetoAPS.",
    "page": 49,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 3)",
    "content": "foundinabout30%ofpatientswithSLEandmaybeasso-completekidneyrecoveryin4of5eculizumab-treatedpa-\n325\nciatedwithvenousand/orarterialmacro-ormicrovasculartients.Efcacyofeculizumabtreatmentwasalsoreported\nthrombosis,thrombocytopenia,adversepregnancyoutcomes,inpatientswithlupusandheterozygousdeletionincomple-\nandneurologicabnormalities.Kidneydamageisawell-mentfactorHCFHR1-CFHR3genepresentingwithTMA,\nrecognizedcomplicationofAPS,presentingasrenalarteryandareviewof20patientsshowedakidneyrecoveryrateof\nthrombosisorstenosis,renalveinthrombosis,orinjurytothe85%inpatientswithSLEand/orAPSaftertreatmentwith\n307326\nkidneymicrovasculature,alsoknownasAPSnephropathy.eculizumab.Arecentreporton9patientswithTMA\nTherearefewdataonthemanagementofAPSnephropathy.associatedwithSLEand/orAPSshowedthatkidneyfunction\nInaretrospectivestudyof97patientswithkidneyTMA,improvedby25%inhalfofthepatientsafter4weeksof\n62.9%testedpositiveforaPLA,38.1%testedpositiveforeculizumabtreatment,and2of3patientswereabletodis-\n308327\nlupusanticoagulant,and13.4%hadAPS.Completeandcontinuedialysis. partialresponserateswere38.1%and22.6%,respectively,Anotherrecentreporton11patientswithTMAandLN\nafter12monthsofimmunosuppressivetreatment.Thirty-showedcomplementregulatoryproteinmutationsin6pa-\n317\nsevenof61patientswhowereaPLA-positivealsoreceivedtients,andresponsetoeculizumabtreatmentin10patients.",
    "page": 49,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 4)",
    "content": "anticoagulationtherapy,andanticoagulatedpatientsshowedaPriortotheadventofeculizumab,plasmaexchangeand/or\nhighercompleteresponserate(59.5%vs.30.8%).ThepartialplasmainfusionwastheonlytreatmentforaHUS,withef-\nresponseratewas18.9%and26.9%inpatientswhohadorcacyinlessthanhalfofpatientsandlittlebenetinpatients\n300,328,329\nhadnotreceivedanticoagulanttherapy,respectively.There-withmembranecofactorproteinmutations.As\nfore,itisreasonabletotreatAPSnephropathywithlong-termcomplementstudiesoftentakesometimetobereturned,\nanticoagulationwithwarfarin.Directoralanticoagulantsareinitiationofplasmaexchangeiswarrantedduringthewaiting\nnotrecommended,astheywereinferiortowarfarininpre-period,orifaccesstoeculizumabislimited.Therationaleand\n309,310\nventingthromboemboliceventsinthissetting.objectivesofplasmainfusionandplasmaexchangeinclude\nCatastrophicAPSischaracterizedbythrombosis,oftenofthereplacementofabsentormutatedcirculatingcomplement\nrapidonset,affectingmultipleorgans,anditisassociatedregulatorssuchascomplementregulatorygenesfactorH\nwithhighmortality.Treatmentincludesbothtotalanti-(CFH)andtheremovalofantibodiesdirectedtocomplement\n311\ncoagulationandhigh-doseglucocorticoids.Plasmaex-regulatoryproteinsormutatedfactorsthatplayapermissive\n312\nchangeisoftenusedincatastrophicAPSandhasbeenroleinaberrantcomplementactivation.Intheabsenceof\nassociatedwithimprovedpatientsurvivalinretrospectiveeculizumab,theefcacyofplasmaexchangeandplasma\n313\nstudies.Therearerecentanecdotalreportsonthepotentialinfusionvaries,andthedurationoftherapyisdependenton\n314,315330333\nefcacyofrituximabincatastrophicAPS.Ithasbeenthetreatmentresponse.Datafrom31adultpatients(26\nshownthatcomplementactivationisinvolvedinthepatho-treatedwithplasmatherapyand5plasma-resistantpatients\ngenesisoftissueinjuryinducedbyaPLA,andthereistreatedwitheculizumab)showedrecoveryofkidneyfunction\n325\nemergingevidenceontheefcacyofeculizumabintheinapproximately40%ofpatientsgivenplasmatherapy. 316318\ntreatmentofcatastrophicAPS. Complement-mediatedTMAandatypicalhemolyticuremic10.3.2Pregnancyinpatientswithlupusnephritis\nManycasesofkidneyTMAwithADAMTS13\nsyndrome(aHUS). activity10%andnegativeaPLAcorrespondtocomplement-PracticePoint10.3.2.1:PatientswithactiveLNshouldbe\nmediatedTMA,andthesepatientsideallyshouldbeevaluatedcounseledtoavoidpregnancywhilethediseaseisactiveor\n319,320\nwithcomplementstudieswhentheyareavailable.aHUSiswhentreatmentwithpotentiallyteratogenicdrugsis\narareandsevereformofTMAcausedbydysregulationoftheongoing,andfor6monthsafterLNbecomesinactive. KidneyInternational\nS49\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\nPracticePoint10.3.2.2:Toreducetheriskofpregnancy\n10.3.3Treatmentoflupusnephritisinchildren\ncomplications,hydroxychloroquineshouldbecontinued\nduringpregnancy,andlow-doseaspirinshouldbestarted\nPracticePoint10.3.3.1:TreatpediatricpatientswithLN\nbefore16weeksofgestation.",
    "page": 49,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 5)",
    "content": "usingimmunosuppressionregimenssimilartothoseused\ninadults,butconsiderissuesrelevanttothispopulation,\nPracticePoint10.3.2.3:Glucocorticoids,hydroxy-\nsuchasdoseadjustment,growth,fertility,andpsychosocial\nchloroquine,azathioprine,tacrolimus,andcyclosporine\nfactors,whendevisingthetherapyplan. areconsideredsafeimmunosuppressivetreatmentsduring\nApproximately20%ofSLEisdiagnosedbeforetheageof18\npregnancy. years,andgeneticcomponentsaremorecommoninchildhood-\n341343\nAdversepregnancyoutcomes,suchaspreeclampsia,pre-\nonsetSLE.Thereissuggestiveevidencethatdiseaseis\ntermbirth,andfetalloss,aremorefrequentinpatientswith\noftenmoresevereinthepediatricpopulation.Inadolescent\n334,335\nactiveLN.CommonlyusedmedicationsforLNin-\npatientswithSLEandisolatedproteinuria,orthostaticor\nductionandmaintenancetherapy,particularlycyclophos-\nposturalproteinuriashouldbeexcluded,asthisphenomenon\n344,345\nphamideandMMFformulations,aretoxictothefetusand\nhasbeenobservedfrequentlyinthispopulation. teratogenic,respectively.Adiscussionofacceptablemethods\nTherearefewlarge-scaleRCTstoguidetreatmentof\nofcontraceptionshould,therefore,takeplaceaspartof\nchildrenwithLN,andmuchofthecurrentliteraturereports\ninitiatingtreatmentforLN.Becauseoftheincreasedriskof\ntheresultsofadultregimensappliedtothispopulation.The\nﬁﬁﬁ\nclottinginpatientswithSLEandantiphospholipidantibodies,\ndataareinsufcienttoconrmsuperiorityofefcacyforany\nuseofestrogen-containingbirthcontrolshouldbeavoidedor\nparticulartreatmentregimen.Recentlyreportedlong-term\nminimized.Arisk-factorchecklisthasbeenproposedbysome\ndatafrom92patientswithbiopsy-provenLNoccurring\norganizationstostratify,plan,andcounselpregnancyinpa-\nbeforetheageof18years,presentinginthetimeperiod\n336\ntientswithlupus. 20012020,showedsurvivalrateswithoutadvancedCKD,\nHydroxychloroquineisconsideredsafeinpregnancyand\nkidneyfailure,ordeathof94.2%,92.7%,and83.2%at5,10,\nmaydecreasetherateofpretermbirthandintrauterine\nand20years,respectively.Inductionimmunosuppression\ngrowthretardation,whereaswithdrawalofhydroxy-\nwasdoneusingglucocorticoidandMPAA(36%)orcyclo-\nchloroquinehasbeenassociatedwithLNare,soitshouldbe\nphosphamide(34%),whileMPAAwerethemaintenance\n43,48,337\n346\ncontinuedwhenanLNpatientbecomespregnant.",
    "page": 49,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 6)",
    "content": "immunosuppressivemedicationin55%.Severalissues\nLow-doseaspirin(100mg/d)mayalsoreducetheriskof\nmustbeaddressedwhentreatingpediatriclupus,including\npreeclampsiaandintrauterinegrowthretardationandcanbe\nadherenceconcerns,whichmayfavori.v.medications;\nstartedatconceptionorassoonaspregnancyisrecog-\ngrowthconcerns,whichmayfavorlimitingglucocorticoid\n338,339\nnized.TheincidenceofLNareinpregnancyhasbeen\nexposure;fertilityconcerns,especiallyaspatientsapproach\nreportedtobe11%28%andishigherifpatientshavelow\nadolescence,whichmayfavorlimitingcyclophosphamide\nserumcomplementlevelsorhighanti-dsDNAantibodyti-\nexposure;andpsychosocialconcernsrelatingtoschooland\n334\nters.ActiveLNduringpregnancycanbetreatedwith\nsocializationwithpeers.Specialconsiderationsregarding\nglucocorticoidsplusazathioprineand/oraCNI,althoughin\nglucocorticoiddosinginchildrenareincludedunderPrac-\nthersttrimester,theuseofglucocorticoidsisassociatedwith\nticePoint10.2.3.1.1.Treatmentdecisionsforhyperlipidemia\nanincreasedriskofgestationaldiabetesandcleftpalate.For\narerisk-stratied,andstatinsmaybegiventochildrenaged\npatientsonmaintenancetherapy,iftheyareonazathioprine,\n8yearsorabove.ChildrenwithLNshouldbecomanagedby\nthiscanbecontinued,butiftheyareonMPAA,thismustbe\npediatricnephrologistsandrheumatologistswithexpertise\ndiscontinuedorchangedtoazathioprine.Althoughthereare\ninlupus,andtheexpertiseofotherprofessionals,suchas\n214\nemergingdataontheuseofbelimumabinpregnancy,this\nclinicalpsychologists,psychiatrists,orsocialworkers,canbe\ndrugislabeledascategoryCandcannotberecommendedfor\nhelpful. useinpregnancyatthistime.Prescribinginformationfrom\nthemanufacturerstatestoavoidtheuseofvoclosporinin\n10.3.4Managementoflupuspatientswithkidneyfailure\npregnantwomenduetothealcoholcontentofthedrug\nformulation,whilethereareinsufcientdatatoconclude\nPracticePoint10.3.4.1:PatientswithLNwhodevelop\nwhetherthereisadrug-associatedriskformajorbirthdefects,\nkidneyfailuremaybetreatedwithhemodialysis,peritoneal\nmiscarriage,oradversematernalorfetaloutcomes.Datafrom\ndialysis,orkidneytransplantation;andkidneytrans-\nanimalstudiesshowedembryo/feticidaleffectsbutno\nplantationispreferredtolong-termdialysis. treatment-relatedfetalmalformations. Therearenodatatofavoroneformofdialysisover\nHydroxychloroquine,tacrolimus,low-doseazathioprine,\nanotherinkidneyfailureduetoLN.Patientswithlupus\nandprednisonehavelimitedtransferintobreastmilkandare\nreceivinghemodialysisdisplaysimilar3-yearsurvivalrates\nconsideredsafewithbreastfeeding.MPAAarecontraindicated\nandmortalityduetoCVorinfectiouscomplicationsto\n340\n347349\nwhenpatientsarebreastfeeding. thoseofpatientsreceivingperitonealdialysis. KidneyInternational\nS50\n(2024)105(Suppl1S),S1–S69\nlupusnephritis\nwww.kidney-international.org\nTherefore,kidneyreplacementtherapyshouldbeindivid-includingbiologicmedicationstargetingspecicpathogenic\nualized,takingintoaccountpatientcharacteristicsandpathways.",
    "page": 49,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "lupusnephritis (Part 7)",
    "content": "preferences.Establishrenalresponsecriteriathatreectresolutionof\n(cid:4)\nKidneytransplantationispreferredtodialysis.Kidneydiseaseactivityatthetissuelevelandarealsopredictiveof\ntransplantoutcomesaresimilartothoseinpatientswholong-termkidneysurvivalandpatientsurvivalwithout\ndevelopedkidneyfailureduetoothertypesofkidneyneedofkidneyreplacementtherapy. 350,351\ndisease,andtransplantedpatientshavelowermor-Establishcriteriafordurationofmaintenanceimmuno-\n(cid:4)\n352\ntalitythanpatientswithlupuswhoremainondialysis.suppressionandthesafewithdrawaloftherapy. AsclinicaloutcomesarebetterinpatientswithshorterRCTsareneededtotestthefollowingquestions:\n(cid:4)\n353,354\ndurationsofdialysis,transplantationmaybecarriedWhatistheoptimaltherapyforpatientswithsevereClass\noutassoonasdiseaseisquiescent.AlthoughlupusactivityIII/IVLN(i.e.,patientspresentingwithsevereacute\ntendstodecreaseafterkidneyfailuredevelops,patientscankidneydiseaseand/ormarkedlyabnormalSCrlevelor\n355\nstillare,soperiodicmonitoringisrequired.LNcaneGFR)whohavebeenexcludedfromthemajorityof\nrecurinkidneyallografts,buttheriskislow,andaresdoclinicaltrialstodate? 356358\nnotgenerallyresultinallograftloss.OneimportantWhatistheoptimaltherapyforpureClassVLN? considerationisthatpatientswhohaveantiphospholipidDoantimalarialsimprovetheresponsivenessofLNto\nantibodiesmayexperiencedialysisvascularaccessclottingtreatmentand/orhelpmaintaindiseasequiescenceand\norallograftthrombosisandmayrequireprophylacticpreventares? 359361\nanticoagulation.Istherearoleforcomplementinhibitionintheman-\nagementofLN? Researchrecommendations\nWhataretheoptimalorprioritizedtherapiesforchild-\nIdentifyandvalidatebiomarkersofkidneyhistologythat\nhoodLN? (cid:4)\nﬁﬁ\ncanbeusedtofollowthetissueresponsetotreatmentin\nWhataretheefcacyandsafetyprolesofCNIs,\nreal-timetohelpinmanagingimmunosuppression. includingtheoptimaldrugexposurewhenusedasinitial\nIdentifyandvalidatebiomarkersofimpendingLNarethat\normaintenancetreatmentofLN?Whatarethelong-term\n(cid:4)\ncanbeusedtodecideifpreemptiveimmunosuppressive\nimplicationsofsuchtreatment? therapyisindicated. Whataretheoptimalglucocorticoid-reductionprotocols\nClassifyLNonthebasisofmolecularpathogenesisand\nforLNmanagement? (cid:4)\nhistologyasopposedtohistologyalone.Thisclassication\nWhatistheeffectontheincidenceofdiseaserelapses\nideallycouldbeusedinconjunctionwithnovel,targeted\nfromB-celldirectedtherapiesinitiatedduringthe\ntherapiesforLNtoselectthemostappropriatetreatment,\nmaintenancephase? KidneyInternational\nS51\n(2024)105(Suppl1S),S1–S69",
    "page": 49,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Methodsforguidelinedevelopment (Part 1)",
    "content": "Aim\nDeningscopeandtopicsandformulatingkeyclinical\nThisisanupdateoftheLupusnephritischapteroftheKDIGO\nquestions. Duetoresourcingandtheprobabilityofpractice-\nClinicalPracticeGuidelinefortheManagementofGlomerular\nchangingstudies,clinicalquestionsoneffectivenessandsafetyof\n362\nDiseasespublishedin2021.Basedontherecentlypublisheddata\ninterventionsincludedintheguidelineupdatewerelimitedtoRCTs. intheeld,itwasdecidedthataguidelineupdatewasrequired. Guidelinetopicsandclinicalquestionsfocusingonnonrandomized\nTheobjectiveofthisprojectwastoupdatetheevidence-based\nstudieswerenotincludedintheguidelineupdate(Supplementary\nclinicalpracticeguidelineforthemanagementofLN.Theguide-\nTableS1).TheguidelineWorkGroup,withassistancefromthe\nlinedevelopmentmethodsaredescribedbelow. ERT,determinedtheoverallscopeoftheguideline.Apreliminarylist\noftopicsandkeyclinicalquestionswasinformedbytheprevious\n362\nKDIGOguideline.Themajorityofclinicalquestionsforthis\nOverviewoftheprocess\nguidelinewerebaseduponRCTstoavoidbiasbydesign.Clinical\nThisguidelineadheredtointernationalbestpracticesforguideline\n363\nquestionsadheredtothepopulation,intervention,comparator,\ndevelopment(AppendixB:SupplementaryTablesS2andS3).This\noutcomes,andstudydesign(PICOD)format(alistofcriticaland\nguidelinehasbeendevelopedandreportedinaccordancewiththe\n364\nimportantoutcomeswascompiledaftervotingbytheWorkGroup\nAGREEIIreportingchecklist. [Table1]).ClinicalquestionsweremappedtoexistingCochrane\nTheprocessesundertakenforthedevelopmentoftheKDIGO\nKidneyandTransplantsystematicreviews.Thesesystematicreviews\n2024ClinicalPracticeGuidelinefortheManagementofLupus\nwereupdatedaccordingly.Forclinicalquestionsthatdidnotmapto\nNephritisincluded:\nanyCochraneKidneyandTransplantsystematicreviews,denovo\nAppointingWorkGroupmembersandtheERT\n(cid:4)\nsystematicreviewswereundertaken.Thepreviousguidelinewas\nDeningscopeoftheguidelineupdate\n(cid:4)\nreviewedtoensureallidentiedstudieswereincludedintheevi-\nImplementingliteraturesearchstrategiestoupdatetheevidence\n(cid:4)\n362\ndencereview.DetailsofthePICODquestionsandassociated\nbasefortheguideline\nCochraneKidneyandTransplantsystematicreviewsareprovidedin\nSelectingstudiesaccordingtopredenedinclusioncriteria\n(cid:4)\n121\nTable2. Conductingdataextractionandcriticalappraisaloftheupdated\n(cid:4)\nAllevidencereviewswereconductedinaccordancewiththe\nliterature\n365\nCochraneHandbook,andguidelinedevelopmentadheredtothe\nUpdatingtheevidencesynthesisandmeta-analysistoinclude\n(cid:4)\nstandardsofGRADE(GradingofRecommendations,Assessment,\nnewlyidentiedstudies\n366\nDevelopment,andEvaluation). Updatingthecertaintyoftheevidenceforeachoutcome\n(cid:4)\nLiteraturesearchesandarticleselection.",
    "page": 53,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Methodsforguidelinedevelopment (Part 2)",
    "content": "FortheKDIGO2024\nFinalizingguidelinerecommendationsandsupportingrationale\n(cid:4)\nClinicalPracticeGuidelinefortheManagementofLupusNephritis,\nGradingthestrengthoftherecommendations,basedonthecer-\n(cid:4)\nupdatedliteraturesearcheswereconductedinMEDLINE(via\ntaintyoftheevidenceandotherconsiderations\nPubMed),Embase,andtheCochraneCentralRegisterofControlled\nConveningapublicreviewoftheguidelinedraftinMarch2023\n(cid:4)\nTrials.Thesearcheswererestrictedtorecordsenteredintotheda-\nAmendingtheguidelinebasedontheexternalreviewfeedbackand\n(cid:4)\ntabasessinceJanuary1,2020.Thiswasdonetoprovidea6-month\nupdatingtheliteraturesearch\noverlapwiththepriorsearches.Thesearcheswereconductedon\nFinalizingandpublishingtheguideline\n(cid:4)\nJuly7,2022andupdatedonApril25,2023.Thesesearchupdates\nCommissioningofWorkGroupandERT. TheKDIGOCo-\nincludedtermsforbothLNandantineutrophilcytoplasmicanti-\nChairsappointedtheWorkGroupCo-Chairs,whothenassem-\nbodies(ANCA)vasculitis(whichunderwentupdatingconcurrently\nbledtheWorkGroup,toincludecontentexpertsinadult\nwiththechapteronlupusnephritis). nephrology,epidemiology,andpublichealth.TheWorkGroupwas\nresponsibleforwritingtherecommendationsandpracticepoints\nTable1|Hierarchyofoutcomes\nandunderlyingrationale,aswellasgradingthestrengthofeach\nrecommendation. HierarchyOutcomes\nForthe2024update,theBrownUniversitySchoolofPublic\nCriticaloutcomesAll-causemortality\n(cid:4)\nHealthCenterforEvidenceSynthesisinHealthwascontractedto\nKidneyfailure\n(cid:4)\nupdatethesystematicevidencereviewandprovideexpertisein\n50%lossofGFR\n(cid:4)\nguidelinedevelopmentmethodology.TheBrownERTconsistedofa\nInfection\n(cid:4)\nGlucocorticoid-relatedadverseevents\n(cid:4)\nseniorphysicianmethodologistwholedtheERTforthe2012\nMalignancy\n(cid:4)\nKDIGOClinicalPracticeGuidelineforGlomerulonephritis,anadult\nImportantoutcomesCompleteremission/relapse\n(cid:4)\nnephrologist,andalibrarianmethodologist,allwithexpertisein\nAnnualGFRloss(minimum3yearsfollow-up)\n(cid:4)\nevidencesynthesisandguidelinedevelopment,includingforKDIGO\nGFR,glomerularltrationrate. guidelines.CochraneKidneyandTransplantwascontractedto\nThecriticalandimportantoutcomeswerevotedonbytheWorkGroupusingan\nconductsystematicevidencereviewandprovideexpertiseinguide-\n––\nadaptedDelphiprocess(19Likertscale).Criticaloutcomeswererated79,and\nlinedevelopmentmethodologyforthe2021Guideline.–\nimportantoutcomeswererated46onthe9-pointscale. KidneyInternational\nS52\n(2024)105(Suppl1S),S1–S69",
    "page": 53,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "methodsforguidelinedevelopment (Part 1)",
    "content": "www.kidney-international.org\nTable2|ClinicalquestionsandsystematicreviewtopicsinPICODformat\nPICODcriteriaLupusnephritis\nClinicalquestionInpatientswithbiopsy-provenLN,comparedtonotreatment,placebo,orstandardofcare,doesantimalarial\ntherapyimproveclinicalefcacyoutcomesandreduceadverseeffects? PopulationPatientswithbiopsy-provenLN\nInterventionAntimalarialtherapy\nComparatorNotreatment,placebo,orstandardofcare\nOutcomesOutcomeslistedinTable1\nStudydesign2021Guideline:RCTsandobservationalstudies\n2024Guideline:RCTspublishedinpeer-reviewedjournals\nCochranesystematicreviewsNonerelevant\nSoFtablesSupplementaryTableS4\nClinicalquestionInpatientswithnonproliferative(ClassI,II,V,orVI)LN,whatimmunosuppressiveagents,comparedto\nnotreatment,placebo,orotherimmunosuppressivetherapies,improveefcacyoutcomes,andreduce\nadverseeffects? PopulationPatientswithbiopsy-provennonproliferative(ClassI,II,V,orVI)LN\nInterventionImmunosuppressivetherapy\nComparatorNotreatment,placebo,orotherimmunosuppressivetherapies\nOutcomesOutcomeslistedinTable1\nStudydesignRCTs\nCochranesystematicreviewsNonerelevant\nSoFtablesSupplementaryTablesS30,S32,S33\nClinicalquestionInpatientswithbiopsy-provenproliferative(ClassIII,IV,III/V,orIV/V)LN,whatimmunosuppressiveagents,\ncomparedtonotreatment,placebo,orotherimmunosuppressivetherapies,improveclinicalefcacy\noutcomes,andreduceadverseeffects? PopulationPatientswithbiopsy-provenproliferative(ClassIII,IV,III/V,orIV/V)LN\nInterventionImmunosuppressivetherapy\nComparatorNotreatment,placebo,orotherimmunosuppressivetherapies\nOutcomesOutcomeslistedinTable1\nStudydesignRCTs\nCochranesystematicreviewsTunnicliffeDJ,etal.Immunosuppressivetreatmentforproliferativelupusnephritis.CochraneDatabaseof\n121\nSystematicReviews.2018:6;CD002922\n––\nSoFtablesSupplementaryTablesS5S29,S31,andS34S49\nLN,lupusnephritis;MCD,minimalchangedisease;PICOD,population,intervention,comparator,outcomes,studydesign;RCT,randomizedcontrolledtrial;SoF,summaryof\nndings. ThetitlesandabstractsresultingfromthesearcheswerescreenedWasthereadequatesequencegeneration(selectionbias)? (cid:4)\nby2membersoftheERTwhoindependentlyassessedretrievedWasallocationadequatelyconcealed(selectionbias)? (cid:4)\nabstracts,andifnecessary,thefulltext,todeterminewhichstudiesWasknowledgeoftheallocatedinterventionsadequatelypre-\n(cid:4)\nsatisedtheinclusioncriteria.Disagreementaboutinclusionwasventedduringthestudy(detectionbias)? resolvedbydiscussionwithathirdmemberoftheERT.Participantsandpersonnel(performancebias)\n(cid:4)\nFortheKDIGO2021guideline,atotalof25,925citationswereOutcomeassessors(detectionbias)\n(cid:4)\nscreened.Ofthese,479RCTsand102observationalstudieswereWereincompleteoutcomedataadequatelyaddressed(attrition\n(cid:4)\nincludedintheevidencereviewforalldiseases.Forthe2024update,bias)? atotalof1556citationswerescreened(forbothLNandANCAArereportsofthestudyfreeofsuggestionofselectiveoutcome\n(cid:4)\nvasculitis)(Figure14).Fromthese,wefound21neweligiblearticlesreporting(reportingbias)?",
    "page": 54,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "methodsforguidelinedevelopment (Part 2)",
    "content": "onLNthataddressed16newRCTs,in17publications,and4newWasthestudyapparentlyfreeofotherproblemsthatcouldputit\n(cid:4)\nanalysesofpreviouslyincludedRCTs.atriskofbias? Allcriticalappraisalwasconductedindependentlyby2members\nDataextraction. FortheKDIGO2024ClinicalPracticeGuide-\noftheERT,withdisagreementsregardingtheriskofbiasadjudica-\nlinefortheManagementofLupusNephritis,dataextractionwas\ntionsresolvedbyconsultationwithathirdreviewauthor. performedby1memberoftheBrownERTandconrmedbythe2\nEvidencesynthesisandmeta-analysis.Measuresoftreatment\nothermembersoftheERT.TheBrownERTextracteddataintothe\nformsdesignedbytheCochraneERT.TheCochraneERTdesigned\neffect. Dichotomousoutcome(all-causemortality,kidney\ndataextractionformstocapturedataonstudydesign,study\nfailure,50%lossofGFR,infection,malignancy,completeremis-\nparticipantcharacteristics,interventionandcomparatorcharacter-\nsion/relapse)resultswereexpressedasRRwith95%CI.When\nistics,andcriticalandimportantoutcomes.Anydifferencesin\ncontinuousscalesofmeasurementwereusedtoassesstheeffectsof\nextractionbetweenmembersoftheERTwereresolvedthrough\ntreatment,suchasannualGFRloss,themeandifference(MD)with\ndiscussion.Athirdreviewerwasincludedifconsensuscouldnotbe\n95%CIwasused. achieved. Datasynthesis. DatawerepooledusingtheMantel-Haenszel\nCriticalappraisalofstudies. Themajorityofreviewsunder-\nrandom-effectsmodelfordichotomousoutcomesandtheinverse\ntakenwereinterventionreviewsthatincludedRCTs.Forthesere-\nvariancerandom-effectsmodelforcontinuousoutcomes.Therandom-\nviews,theCochraneRiskofBiastoolwasusedtoassessindividual\neffectsmodelwaschosenbecauseitprovidesaconservativeestimateof\n367\n365\nstudylimitationsbasedonthefollowingitems:\neffectinthepresenceofknownandunknownheterogeneity. KidneyInternational\nS53\n(2024)105(Suppl1S),S1–S69",
    "page": 54,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "methodsforguidelinedevelopment (Part 1)",
    "content": "www.kidney-international.org\nStudies included for lupus nephritis\nRecords removed before screening:\nin previous version of the guidelineand LN chapters: PubMed, Embase,\nDuplicate records removed (n = 0)\n(n = 81 RCTs, 16 observational studies)Cochrane CENTRAL (n = 1556)\nRecords screened\nRecords excluded\n(n = 1556)\n(n = 1405)\nReports sought for retrievalReports not retrieved\n(n = 151)(n = 0)\nReports excluded:\nReports assessed for eligibility\nWrong population (n = 12)\n(n = 151)\nWrong study design (n = 105)\nNo outcomes of interest (n = 8)\nPreviously included (n = 5)\nNew studies included in\nreview for LN chapter\n(n = 21*)\nTotal studies included in review for LN\n(n = 97 RCTs, 16 observational studies)\nﬂﬁ\nFigure14|Searchyieldandstudyowdiagram.*16RCTsin17records,and4newrecordsfrompreviouslyidentiedstudies.ANCA,\nantineutrophilcytoplasmicantibody;LN,lupusnephritis;RCT,randomizedcontrolledtrial. Assessmentofheterogeneity.Sensitivityanalysis. Heterogeneitywasassessedbyvi-Thefollowingsensitivityanalyseswere\nsualinspectionofforestplotsofstandardizedmeaneffectsizes,andconsidered:\nofriskratios,andbytests.APvalueof0.1wasusedtodenoteRepeatingtheanalysisexcludingunpublishedstudies\n(cid:4)\nstatisticalheterogeneity,andanIwascalculatedtomeasuretheRepeatingtheanalysis,takingaccountoftheriskofbias,as\n(cid:4)\nproportionoftotalvariationintheestimatesoftreatmenteffectthatspecied\n365\nwasduetoheterogeneitybeyondchance.WeusedconventionsofRepeatingtheanalysisexcludinganyverylongorlargestudies,to\n(cid:4)\n368\ninterpretationasdenedbyHigginsetal.establishhowmuchtheydominatetheresults\nRepeatingtheanalysisexcludingstudiesusingthefollowinglters:\nAssessmentofpublicationbias. (cid:4)\nWemadeeveryattemptto\nlanguageofpublication,sourceoffunding(industryvs.other),\nminimizepublicationbiasbyincludingunpublishedstudies(for\nandcountryinwhichthestudywasconducted. example,bysearchingonlinetrialregistries).Toassesspublication\nHowever,theavailabledatawereinsufcienttodeterminethe\nbias,weusedfunnelplotsofthelogoddsratio(effectvs.standard\ninuenceofthesefactorsontheeffectsizeofcriticalandimportant\nerroroftheeffectsize)whenasufcientnumberofstudieswere\n365\noutcomes. available(i.e.,10studies).Otherreasonsfortheasymmetryof\nGradingthecertaintyoftheevidenceandthestrengthofa\nfunnelplotswereconsidered. Subgroupanalysisandinvestigationofheterogeneity.guidelinerecommendation.GRADINGthecertaintyoftheevidence\nSubgroup\nanalysiswasundertakentoexplorewhethertherewereclinicaldif-\nforeachoutcomeacrossstudies.",
    "page": 55,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "methodsforguidelinedevelopment (Part 2)",
    "content": "Theoverallcertaintyoftheevi-\nferencesamongthestudiesthatmayhavesystematicallyinuenced\ndencerelatedtoeachcriticalandimportantoutcomewasassessed\n366,369\nthedifferencesthatwereobservedinthecriticalandimportant\nusingtheGRADEapproach,whichassessesthecertaintyofthe\noutcomes.However,subgroupanalysesarehypothesis-forming\nevidenceforeachoutcome.Foroutcomesthatarebasedondatafrom\nratherthanhypothesis-testingandshouldbeinterpretedwith\nRCTs,theinitialgradeforthecertaintyoftheevidenceisconsideredto\ncaution.Thefollowingsubgroupswereconsidered:baselinekidney\nbehigh.Forobservationalstudies,theinitialcertaintyoftheevidence\nfunction(GFR,proteinuria,presenceofalbuminuria,presenceof\nislow.Thecertaintyoftheevidenceisloweredintheeventofstudy\nmacroscopichematuria),histopathologicclassofdisease,primary\nlimitations;importantinconsistenciesinresultsacrossstudies;indi-\nversussecondaryformsofdisease,sex,andadultversuspediatric. rectnessoftheresults,includinguncertaintyaboutthepopulation,\nThetestofsubgroupdifferencesusedtheIstatisticandaPvalueof\nintervention,andoutcomesmeasuredintrialsandtheirapplicability\n365\n0.10(notingthatthisisaweaktest). totheclinicalquestionofinterest;imprecisionintheevidencereview\nKidneyInternational\nS54\n(2024)105(Suppl1S),S1–S69",
    "page": 55,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "methodsforguidelinedevelopment (Part 1)",
    "content": "www.kidney-international.org\nTable3|Gradingofcertaintyoftheevidence\nGradeCertaintyofevidenceMeaning\nAHighWearecondentthatthetrueeffectisclosetotheestimateoftheeffect. BModerateThetrueeffectislikelytobeclosetotheestimateoftheeffect,butthereisapossibilitythatitissubstantiallydifferent. CLowThetrueeffectmaybesubstantiallydifferentfromtheestimateoftheeffect. DVerylowTheestimateoftheeffectisveryuncertain,andoftenitwillbefarfromthetrueeffect. Table4|GRADEsystemforgradingcertaintyofevidence\nStartinggradeforthe\n——\nStudydesigncertaintyofevidenceStep2lowergradeStep3raisegradeforobservationalevidence\nRCTsHighStudylimitations:Strengthofassociation\n–þ<>\n1,serious1,largeeffectsize(e.g.,0.5or2)\n–þ<>\n2,veryserious2,verylargeeffectsize(e.g.,0.2or5)\nModerateInconsistency:\n––\n1,seriousEvidenceofadoseresponsegradient\n2,veryserious\nObservationalstudiesLowIndirectness:Allplausibleconfoundingwouldreducethedemonstratedeffect\n1,serious\n2,veryserious\nVerylowImprecision:\n1,serious\n2,veryserious\nPublicationbias:\n1,serious\n2,veryserious\nRCT,randomizedcontrolledtrial;GRADE,GradingofRecommendationsAssessment,Development,andEvaluation. results;andconcernsaboutpublicationbias.Forimprecision,dataThenaldraftwassentforexternalpublicreview,andreviewers\nwerebenchmarkedagainstoptimalinformationsize,loweventratesprovidedopen-endedresponses.Basedontheexternalstakeholder\nineitherarm,CIsthatindicateappreciablebenetandharm(25%feedback,thedraftwasfurtherrevisedbytheWorkGroup.AllWork\ndecreaseand25%increaseintheoutcomeofinterest),andsparsedataGroupmembersprovidedfeedbackoninitialandnaldraftsofthe\n(only1study),allindicatingconcernsabouttheprecisionofthere-guidelinestatementsandtext,andapprovedthenalversionofthe\n369\nsults.Thenalgradeforthecertaintyoftheevidenceforanguideline.TheERTalsoprovidedadescriptivesummaryofthe\noutcomecouldbehigh,moderate,low,orverylow(Table3).Forcertaintyofevidenceinsupportoftherecommendations. observationalstudiesandotherstudytypes,itispossibleforthe\nGradingthestrengthoftherecommendations. Thestrengthofa\n“”\ncertaintyoftheevidencetobeupgradedfromaratingoflowcertainty,\nrecommendationisgradedasLevel1,werecommendorLevel2,\n“”\naccordingtothespeciedcriteria.ForfurtherdetailsontheGRADE\nwesuggest(Table5).Thestrengthofarecommendationwas\napproachforratingcertaintyoftheevidence,seeTable4. determinedbythebalanceofbenetsandharmsacrossallcritical\nandimportantoutcomes,thegradingoftheoverallcertaintyofthe\nSummaryofndings(SoF)tables. TheSoFtablesweredeveloped\nevidence,patientvaluesandpreferences,resourceuseandcosts,and\ntoincludeadescriptionofthepopulation,intervention,andcompar-\nconsiderationsforimplementation(Table6). ator.Inaddition,theSoFtablesincludedresultsfromthedatasynthesis\nBalanceofbenetsandharms.",
    "page": 56,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "methodsforguidelinedevelopment (Part 2)",
    "content": "asrelativeandabsoluteeffectestimates.ThegradingofthecertaintyofTheWorkGroupandERT\nevidenceforeachcriticalandimportantoutcomeisalsoprovidedinthedeterminedtheanticipatednethealthbenetonthebasisofex-\nSoFtables.Forthe2024update,theSoFtableswereupdatedorcreatedpectedbenetsandharmsacrossallcriticalandimportantoutcomes\nmanually.TheSoFtablesareavailableintheDataSupplement:fromtheunderlyingevidencereview. AppendixCandAppendixD(https://kdigo.org/guidelines/gd/). Theoverallcertaintyoftheevidence. Theoverallcertaintyofthe\nevidencewasbasedonthecertaintyoftheevidenceforallcritical\nDevelopingtherecommendations. FortheKDIGO2024Clinical\nandimportantoutcomes,takingintoaccounttherelativeimpor-\nPracticeGuidelinefortheManagementofLupusNephritis,the\ntanceofeachoutcometothepopulationofinterest.Theoverall\nexistingrecommendationswerereviewedandrevised,asnecessary,\ncertaintyoftheevidencewasgraded(A,B,C,orDTable3). andnewrecommendationsweredraftedbytheWorkGroupandCo-\nPatientvaluesandpreferences. Nopatientsorcaregiverswere\nChairs.Recommendationswererevisedinamultistepprocessby\ninvolvedintheWorkGroup.TheWorkGroup,fromtheirexperi-\nemailandteleconferences.TheBrownERTparticipatedinthese\nenceinmanagingpatientswithGDandtheirunderstandingofthe\ndiscussionstoensureconsistencywiththeevidencebaseandto\nbestavailablescienticliterature,madejudgmentsonthevaluesand\nprovideadditionalfeedback. KidneyInternational\nS55\n(2024)105(Suppl1S),S1–S69",
    "page": 56,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "methodsforguidelinedevelopment (Part 1)",
    "content": "www.kidney-international.org\nTable5|KDIGOnomenclatureanddescriptionforgradingrecommendations\nImplications\nGradePatientsCliniciansPolicy\nLevel1MostpeopleinyoursituationwouldMostpatientsshouldreceivetheTherecommendationcanbeevaluated\n“”\nWerecommendwanttherecommendedcourseofrecommendedcourseofaction.asacandidatefordevelopingapolicy\naction,andonlyasmallproportionoraperformancemeasure. wouldnot. Level2ThemajorityofpeopleinyoursituationDifferentchoiceswillbeappropriateforTherecommendationislikelytorequire\n“”\nWesuggestwouldwanttherecommendedcoursedifferentpatients.Eachpatientneedssubstantialdebateandinvolvementof\nofaction,butmanywouldnot.helptoarriveatamanagementstakeholdersbeforepolicycanbe\ndecisionconsistentwithherorhisdetermined. valuesandpreferences. KDIGO,KidneyDisease:ImprovingGlobalOutcomes. Table6|Determinantsofthestrengthofrecommendation\nFactorsComment\nBalanceofbenetsandharmsThelargerthedifferencebetweenthedesirableandundesirableeffects,themorelikelyastrongrecommendation\nisprovided.Thenarrowerthegradient,themorelikelyaweakrecommendationiswarranted. CertaintyofevidenceThehigherthecertaintyofevidence,themorelikelyastrongrecommendationiswarranted.However,thereare\nexceptionsforwhichloworverylowcertaintyoftheevidencewillwarrantastrongrecommendation. ValuesandpreferencesThemorevariabilityinvaluesandpreferences,orthemoreuncertaintyinvaluesandpreferences,themorelikelya\nweakrecommendationiswarranted.Valuesandpreferenceswereobtainedfromtheliterature,whenpossible,or\nwereassessedbythejudgmentoftheWorkGroupwhenrobustevidencewasnotidentied. ——\nResourceuseandcostsThehigherthecostsofaninterventionthatis,themoreresourcesconsumedthelesslikelyastrong\nrecommendationiswarranted. preferencesofpatients.FormalqualitativeevidencesynthesisonPracticepointsweresometimesformattedasatable,agure,oran\npatientprioritiesandpreferenceswasundertakenbytheCochranealgorithmtomakethemeasiertouseinclinicalpractice. ERT,buttherewaslimitedevidenceavailabletoinformthe\nformulationofguidelinerecommendations(AppendixD). Formatforguidelinerecommendations\nResourcesandothercosts. Healthcareandnon-healthcarere-\nEachguidelinerecommendationprovidesanassessmentofthe\nsources,includingallinputsinthetreatmentmanagement\nstrengthoftherecommendation(Level1;orLevel2)andthecer-\n370\npathway,wereconsideredingradingthestrengthofarecom-\ntaintyoftheevidence(A,B,C,D).Therecommendationstatements\nmendation.Thefollowingresourceswereconsidered:directhealth-\narefollowedbyKeyinformation(Balanceofbenetsandharms,\ncarecosts;non-healthcareresources,suchastransportationand\nCertaintyoftheevidence,Valuesandpreferences,Resourceuseand\nsocialservices;informalcaregiverresources(e.g.,timeoffamilyand\ncosts,Considerationsforimplementation),andRationale.Each\ncaregivers);andchangesinproductivity.Economicevaluations,\nrecommendationislinkedtorelevantSoFtables.Anunderlying\nincludingcost-effectivenessanalysis,werenotconductedforanyof\nrationalemaysupportapracticepoint. theguidelinetopics.",
    "page": 57,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "methodsforguidelinedevelopment (Part 2)",
    "content": "Limitationsoftheguidelinedevelopmentprocess\nPracticepoints\nTheevidencereviewprioritizedRCTsastheprimarysourceof\nInadditiontogradedrecommendations,KDIGOguidelinesnowevidence.Foraselectnumberofclinicalquestionsinthis\n“”\nincludepracticepointstohelpcliniciansbetterevaluateandguideline,theERTundertookacomprehensiveevidencereview\nimplementtheguidancefromtheexpertWorkGroup.PracticepointsbeyondRCTs.However,thesereviewswerenotexhaustive,as\nareconsensusstatementsaboutaspecicaspectofcare,andtheyspecialtyorregionaldatabaseswerenotsearched,andmanual\nsupplementrecommendationsforwhichalargerquantityofevidencesearchingofjournalswasnotperformedforthesereviews.In\nwasidentied.Theyareissuedwhenaclinicalquestionwasnotthedevelopmentoftheseguidelines,noscopingexercisewith\nsupportedbyasystematicreview,oftentohelpreadersimplementthepatients,limitedsearchesofthequalitativeliterature,nor\nguidancefromgradedrecommendation.Practicepointsrepresenttheformalqualitativeevidencesynthesisexaminingpatientexpe-\nexpertjudgmentoftheguidelineWorkGroup,buttheyalsomayberiencesandprioritieswereundertaken.Asnoted,although\nbasedonlimitedevidence.Forexample,practicepointswereprovidedresourceimplicationswereconsideredintheformulationof\nonmonitoring,frequencyoftesting,dosingadjustmentsfortherecommendations,formaleconomicevaluationswerenotun-\nseverityofCKD,anduseoftherapiesinspecicsubgrouppopulations.dertakenforalltopics. KidneyInternational\nS56\n(2024)105(Suppl1S),S1–S69\nbiographicanddisclosureinformation\nwww.kidney-international.org",
    "page": 57,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Biographicanddisclosureinformation (Part 1)",
    "content": "BHRreportsreceivingconsultancyfeesfromAlexion,AstraZe-\nJürgenFloege,MD(WorkGroup\nneca,Aurinia,BristolMyersSquibb,Exagen,Genentech,\nCo-Chair),isheadoftheDivisionof\nGlaxoSmithKline,KezarLifeSciences,Kyverna,Novartis,and\nNephrologyandImmunologyatthe\nOtsuka;andgrant/researchsupportfromBiogen*. UniversityofAachen,Aachen,Ger-\n*Moniespaidtoinstitution. manysince1999. ProfessorFloegeisaformerex-\necutivecouncilmemberofInterna-\nIsabelleM.Ayoub,MD,isanAsso-\ntionalSocietyofNephrology(ISN),\nciateProfessorofMedicineinthe\nEuropeanRenalAssociation-\nDivisionofNephrologyatTheOhio\nEuropeanDialysisandTransplantAssociation(ERA-EDTA),\nStateUniversityWexnerMedical\nandKidneyDisease:ImprovingGlobalOutcomes(KDIGO). Center.Sheworksinabusylupus,\nHeisaDistinguishedFellowoftheERA-EDTAandrecipientof\nvasculitis,andglomerulonephritis\nthe2018ERA-EDTAAwardforOutstandingClinicalContri-\nclinic.SheistheDirectorofthe\nbutionstoNephrology,pastPresidentoftheGermanSocietyof\nNephrologyClinicalTrialsUnitat\nNephrology,aswellasanhonorarymemberoftheJapanese,\nOhioStateUniversity.DrAyoubs\nPolish,Portuguese,Serbian,andSlovakianSocietiesof\nprimaryfocusisintheareaofglomerulardiseaseswitha\nNephrology.TogetherwithProfessorsRichardJohnson,Mar-\nresearchinterestinevaluatingexperimentaltherapeuticsin\ncelloTonelli,andJohnFeehally,heeditsthebest-sellingtext-\nglomerulardiseases. bookComprehensiveClinicalNephrology.Heisassociateeditor\nIMAreportsreceivingfundingfortraveland/oraccom-\nofKidneyInternationalandamemberoftheeditorialboardof\nmodationfromAuriniaandservingontheadvisoryboard\nJournaloftheAmericanSocietyofNephrology(JASN),Journalof\nforAurinia. Nephrology,andotherjournals.Until2017,heservedasasso-\nciateeditorofNephrologyDialysisTransplantation(NDT). TakMaoChan,MBBS,MD,DSc,\nHisresearchinterestsencompassprogressionofkidney\nMRCP,FHKCP,FHKAM,FRCP,\ndisease,inparticular,kidneybrosis,immune-mediated\nFASN,istheYuChiu-KwongChair\nkidneydisease,andIgAnephropathy,aswellaschronickid-\nofMedicineandChiefofNephrology\nneydisease-mineralandbonedisorders(CKD-MBD)and\nattheSchoolofClinicalMedicine,\ncardiovasculardiseaseinuremicpatients. TheUniversityofHongKong,China. Hisscienticworkencompassesabout700originalpapers,\nHeobtainedhisMBBS,MD,andDSc\nreviews,andeditorials,and40bookchapters. fromtheUniversityofHongKong\nJFreportsreceivingconsultancyfeesand/orspeakerhonoraria\n(HKU).HewaspromotedtoPer-\nfromAstraZeneca,Bayer,Calliditas,Chinook,Glax-\nsonalChairProfessoratHKUin2005,andwasappointedYu\noSmithKline,Novartis,Omeros,Otsuka,Stadapharm,and\nChairofNephrologyin2008,thenYuChiu-KwongChairof\nTravere;andservingondatasafetymonitoringboardsfor\nMedicinein2011,andhasbeenChiefofNephrologysince\nNovoNordiskandVisterra.",
    "page": 58,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Biographicanddisclosureinformation (Part 2)",
    "content": "2010.HehasservedasAssociateDean,memberoftheSenate,\nandmemberoftheUniversitySelection&PromotionCom-\nBradH.Rovin,MD,FACP,FASNmittee,andisnowamemberoftheUniversityCouncilat\n(WorkGroupCo-Chair),istheLeeHKU.HewasPresidentoftheAsianPacicSocietyof\nA.HebertProfessorofNephrologyatNephrology(APSN),ChairmanoftheHospitalAuthority\nTheOhioStateUniversityWexnerCoordinatingCommitteeforInternalMedicine,andCouncil\nMedicalCenter,Columbus,Ohio,MemberoftheInternationalSocietyofNephrology.Hehas\nUSA.HeistheDivisionDirectorofbeenPresidentofTheHongKongCollegeofPhysicians\nNephrologyandMedicalDirectorofsince2022. TheOhioStateUniversityCenterforDr.Chansresearchfocusesonlupusnephritisandviral\nClinicalResearchManagement.Dr.hepatitisinpatientswithkidneydiseases.Hisworkcontrib-\nRovinconductstranslationalresearchonautoimmuneutedtotheestablishmentofmycophenolateasstandard-of-\nglomerulardiseasesandappliesthesestudiestoclinicaltrialcareinductionandmaintenancetherapyforlupusnephritis\ndevelopmentanddesignforinvestigator-initiatedandandhighlightedtheroleofdifferentimmunosuppressive\nindustry-sponsoredtrialsofnoveltherapeutics.treatmentssuchascalcineurininhibitorsandmammalian\nKidneyInternational\nS57\n(2024)105(Suppl1S),S1–S69\nbiographicanddisclosureinformation\nwww.kidney-international.org\ntargetofrapamycin(mTOR)inhibitors,andtheimportanceMexicoandcompletedanInternationalSocietyof\nofpreventingnephriticareandchronickidneydiseaseNephrologyGlomerularDiseasesfellowshipatTheOhio\n(CKD)inlupusnephritismanagement.HisworkalsoStateUniversity.HehasaMasterofMedicalScienceanda\nestablishedtheroleofantiviraltherapyforthepreventionofPhDdegreefromtheNationalUniversityofMexicoforhis\nhepatitisBareinkidneytransplantrecipients.Translationalstudyoflupusnephritispathophysiologyandbiomarker\nstudiesfromhislaboratoryinvestigateimmunopathogenicdevelopment. ﬂﬁ\nmechanismsinkidneyinammationandbrosis,andtheHisprimaryresearchareaiscenteredonnoninvasive\nroleofresidentkidneycells.Dr.Chanspublicationshavebiomarkersandprognosisofglomerulardiseases,especially\nappearedintheNewEnglandJournalofMedicine,Kidneylupusnephritisandantineutrophilcytoplasmicantibody\nInternational,JournaloftheAmericanSocietyofNephrology,(ANCA)vasculitis.Hecurrentlyfollowsalocallupus\nArthritisRheumatology,NatureReviewsNephrology,Hepatol-nephritiscohortcomprisingmorethan700subjects,andthe\nogy,andUpToDate.HereceivedtheAPSNKenzoOshimalocalglomerulardiseasesregistry,andactivelyparticipatesin\nAwardin2014.clinicaltrialsintheseareas. TMCreportsreceivingsupportforstudiesormanuscriptsJMMVreportsreceivingfundingforeducationalpre-\npertainingtothistopicfromAstellasandGlaxoSmithKline;sentationsfromAstraZeneca,BoehringerIngelheim,Glax-\nandconsultancyfeesfromAstraZeneca,GlaxoSmithKline,oSmithKline,andRoche;andservingontheadvisoryboard\nandNovartis.forKezarLifeSciences.",
    "page": 58,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Biographicanddisclosureinformation (Part 3)",
    "content": "KDIGOChairs\nZhi-HongLiu,MD,isaprofessorof\nmedicineandacademicianattheMichelJadoul,MD,receivedhisMD\nChineseAcademyofEngineering,degreein1983attheUniversité\nChina.SheistheDirectoroftheCatholiquedeLouvain(UCLouvain),\nNationalClinicalResearchCenterofBrussels,Belgium.Dr.Jadoultrained\nKidneyDisease,JinlingHospital,andininternalmedicineandnephrology\nDeanoftheZhejiangUniversityunderthementorshipofProfessor\nSchoolofMedicine.Dr.LiuistheCharlesvanYperseledeStrihou.He\npastPresidentoftheChineseSocietyhasservedaschairoftheDepart-\nofNephrology.ShewasanexecutivecommitteememberofmentofNephrologyoftheCliniques\ntheInternationalSocietyofNephrologyandKDIGO.SheisUniversitairesSaint-Luc(2003-2023)andiscurrentlyafull\ntheEditor-in-ChiefofKidneyDiseases,ChineseJournalofclinicalprofessoratUCLouvain.Dr.Jadoulsclinicalactivities\nNephrology,andDialysis&Transplantation.focusonthefollow-upofhemodialysisandchronickidney\nDr.Liuhasdevotedherselftopatientcare,research,anddisease(CKD)patients,andhismainresearchinterests\nmedicaleducation.Herprimaryinterestisintheeldofinclude2-microglobulinamyloidosis,hepatitisC,andother\nkidneydisease,withaspecialinterestinglomerulonephritiscomplications(e.g.,falls,bonefractures,suddendeath)in\nanddiabeticnephropathy.Shehasedited5booksonkidneyhemodialysispatients,aswellascardiovascularcomplications\ndisease,andisthechiefscientistoftheNationalBasicafterkidneytransplantationandvariouscausesofkidney\nResearchProgramofChina(973Program)andwashonoreddisease(e.g.,drug-induced). withtheNationalScienceandTechnologyProgressAwardofDr.Jadoulhascoauthoredover350scienticpapers,most\nChina.ofthempublishedinmajornephrologyjournals.Heis\nZ-HLdeclarednocompetinginterests.currentlyservingasanassociateeditorofNephrologyDialysis\nTransplantation,andheisalsoacountryco-investigatorforthe\nJuanManuelMejía-Vilet,MD,PhD,\nDialysisOutcomesandPracticePatternsStudy(DOPPS)\nisaconsultantnephrologistatInsti-\n(2001present).In2008,hereceivedtheInternationalDistin-\ntutoNacionaldeCienciasMédicasy\nguishedMedalfromtheU.S.NationalKidneyFoundation\nNutriciónSalvadorZubirán,Mexico,\n(NKF).HewaspreviouslyamemberoftheEuropeanRenal\naclinicalresearcherfortheMexican\nAssociationCouncil(20132016).Presently,Dr.Jadoulisa\nNationalResearchSystem,anda\nKidneyDisease:ImprovingGlobalOutcomes(KDIGO)Co-\nprofessorofmedicinefortheNa-\nChair. tionalUniversityofMexico,Pan-\nMJreportsreceivingconsultancyfeesfromAstellas*,Astra-\namericanUniversity,andthe\nZeneca*,Bayer*,BoehringerIngelheim*,Cardiorenal*,CSL\nMonterreyInstituteofTechnologyandHigherEducation.",
    "page": 58,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Biographicanddisclosureinformation (Part 4)",
    "content": "Vifor*,FreseniusMedicalCareAsiaPacic*,GlaxoSmith-\nDr.Mejia-ViletreceivedhismedicaldegreefromtheKline*,Mundipharma*,andVertex*;grants/researchsupport\nUniversityofSanLuisPotosi.HewastrainedininternalfromAmgenandAstraZeneca*;speakerhonorariafrom\nmedicineandnephrologyattheNationalUniversityof\nAstraZeneca*,Bayer*,andBoehringerIngelheim*;providing\nKidneyInternational\nS58\n(2024)105(Suppl1S),S1–S69\nbiographicanddisclosureinformation\nwww.kidney-international.org\nexperttestimonyforAstellas*andStada-Eurogenerics*;MATreportsreceivingpaymentforprovidingexperttesti-\nreceivingtravelsupportfromAstraZeneca*.monyfromGileadSciences(notrelatedtotheguideline\n*Moniespaidtoinstitution.topic). EvidenceReviewTeam\nMorganE.Grams,MD,PhD,MHS,\nEthanM.Balk,MD,MPH,isAsso-\nistheCo-DirectoroftheNewYork\nciateDirectoroftheCenterforEvi-\nUniversityDivisionofPrecision\ndenceSynthesisinHealth,and\nMedicine,amultidisciplinary\nProfessorofHealthServices,Policy\nresearchunitthataimstoproduce\nandPracticeatBrownUniversity\nevidencetoinformthedeliveryof\nSchoolofPublicHealthinProvi-\nhigh-quality,equitablepatientcare,\ndence,RI,USA.HehasbeenProject\nrespondingrapidlytochangesin\nDirectoroftheERTandhascollab-\nhealthcareguidelines,delivery,safety,\noratedonnumerousKidneyDisease:\nandregulation.Apracticingnephrologist,PhD-trainedepide-\nImprovingGlobalOutcomes(KDIGO)guidelinessince2008,\nmiologist,andtheSusanandMorrisMarkProfessorofMed-\nandKidneyDiseaseOutcomesQualityInitiative(KDOQI)\nicineandPopulationHealthatNewYorkUniversity,Dr.Grams\nguidelinessince2000.Asprojectdirectorforthisguideline,he\nisCo-PrincipalInvestigatoroftheChronicKidneyDisease\nplayedapivotalroleinprovidingmethodologicalexpertisein\nPrognosisConsortium(CKD-PC),aconsortiumofover30\ntheguidelinedevelopmentprocessandassistedinthe\nmillionparticipants,100cohorts,and250investigatorsfrom\ncollection,evaluation,grading,andsynthesisofevidenceand\naroundtheglobe.Inthisrole,Dr.GramsandtheCKD-PC\ntherevisionsofthenalevidencereport.Dr.Balkalsopro-\nteamfocusondeveloping,testing,andimplementingana-\nvidedmethodologicalguidanceandtrainingofWorkGroup\nlyticstrategiestoanswerclinicallymeaningfulquestions\nmembersregardingtopicrenement,keyquestionformula-\nusingasmuchoftheworldsdataonkidneymeasuresand\ntion,dataextraction,studyassessment,evidencegrading,and\noutcomesaspossible.Shealsoleadseffortstointegrate\nrecommendationformulation.Hisprimaryresearchinterests\nmultimodalomicsdataastheyrelatetokidneydisease.She\nareevidence-basedmedicine,systematicreview,clinical\nwasthewinneroftheYoungInvestigatorAwardin2018\npracticeguidelinedevelopment,andcriticalliterature\ngivenbytheAmericanSocietyofNephrology/American\nappraisal. HeartAssociationKidneyCouncil,thetopawardforin-\nEMBdeclarednocompetinginterests. vestigatorsunder45yearsofage,andsheisamemberofthe\nAmericanSocietyofClinicalInvestigation.Sheattended\nCraigE.Gordon,MD,MS,isAsso-\nmedicalschoolatColumbiaUniversityandcompletedher\nciateProfessorofMedicineatTufts\nnephrologyfellowshipatJohnsHopkinsUniversity.",
    "page": 58,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Biographicanddisclosureinformation (Part 5)",
    "content": "UniversityMedicalCenterinBoston,\nMEGdeclarednocompetinginterests. MA,USA.Dr.Gordongraduated\nfromNewYorkUniversitySchoolof\nMethodsChair\nMedicineandreceivedamasters\nMarcelloA.Tonelli,MD,SM,MSc,degreeinclinicalcareresearch\nFRCPC,isanephrologist,professor,fromtheTuftsUniversitySchoolof\nandclinicianscientistattheUniversityGraduateBiomedicalSciences.Dr. ofCalgary,Calgary,Alberta,Canada.Gordonpreviouslyservedastheassistantprojectdirectorof\nDr.TonellisresearchfocusesontheERTforthe2020KDIGOClinicalPracticeGuidelineon\nimprovingthecareofpeoplewiththeEvaluationandManagementofCandidatesforKidney\nchronickidneydiseaseandothernon-TransplantationandassociatedirectoroftheERT,andassis-\ncommunicablediseases.Heischairtantprojectdirectorforthe2018andthe2022KDIGO\nemeritusoftheCanadianTaskForceonClinicalPracticeGuidelineonHCVinCKD. PreventiveHealthCare,apastPresidentoftheCanadianSocietyDr.GordonprovidedmethodologicexpertisetotheWork\nofNephrology,andthePresident-ElectoftheInternationalSo-Groupduringtheguidelinedevelopmentprocessandassisted\ncietyofNephrology.HeisamemberoftheGoverningCouncilforinthecollection,evaluation,grading,andsynthesisofevi-\ntheCanadianInstitutesofHealthResearchandtheDirectorofthedencefortheguideline,aswellasprovidingguidancetoWork\n’ﬁ\nWorldHealthOrganizationsCollaboratingCentreforthePre-Groupmembersintheareasoftopicrenement,keyquestion\nventionandControlofChronicKidneyDisease.formulation,dataextraction,studyassessment,evidence\nDr.TonellihasbeennamedaHighlyCitedResearchereachgrading,andrecommendationformulation.Hisprimary\nyearsince2015byThomsonReutersWebofScience,corre-researchandclinicalinterestsareinthemanagementofHCV\nspondingtoarankinthetop0.1%bycitationsofallre-inpatientswithCKD,polycystickidneydisease,and\nsearchersworldwide. KidneyInternational\nS59\n(2024)105(Suppl1S),S1–S69\nbiographicanddisclosureinformation\nwww.kidney-international.org\nthromboticmicroangiopathies,aswellasevidence-basedunderstandingofthemethodsandtoolsusedinevidence\nmedicineandsystematicreviewrelatedtootherareasofsynthesisresearch.AsaresearchassociateandthePro-\nnephrology.gramManagerfortheBrownEvidence-basedPractice\nCEGreportsreceivingconsultancyfeesforAlexion;servinginCenter(EPC),shehascontributedtotheproductionof\nthespeakerbureauforAlexion;andreceivingfundingforover20evidence-synthesisproducts(systematicreviews,\ntraveland/oraccommodationfromAlexion.technologyassessments,andothersimilarproducts)ona\nwidevarietyofclinicalandpublichealthtopics.Asa\ndoctoratestudentinHealthServicePolicyandPracticein\nGaelenAdam,MLIS,MPH,has\nBrownUniversitysSchoolofPublicHealth,shehas\nworkedaslibrarian,editor,and\nleveragedextensiveexperienceinsearchstrategydesignto\nresearchassociateatBrownsCenter\nconductresearchinmethodstoincorporatetext-mining,\nforEvidenceSynthesisinHealth\nmachine-learning,andtext-modelingtechnologiesto\n(CESH)since2013.Intheseroles,\nimprovetheprocessofsearchingandscreeningstudiesfor\nshehasbeeninvolvedinallstepsof\nsystematicreviews.",
    "page": 58,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Biographicanddisclosureinformation (Part 6)",
    "content": "theprojectsundertakenbyCESH\nGAdeclarednocompetinginterests. andhasdevelopedadeep\nKidneyInternational\nS60\n(2024)105(Suppl1S),S1–S69\nacknowledgments\nwww.kidney-international.org",
    "page": 58,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "Acknowledgments",
    "content": "Kuttikkattu,AndreasKronbichler,HenryLeher,Claudia\nAspecialdebtofgratitudeisowedtotheKDIGOCo-Chairs,\nFernandaLeivaGómez,AntonioAlanmarLeónMartinez,\nMorganGramsandMichelJadoul,andimmediatepastCo-\nEdgarLerma,LizLightstone,CarlosLins,AnaMalvar,Partha\nChairWolfgangWinkelmayer,fortheirinvaluableoversight\nPratimMandal,MarioManunta,CarmenMarruffo,Safak\nthroughoutthedevelopmentofthisguideline.Inparticular,\nMirioglu,DanaMiskulin,AndrésMontalvo,OdirleiMon-\nwethankEthanBalk,CraigGordon,andGaelenAdamfor\nticielo,YussaraMorales,RogelioMoscoso,EugenMota,Jorge\ntheirsubstantialcontributiontotherigorousassessmentof\nNovoa,TaniaOliveira,VuddhidejOphascharoensuk,Fabián\ntheavailableevidence.WealsoacknowledgeDebbieMaizels\nOrtega,AlbertoOrtiz,IvanPadjen,AdrianaPenalba,NuriaS.\nforhervitalcontributionstotheartworkpresentedinthis\nPerezRomano,AlissonPugliesi,DanielRamírez,LuisManuel\nguideline.\nRamirezGomez,CarlosRodrigues,JorgeRojas-Rivera,\nThefollowingindividualsprovidedfeedbackduringthe\nSebastianSahores,AnnaSalmela,DomenicoSantoro,Anin-\npublicreviewofthedraftguideline:\nditaSantosa,DeepakSharma,HabibSkhiri,MariaJoséSoler\nDéboraAguiar,CarolinaAlbanezAndrade,ElisaAlbu-\nRomeo,MustafaSulaiman,CarlosEduardoGarcezTeixeira,\nquerque,Hans-JoachimAnders,MabelAoun,SuheirAssady,\nManuelUgarte-Gil,ClaraYnésUviedoMartínez,Debora\nKaungMyatAung,JoanneBargman,SusieBarnes,Rommel\nVeghini,JhonatanVeladorMendoza,GisellaVischini,Charles\nBataclan,CristianCamacho,CoreyCavanaugh,Marlene\nWilliams,andManjushaYadla.\nCisneros,RolandoClaureDelGranado,FabrizioConti,\nParticipationinthepublicreviewdoesnotnecessarily\nHenryCremisi,AnkanaDaga,KaderDaghastanli,MarceloDe\nconstituteendorsementofthecontentofthisreportbythe\nRosa,PasqualeEsposito,FlorGarciaLópez,MairaGenaro,\naboveindividuals,ortheorganizationsorinstitutionsthey\nErimGülcan,AstridGutierrez,RamyHassan,Mohammad\nrepresent.\nImnulIslam,ChandraMauliJha,JoséJúnior,Ambily\nKidneyInternational\nS61\n(2024)105(Suppl1S),S1–S69",
    "page": 62,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "References (Part 1)",
    "content": "’ﬁ\n23.WeeningJJ,DAgatiVD,SchwartzMM,etal.Theclassicationof\n1.BendapudiPK,HurwitzS,FryA,etal.Derivationandexternalvalidation\nglomerulonephritisinsystemiclupuserythematosusrevisited.JAm\nofthePLASMICscoreforrapidassessmentofadultswiththrombotic\nSocNephrol.2004;15:241250. microangiopathies:acohortstudy.LancetHaematol.2017;4:e157e164. 24.Galindo-IzquierdoM,Rodriguez-AlmarazE,Pego-ReigosaJM,etal. 2.AlarconGS,McGwinGJr,PetriM,etal.Baselinecharacteristicsofa\nCharacterizationofpatientswithlupusnephritisincludedinalarge\nmultiethniclupuscohort:PROFILE.Lupus.2002;11:95101. cohortfromtheSpanishSocietyofRheumatologyRegistryofPatients\n3.BastianHM,RosemanJM,McGwinGJr,etal.Systemiclupus\nWithSystemicLupusErythematosus(RELESSER).Medicine(Baltimore). erythematosusinthreeethnicgroups.XII.Riskfactorsforlupus\n2016;95:e2891. nephritisafterdiagnosis.Lupus.2002;11:152160. 25.Pons-EstelGJ,AlarconGS,BurgosPI,etal.Mestizoswithsystemiclupus\n4.FeldmanCH,HirakiLT,LiuJ,etal.Epidemiologyandsociodemographics\nerythematosusdeveloprenaldiseaseearlywhileantimalarialsretardits\nofsystemiclupuserythematosusandlupusnephritisamongUSadults\nappearance:datafromaLatinAmericancohort.Lupus.2013;22:899907. withMedicaidcoverage,2000-2004.ArthritisRheum.2013;65:753763. 26.KasitanonN,FineDM,HaasM,etal.Hydroxychloroquineusepredicts\n5.Pons-EstelBA,CatoggioLJ,CardielMH,etal.TheGLADELmultinational\ncompleterenalremissionwithin12monthsamongpatientstreated\nLatinAmericanprospectiveinceptioncohortof1,214patientswith\nwithmycophenolatemofetiltherapyformembranouslupusnephritis. systemiclupuserythematosus:ethnicanddiseaseheterogeneity\n“”–\nLupus.2006;15:366370. amongHispanics.Medicine(Baltimore).2004;83:117. 27.Mejia-ViletJM,Cordova-SanchezBM,Uribe-UribeNO,etal. 6.MokCC,KwokRC,YipPS.Effectofrenaldiseaseonthestandardized\nImmunosuppressivetreatmentforpuremembranouslupus\nmortalityratioandlifeexpectancyofpatientswithsystemiclupus\nnephropathyinaHispanicpopulation.ClinRheumatol.2016;35:2219\nerythematosus.ArthritisRheum.2013;65:21542160. 2227. 7.SuleS,FivushB,NeuA,etal.Increasedriskofdeathinpediatricand\n28.SisoA,Ramos-CasalsM,BoveA,etal.Previousantimalarialtherapyin\nadultpatientswithESRDsecondarytolupus.PediatrNephrol.2011;26:\npatientsdiagnosedwithlupusnephritis:inuenceonoutcomesand\n9398. survival.Lupus.2008;17:281288. 8.YapDY,TangCS,MaMK,etal.Survivalanalysisandcausesofmortality\n29.Zavala-MirandaMF,Perez-AriasAA,Marquez-MacedoSE,etal. inpatientswithlupusnephritis.NephrolDialTransplant.2012;27:3248\nCharacteristicsandoutcomesofaHispaniclupusnephritiscohort\n3254. fromMexico.Rheumatology(Oxford).2023;62:11361144. 9.HirakiLT,FeldmanCH,LiuJ,etal.Prevalence,incidence,and\n30.KaiserR,ClevelandCM,CriswellLA.Riskandprotectivefactorsfor\ndemographicsofsystemiclupuserythematosusandlupusnephritis\nthrombosisinsystemiclupuserythematosus:resultsfromalarge,\nfrom2000to2004amongchildrenintheUSMedicaidbeneciary\nmulti-ethniccohort.AnnRheumDis.2009;68:238241. population.ArthritisRheum.2012;64:26692676.",
    "page": 63,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "References (Part 2)",
    "content": "31.PetriM.Useofhydroxychloroquinetopreventthrombosisinsystemic\n10.MalvarA,PirruccioP,AlbertonV,etal.Histologicversusclinical\nlupuserythematosusandinantiphospholipidantibody-positive\nremissioninproliferativelupusnephritis.NephrolDialTransplant. patients.CurrRheumatolRep.2011;13:7780. 2017;32:13381344. 32.Ruiz-IrastorzaG,EgurbideMV,PijoanJI,etal.Effectofantimalarialson\n11.ZickertA,SundelinB,SvenungssonE,etal.Roleofearlyrepeatedrenal\nthrombosisandsurvivalinpatientswithsystemiclupus\nbiopsiesinlupusnephritis.LupusSciMed.2014;1:e000018. erythematosus.Lupus.2006;15:577583. 12.AppelGB,ContrerasG,DooleyMA,etal.Mycophenolatemofetilversus\n33.TektonidouMG,LaskariK,PanagiotakosDB,etal.Riskfactorsfor\ncyclophosphamideforinductiontreatmentoflupusnephritis.JAmSoc\nthrombosisandprimarythrombosispreventioninpatientswith\nNephrol.2009;20:11031112. systemiclupuserythematosuswithorwithoutantiphospholipid\n13.AustinHA3rd,KlippelJH,BalowJE,etal.Therapyoflupusnephritis. antibodies.ArthritisRheum.2009;61:2936. Controlledtrialofprednisoneandcytotoxicdrugs.NEnglJMed. 34.FesslerBJ,AlarconGS,McGwinGJr,etal.Systemiclupuserythematosus\n1986;314:614619. inthreeethnicgroups:XVI.Associationofhydroxychloroquineusewith\n14.ChanTM,LiFK,TangCS,etal.Efcacyofmycophenolatemofetilin\nreducedriskofdamageaccrual.ArthritisRheum.2005;52:14731480. patientswithdiffuseproliferativelupusnephritis.HongKong-\n35.PakchotanonR,GladmanDD,SuJ,etal.Moreconsistentantimalarial\nGuangzhouNephrologyStudyGroup.NEnglJMed.2000;343:1156\nintakeinrst5yearsofdiseaseisassociatedwithbetterprognosisin\n1162. patientswithsystemiclupuserythematosus.JRheumatol.2018;45:90\n15.ChanTM,TseKC,TangCS,etal.Long-termstudyofmycophenolate\n94. mofetilascontinuousinductionandmaintenancetreatmentfor\n36.Pokroy-ShapiraE,GelernterI,MoladY.Evolutionofchronickidney\ndiffuseproliferativelupusnephritis.JAmSocNephrol.2005;16:1076\ndiseaseinpatientswithsystemiclupuserythematosusoveralong-\n1084. periodfollow-up:asingle-centerinceptioncohortstudy.Clin\n16.DooleyMA,JayneD,GinzlerEM,etal.Mycophenolateversus\nRheumatol.2014;33:649657. azathioprineasmaintenancetherapyforlupusnephritis.NEnglJMed. 37.Pons-EstelGJ,AlarconGS,McGwinGJr,etal.Protectiveeffectof\n2011;365:18861895. hydroxychloroquineonrenaldamageinpatientswithlupusnephritis:\n17.HoussiauFA,VasconcelosC,DCruzD,etal.Immunosuppressivetherapy\nLXV,datafromamultiethnicUScohort.ArthritisRheum.2009;61:830\ninlupusnephritis:theEuro-LupusNephritisTrial,arandomizedtrialof\n839. low-doseversushigh-doseintravenouscyclophosphamide.Arthritis\n38.ShaharirSS,GhaforAH,SaidMS,etal.Adescriptivestudyofthefactors\nRheum.2002;46:21212131. associatedwithdamageinMalaysianpatientswithlupusnephritis. 18.LewisEJ,HunsickerLG,LanSP,etal.Acontrolledtrialofplasmapheresis\nLupus.2014;23:436442. therapyinseverelupusnephritis.TheLupusNephritisCollaborative\n39.HodisHN,QuismorioFPJr,WickhamE,etal.Thelipid,lipoprotein,and\nStudyGroup.NEnglJMed.1992;326:13731379.",
    "page": 63,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "References (Part 3)",
    "content": "apolipoproteineffectsofhydroxychloroquineinpatientswithsystemic\n19.LiuZ,ZhangH,LiuZ,etal.Multitargettherapyforinductiontreatment\nlupuserythematosus.JRheumatol.1993;20:661665. oflupusnephritis:arandomizedtrial.AnnInternMed.2015;162:1826. 40.TamLS,GladmanDD,HallettDC,etal.Effectofantimalarialagentson\n20.PollakVE,PiraniCL,SchwartzFD.Thenaturalhistoryoftherenal\nthefastinglipidproleinsystemiclupuserythematosus.JRheumatol. manifestationsofsystemiclupuserythematosus.JLabClinMed. 2000;27:21422145. 1964;63:537550. 41.LakshminarayananS,WalshS,MohanrajM,etal.Factorsassociatedwith\n21.BajemaIM,WilhelmusS,AlpersCE,etal.RevisionoftheInternational\nlowbonemineraldensityinfemalepatientswithsystemiclupus\nSocietyofNephrology/RenalPathologySocietyclassicationforlupus\nﬁﬁﬁ\nerythematosus.JRheumatol.2001;28:102108. nephritis:claricationofdenitions,andmodiedNationalInstitutes\n42.EudyAM,Siega-RizAM,EngelSM,etal.Effectofpregnancyondisease\nofHealthactivityandchronicityindices.KidneyInt.2018;93:789796. ’ﬁ\naresinpatientswithsystemiclupuserythematosus.AnnRheumDis. 22.MarkowitzGS,DAgatiVD.TheISN/RPS2003classicationoflupus\n2018;77:855860. nephritis:anassessmentat3years.KidneyInt.2007;71:491495. KidneyInternational\nS62\n(2024)105(Suppl1S),S1–S69",
    "page": 63,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "www.kidney-international.org\n43.LerouxM,DesveauxC,ParcevauxM,etal.Impactofhydroxychloroquine67.CanneyM,AtiquzzamanM,CunninghamAM,etal.Apopulation-based\nonpretermdeliveryandintrauterinegrowthrestrictioninpregnantanalysisoftheriskofglomerulardiseaserelapseafterCOVID-19\nwomenwithsystemiclupuserythematosus:adescriptivecohortvaccination.JAmSocNephrol.2022;33:22472257. study.Lupus.2015;24:13841391. 68.MageauA,TimsitJF,PerrozzielloA,etal.Theburdenofchronickidney\n44.LiuE,LiuZ,ZhouY.Feasibilityofhydroxychloroquineadjuvanttherapydiseaseinsystemiclupuserythematosus:anationwideepidemiologic\ninpregnantwomenwithsystemiclupuserythematosus.BiomedRes.study.AutoimmunRev.2019;18:733737. 2018;29:980983. 69.Perez-AriasAA,Marquez-MacedoSE,Pena-VizcarraOR,etal.The\nﬂﬂ\n45.SerreJ,BuobD,BoffaJJ.Hydroxychloroquine-inducedpodocytopathyinuenceofrepeatedaresinresponsetotherapyandprognosisin\nmimickingFabrydisease.BMJCaseRep.2019;12:e228876.lupusnephritis.NephrolDialTransplant.2023;38:884893. 46.SperatiCJ,RosenbergAZ.Hydroxychloroquine-inducedmimicofrenal70.PetriM,KimMY,KalunianKC,etal.Combinedoralcontraceptivesin\nFabrydisease.KidneyInt.2018;94:634.womenwithsystemiclupuserythematosus.NEnglJMed.2005;353:\n25502558. 47.CanadianHydroxychloroquineStudyGroup.Arandomizedstudyofthe\neffectofwithdrawinghydroxychloroquinesulfateinsystemiclupus71.BlumenfeldZ,vonWolffM.GnRH-analoguesandoralcontraceptivesfor\nerythematosus.NEnglJMed.1991;324:150154.fertilitypreservationinwomenduringchemotherapy.HumReprod\nUpdate.2008;14:543552. 48.Ruiz-IrastorzaG,Ramos-CasalsM,Brito-ZeronP,etal.Clinicalefcacy\nandsideeffectsofantimalarialsinsystemiclupuserythematosus:a72.AngeliA,GuglielmiG,DovioA,etal.Highprevalenceofasymptomatic\nsystematicreview.AnnRheumDis.2010;69:2028.vertebralfracturesinpost-menopausalwomenreceivingchronic\nglucocorticoidtherapy:across-sectionaloutpatientstudy.Bone. 49.FeldmanCH,HirakiLT,WinkelmayerWC,etal.Seriousinfectionsamong\n2006;39:253259. adultMedicaidbeneciarieswithsystemiclupuserythematosusand\nlupusnephritis.ArthritisRheumatol.2015;67:15771585.73.CurtisJR,WestfallAO,AllisonJ,etal.Population-basedassessmentof\nadverseeventsassociatedwithlong-termglucocorticoiduse.Arthritis\n50.ZhengZH,ZhangLJ,LiuWX,etal.PredictorsofsurvivalinChinese\nRheum.2006;55:420426. patientswithlupusnephritis.Lupus.2012;21:10491056. 74.HansenKE,KlekerB,SafdarN,etal.Asystematicreviewandmeta-\n51.MohammadS,ClowseMEB,EudyAM,etal.Examinationof\nanalysisofglucocorticoid-inducedosteoporosisinchildren.Semin\nhydroxychloroquineuseandhemolyticanemiainG6PDH-decient\nArthritisRheum.2014;44:4754. patients.ArthritisCareRes(Hoboken).2018;70:481485. 75.MokCC,TseSM,ChanKL,etal.EstimationoffractureriskbytheFRAX\n52.YusufIH,SharmaS,LuqmaniR,etal.Hydroxychloroquineretinopathy. toolinpatientswithsystemiclupuserythematosus:a10-year\nEye(Lond).2017;31:828845. longitudinalvalidationstudy.TherAdvMusculoskeletDis.2022;14:\n53.DimaA,JurcutC,ChassetF,etal.Hydroxychloroquineinsystemiclupus\n1759720X221074451.",
    "page": 64,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "erythematosus:overviewofcurrentknowledge.TherAdvMusculoskelet\n76.CenterforMetabolicBoneDiseases.FractureRiskAssessmentTool. Dis.2022;14:1759720X211073001. Availableat:.AccessedMay17,2023.https://www.shefeld.ac.uk/FRAX/\n54.FasanoS,MessinitiV,IudiciM,etal.Hydroxychloroquinedailydose,\n77.BuckleyL,GuyattG,FinkHA,etal.2017AmericanCollegeof\nhydroxychloroquinebloodlevelsandtheriskofaresinpatientswith\nRheumatologyguidelineforthepreventionandtreatmentof\nsystemiclupuserythematosus.LupusSciMed.2023;10:e000841. glucocorticoid-inducedosteoporosis.ArthritisRheumatol.2017;69:\n55.CunhaC,AlexanderS,AshbyD,etal.Hydroxycloroquineblood\n15211537. concentrationinlupusnephritis:adeterminantofdiseaseoutcome? 78.ZhangY,MilojevicD.Protectingbonehealthinpediatricrheumatic\nNephrolDialTransplant.2018;33:16041610. diseases:pharmacologicalconsiderations.PaediatrDrugs.2017;19:193\n56.CerveraR,KhamashtaMA,FontJ,etal.Morbidityandmortalityin\n211. systemiclupuserythematosusduringa10-yearperiod:acomparison\n79.ChoiMY,FloodK,BernatskyS,etal.AreviewonSLEandmalignancy. ofearlyandlatemanifestationsinacohortof1,000patients.Medicine\nBestPractResClinRheumatol.2017;31:373396. (Baltimore).2003;82:299308. 80.GoobieGC,BernatskyS,Ramsey-GoldmanR,etal.Malignanciesin\n57.ForsNievesCE,IzmirlyPM.Mortalityinsystemiclupuserythematosus:an\nsystemiclupuserythematosus:a2015update.CurrOpinRheumatol. updatedreview.CurrRheumatolRep.2016;18:21. 2015;27:454460. 58.TseliosK,GladmanDD,SheaneBJ,etal.All-cause,cause-specicand\n81.Tessier-CloutierB,ClarkeAE,PineauCA,etal.Whatinvestigationsare\nage-specicstandardisedmortalityratiosofpatientswithsystemic\nneededtooptimallymonitorformalignanciesinSLE?Lupus.2015;24:\nlupuserythematosusinOntario,Canadaover43years(1971-2013). 781787. AnnRheumDis.2019;78:802806. 82.GattoM,Agmon-LevinN,SorianoA,etal.Humanpapillomavirusvaccine\n59.YurkovichM,VostretsovaK,ChenW,etal.Overallandcause-specic\nandsystemiclupuserythematosus.ClinRheumatol.2013;32:13011307. mortalityinpatientswithsystemiclupuserythematosus:ameta-\nanalysisofobservationalstudies.ArthritisCareRes(Hoboken).2014;66:83.PellegrinoP,CarnovaleC,PerroneV,etal.Humanpapillomavirus\n608616.vaccineinpatientswithsystemiclupuserythematosus.Epidemiology. 2014;25:155156. 60.SteimanAJ,GladmanDD,IbanezD,etal.Outcomesinpatientswith\nsystemiclupuserythematosuswithandwithoutaprolonged84.BaldwinDS,GluckMC,LowensteinJ,etal.Lupusnephritis.Clinical\nserologicallyactiveclinicallyquiescentperiod.ArthritisCareRescourseasrelatedtomorphologicformsandtheirtransitions.AmJ\n––\n(Hoboken).2012;64:511518.Med.1977;62:1230. 61.ThongKM,ChanTM.Infectiouscomplicationsinlupusnephritis85.HuW,ChenY,WangS,etal.Clinical-morphologicalfeaturesand\ntreatment:asystematicreviewandmeta-analysis.Lupus.2019;28:334outcomesoflupuspodocytopathy.ClinJAmSocNephrol.2016;11:\n346.585592.",
    "page": 64,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "62.GocerogluA,RahmattullaC,BerdenAE,etal.TheDutchTransplantation86.LewisEJ.Lupuspodocytopathy.In:LewisEJ,SchwartzMM,KorbetSM,\ninVasculitis(DUTRAVAS)Study:outcomeofrenaltransplantationinChanTM,eds.LupusNephritis.2nded.Oxford,UK:OxfordUniversity\nantineutrophilcytoplasmicantibody-associatedglomerulonephritis.Press;2010:199210. Transplantation.2016;100:916924. 87.Oliva-DamasoN,PayanJ,Oliva-DamasoE,etal.Lupuspodocytopathy:\n63.PetriM,AllbrittonJ.Antibioticallergyinsystemiclupuserythematosus:aanoverview.AdvChronicKidneyDis.2019;26:369375. case-controlstudy.JRheumatol.1992;19:265269. 88.GutierrezS,PetitiJP,DePaulAL,etal.Lupus-relatedpodocytopathy. 64.VananuvatP,SuwannalaiP,SungkanuparphS,etal.PrimaryprophylaxisCoulditbeanewentitywithinthespectrumoflupusnephritis? forPneumocystisjiroveciipneumoniainpatientswithconnectivetissueNefrologia.2012;32:245246. diseases.SeminArthritisRheum.2011;41:497502. 89.HanTS,SchwartzMM,LewisEJ.Associationofglomerular\n65.SuyamaY,OkadaM,RokutandaR,etal.Safetyandefcacyofupfrontpodocytopathyandnephroticproteinuriainmesangiallupusnephritis. gradedadministrationoftrimethoprim-sulfamethoxazoleinsystemicLupus.2006;15:7175. lupuserythematosus:aretrospectivecohortstudy.ModRheumatol. 90.KraftSW,SchwartzMM,KorbetSM,etal.Glomerularpodocytopathyin\n2016;26:557561. patientswithsystemiclupuserythematosus.JAmSocNephrol.2005;16:\n66.MurdacaG,OrsiA,SpanoF,etal.Vaccine-preventableinfectionsin175179. systemiclupuserythematosus.HumVaccinImmunother.2016;12:632\n91.Shea-SimondsP,CairnsTD,RoufosseC,etal.Lupuspodocytopathy. 643. Rheumatology(Oxford).2009;48:16161618. KidneyInternational\nS63\n(2024)105(Suppl1S),S1–S69",
    "page": 64,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "www.kidney-international.org\n92.WangSF,ChenYH,ChenDQ,etal.Mesangialproliferativelupus116.ChenYE,KorbetSM,KatzRS,etal.Valueofacompleteorpartial\nnephritiswithpodocytopathy:aspecialentityoflupusnephritis.remissioninseverelupusnephritis.ClinJAmSocNephrol.2008;3:4653. Lupus.2018;27:303311. 117.DallEraM,CisternasMG,SmilekDE,etal.Predictorsoflong-termrenal\n93.HuWX,ChenYH,BaoH,etal.Glucocorticoidwithorwithoutadditionaloutcomeinlupusnephritistrials:lessonslearnedfromtheEuro-Lupus\nimmunosuppressanttherapyforpatientswithlupuspodocytopathy:aNephritisCohort.ArthritisRheumatol.2015;67:13051313. retrospectivesingle-centerstudy.Lupus.2015;24:10671075. 118.YapDY,MaMK,MokMM,etal.Long-termdataoncorticosteroidsand\n94.GladmanDD,UrowitzMB,RahmanP,etal.Accrualoforgandamagemycophenolatemofetiltreatmentinlupusnephritis.Rheumatology\novertimeinpatientswithsystemiclupuserythematosus.JRheumatol.(Oxford).2013;52:480486. 2003;30:19551959. 119.BoumpasDT,AustinHA3rd,VaughnEM,etal.Controlledtrialofpulse\n95.DonadioJVJr,HolleyKE,FergusonRH,etal.Treatmentofdiffusemethylprednisoloneversustworegimensofpulsecyclophosphamidein\nproliferativelupusnephritiswithprednisoneandcombinedseverelupusnephritis.Lancet.1992;340:741745. prednisoneandcyclophosphamide.NEnglJMed.1978;299:11511155. 120.SessoR,MonteiroM,SatoE,etal.Acontrolledtrialofpulse\n96.GourleyMF,AustinHA3rd,ScottD,etal.Methylprednisoloneandcyclophosphamideversuspulsemethylprednisoloneinseverelupus\ncyclophosphamide,aloneorincombination,inpatientswithlupusnephritis.Lupus.1994;3:107112. nephritis.Arandomized,controlledtrial.AnnInternMed.1996;125:\n121.TunnicliffeDJ,PalmerSC,HendersonL,etal.Immunosuppressive\n549557. treatmentforproliferativelupusnephritis.CochraneDatabaseSystRev. 97.IlleiGG,AustinHA,CraneM,etal.Combinationtherapywithpulse2018;6:CD002922. cyclophosphamidepluspulsemethylprednisoloneimproveslong-term\n122.MehraS,UsdadiyaJB,JainVK,etal.Comparingtheefcacyoflow-dose\nrenaloutcomewithoutaddingtoxicityinpatientswithlupusnephritis. vshigh-dosecyclophosphamideregimenasinductiontherapyinthe\nAnnInternMed.2001;135:248257. treatmentofproliferativelupusnephritis:asingle-centerstudy. 98.SteinbergAD,KaltreiderHB,StaplesPJ,etal.CyclophosphamideinlupusRheumatolInt.2018;38:557568. nephritis:acontrolledtrial.AnnInternMed.1971;75:165171. 123.MitwalliAH,AlWakeelJS,HurraibS,etal.Comparisonofhighandlow\n99.HoussiauFA,VasconcelosC,DCruzD,etal.The10-yearfollow-updatadoseofcyclophosphamideinlupusnephritispatients:along-term\noftheEuro-LupusNephritisTrialcomparinglow-doseandhigh-doserandomizedcontrolledtrial.SaudiJKidneyDisTranspl.2011;22:935940. intravenouscyclophosphamide.AnnRheumDis.2010;69:6164.",
    "page": 65,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "124.SabryA,Abo-ZenahH,MedhatT,etal.Acomparativestudyoftwo\n100.RathiM,GoyalA,JaryalA,etal.Comparisonoflow-doseintravenousintensiedpulsecyclophosphamideremission-inducingregimensfor\ncyclophosphamidewithoralmycophenolatemofetilinthetreatmentdiffuseproliferativelupusnephritis:anEgyptianexperience.IntUrol\n––\noflupusnephritis.KidneyInt.2016;89:235242.Nephrol.2009;41:153161. 101.LiX,RenH,ZhangQ,etal.Mycophenolatemofetilortacrolimuscompared\n125.El-ShafeyEM,AbdouSH,ShareefMM.Ismycophenolatemofetilsuperior\nwithintravenouscyclophosphamideintheinductiontreatmentforactivetopulseintravenouscyclophosphamideforinductiontherapyof\nlupusnephritis.NephrolDialTransplant.2012;27:14671472.proliferativelupusnephritisinEgyptianpatients?ClinExpNephrol. 2010;14:214221. 102.GinzlerEM,DooleyMA,AranowC,etal.Mycophenolatemofetilor\nintravenouscyclophosphamideforlupusnephritis.NEnglJMed.126.MendoncaS,GuptaD,AliS,etal.Mycophenolatemofetilor\n2005;353:22192228.cyclophosphamideinIndianpatientswithlupusnephritis:Whichis\nbetter?Asingle-centerexperience.SaudiJKidneyDisTranspl.2017;28:\n103. BaoH,LiuZH,XieHL,etal.SuccessfultreatmentofclassVIVlupus\n10691077. nephritiswithmultitargettherapy.JAmSocNephrol.2008;19:20012010. 127.OngLM,HooiLS,LimTO,etal.Randomizedcontrolledtrialofpulse\n104.YeF,WangS,WangM,etal.Clinicalanalysisofmulti-targettreatment\nintravenouscyclophosphamideversusmycophenolatemofetilinthe\nforcomplexlupusnephritis.AmJTranslRes.2022;14:687692. inductiontherapyofproliferativelupusnephritis.Nephrology(Carlton). 105.ZhangY,HanH,ChuL.Neuropsychiatriclupuserythematosus:future\n2005;10:504510. directionsandchallenges;asystematicreviewandsurvey.Clinics(Sao\n128.SedhainA,HadaR,AgrawalRK,etal.Lowdosemycophenolatemofetil\nPaulo).2020;75:e1515. versuscyclophosphamideintheinductiontherapyoflupusnephritisin\n106.ZhangH,LiuZ,ZhouM,etal.Multitargettherapyformaintenance\nNepalesepopulation:arandomizedcontroltrial.BMCNephrol.2018;19:\ntreatmentoflupusnephritis.JAmSocNephrol.2017;28:36713678. 175. 107.RovinBH,SolomonsN,PendergraftWF3rd,etal.Arandomized,\n129.ParikhSV,PendergraftWF,TumlinJA,etal.Treatmentofactivelupus\ncontrolleddouble-blindstudycomparingtheefcacyandsafetyof\nnephritiswithvoclosporin:48weekdatafromtheAURA-LVstudy\ndose-rangingvoclosporinwithplaceboinachievingremissionin\n[abstractno:4].AmJKidneyDis.2017;69:A2. patientswithactivelupusnephritis.KidneyInt.2019;95:219231. 130.Atisha-FregosoY,MalkielS,HarrisKM,etal.PhaseIIrandomizedtrialof\n108.RovinBH,TengYKO,GinzlerEM,etal.Efcacyandsafetyofvoclosporin\nrituximabpluscyclophosphamidefollowedbybelimumabforthe\nversusplaceboforlupusnephritis(AURORA1):adouble-blind,\ntreatmentoflupusnephritis.ArthritisRheumatol.2021;73:121131. randomised,multicentre,placebo-controlled,phase3trial.Lancet. 131.LiuT,NeunerR,ThompsonA,etal.Clinicalpharmacologyconsiderations\n2021;397:20702080.",
    "page": 65,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "fortheapprovalofbelimumabforthetreatmentofadultpatientswith\n109.ArriensC,TengYKO,GinzlerEM,etal.Updateontheefcacyandsafety\nactivelupusnephritis:aregulatoryperspective.Lupus.2022;31:424432. proleofvoclosporin:anintegratedanalysisofclinicaltrialsinlupus\n132.MoharaA,PerezVelascoR,PraditsitthikornN,etal.Acost-utilityanalysis\nnephritis.ArthritisCareRes(Hoboken).2022;75:13991408. ofalternativedrugregimensfornewlydiagnosedseverelupusnephritis\n110.SaxenaA,GinzlerEM,GibsonK,etal.Safetyandefcacyoflong-term\npatientsinThailand.Rheumatology(Oxford).2014;53:138144. voclosporintreatmentforlupusnephritisinthephase3AURORA2\n133.TseKC,TangCS,LamMF,etal.Costcomparisonbetween\nclinicaltrial.ArthritisRheumatol.PublishedonlineJuly19,2023. mycophenolatemofetilandcyclophosphamide-azathioprineinthe\nhttps://doi.org/10.1002/art.42657\ntreatmentoflupusnephritis.JRheumatol.2009;36:7681. 111.FurieR,RovinBH,HoussiauF,etal.Two-year,randomized,controlled\n134.WilsonEC,JayneDR,DellowE,etal.Thecost-effectivenessof\ntrialofbelimumabinlupusnephritis.NEnglJMed.2020;383:11171128. mycophenolatemofetilasrstlinetherapyinactivelupusnephritis. 112.FurieR,RovinBH,HoussiauF,etal.Safetyandefcacyofbelimumabin\nRheumatology(Oxford).2007;46:10961101. patientswithlupusnephritis:open-labelextensionofBLISS-LNstudy. 135.MandrikO,FotheringhamJ,RenS,etal.Thecost-effectivenessof\nClinJAmSocNephrol.2022;17:16201630. belimumabandvoclosporinforpatientswithlupusnephritisinthe\n113.RovinBH,FurieR,TengYKO,etal.Asecondaryanalysisofthe\nUnitedStates.ClinJAmSocNephrol.2022;17:385394. BelimumabInternationalStudyinLupusNephritistrialexamined\n136.BellCF,HuangSP,CyhaniukA,etal.Thecostofaresamongpatients\neffectsofbelimumabonkidneyoutcomesandpreservationofkidney\nwithsystemiclupuserythematosuswithandwithoutlupusnephritis\nfunctioninpatientswithlupusnephritis.KidneyInt.2022;101:403413. intheUnitedStates.Lupus.2022;32:301309. 114.YuX,ChenN,XueJ,etal.Efcacyandsafetyofbelimumabinpatients\n137.MeacockR,DaleN,HarrisonMJ.Thehumanisticandeconomicburden\nwithlupusnephritis:subgroupanalysesofaphase3randomizedtrialin\nofsystemiclupuserythematosus:asystematicreview. theEastAsianpopulation.AmJKidneyDis.2023;81:294306.e1. Pharmacoeconomics.2013;31:4961. 115.ChanTM,TseKC,TangCS,etal.Long-termoutcomeofpatientswith\n138.SahayM,SaivaniY,IsmalK,etal.Mycophenolateversus\ndiffuseproliferativelupusnephritistreatedwithprednisoloneandoral\ncyclophosphamideforlupusnephritis.IndianJNephrol.2018;28:3540. cyclophosphamidefollowedbyazathioprine.Lupus.2005;14:265272. KidneyInternational\nS64\n(2024)105(Suppl1S),S1–S69",
    "page": 65,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "www.kidney-international.org\nﬂﬁ\n139.IsenbergD,AppelGB,ContrerasG,etal.Inuenceofrace/ethnicityon162.SakaiR,KurasawaT,NishiE,etal.Efcacyandsafetyofmultitarget\nresponsetolupusnephritistreatment:theALMSstudy.Rheumatologytherapywithcyclophosphamideandtacrolimusforlupusnephritis:a\n(Oxford).2010;49:128140.prospective,single-arm,single-centre,openlabelpilotstudyinJapan. Lupus.2018;27:273282. 140.Mejia-ViletJM,Arreola-GuerraJM,Cordova-SanchezBM,etal. ComparisonoflupusnephritisinductiontreatmentsinaHispanic163.YangTH,WuTH,ChangYL,etal.Cyclosporineforthetreatmentoflupus\npopulation:asingle-centercohortanalysis.JRheumatol.2015;42:2082nephritisinpatientswithsystemiclupuserythematosus.ClinNephrol. 2091.2018;89:277285. 141.RovinBH,FurieR,LatinisK,etal.Efcacyandsafetyofrituximabin164.BusqueS,CantarovichM,MulgaonkarS,etal.ThePROMISEstudy:a\npatientswithactiveproliferativelupusnephritis:theLupusNephritisphase2bmulticenterstudyofvoclosporin(ISA247)versustacrolimus\n––\nAssessmentwithRituximabstudy.ArthritisRheum.2012;64:12151226.indenovokidneytransplantation.AmJTransplant.2011;11:26752684. 142.DallEraM,SolomonsN,FedericoR,etal.Comparisonofstandardofcare165.ArriensC,PolyakovaS,AdzerikhoI,etal.OP0277AURORAphase3study\ntreatmentwithalowsteroidandmycophenolatemofetilregimenfordemonstratesvoclosporinstatisticalsuperiorityoverstandardofcarein\n––\nlupusnephritisintheALMSandAURAstudies.Lupus.2019;28:591596.lupusnephritis(LN).AnnRheumDis.2020;79:172173. 143.MinaR,vonSchevenE,ArdoinSP,etal.Consensustreatmentplansfor166.RovinBH,ParikhSV,HuizingaB,etal.Managementoflupusnephritis\ninductiontherapyofnewlydiagnosedproliferativelupusnephritisinwithvoclosporin:anupdatefromapooledanalysisof534patients\njuvenilesystemiclupuserythematosus.ArthritisCareRes(Hoboken).[AbstractPO1917].JAmSocNephrol.2020.AbstractSupplement:P594. 2012;64:375383. 167.vanGelderT,HuizingaRB,NoukensJ,etal.Useoftherapeuticdrug\n144.BandhanIH,IslamMN,AhmadHI,etal.Outcomeoflow-dosemonitoringdoesnotaddclinicalvalueforvoclosporininpatientswith\nprednisoloneusefortheinductionofremissioninlupusnephritislupusnephritis[AbstractPO1918].JAmSocNephrol.2020:P594. patients.IntJRheumDis.2022;25:121130. 168.MokCC,YingKY,YimCW,etal.Tacrolimusversusmycophenolate\n145.BharatiJ,RathiM,RamachandranR,etal.Comparisonoftwosteroidmofetilforinductiontherapyoflupusnephritis:arandomised\nregimensininductiontherapyofproliferativelupusnephritis:acontrolledtrialandlong-termfollow-up.AnnRheumDis.2016;75:3036. randomizedcontrolledtrial.IndianJNephrol.2019;29:373375. 169.KamanamoolN,IngsathitA,RattanasiriS,etal.Comparisonofdisease\n146.ZeherM,DoriaA,LanJ,etal.Efcacyandsafetyofenteric-coatedactivitybetweentacrolimusandmycophenolatemofetilinlupus\nmycophenolatesodiumincombinationwithtwoglucocorticoidregimensnephritis:arandomizedcontrolledtrial.Lupus.2018;27:647656. forthetreatmentofactivelupusnephritis.Lupus.2011;20:14841493.",
    "page": 66,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "170.MokCC,HoLY,YingSKY,etal.Long-termoutcomeofarandomised\n147.Ruiz-IrastorzaG,DanzaA,PeralesI,etal.Prednisoneinlupusnephritis:controlledtrialcomparingtacrolimuswithmycophenolatemofetilas\nHowmuchisenough?AutoimmunRev.2014;13:206214.inductiontherapyforactivelupusnephritis.AnnRheumDis.2020;79:\n10701076. 148.Ruiz-ArruzaI,LozanoJ,Cabezas-RodriguezI,etal.Restrictiveuseoforal\nglucocorticoidsinsystemiclupuserythematosusandpreventionof171.LiL,DuY,JiJ,etal.Analysisofthesafetyandefcacyoftacrolimus\ndamagewithoutworseninglong-termdiseasecontrol:ancombinedwithglucocorticoidinthetreatmentoflupusnephritis.Pak\n––\nobservationalstudy.ArthritisCareRes(Hoboken).2018;70:582591.JMedSci.2022;38:12851291. 149.AustinHA3rd,IlleiGG,BraunMJ,etal.Randomized,controlledtrialof172.ZhangX,LiuP,ZhangZ.Analysisoftheclinicaleffectsofthe\nprednisone,cyclophosphamide,andcyclosporineinlupuscombinationofmycophenolatemofetilwitheithertacrolimusor\nmembranousnephropathy.JAmSocNephrol.2009;20:901911.cyclophosphamide.Clinics(SaoPaulo).2020;75:e1820. 150.McKinleyA,ParkE,SpetieD,etal.Oralcyclophosphamideforlupus173.ZhengZ,ZhangH,PengX,etal.Effectoftacrolimusvsintravenous\nglomerulonephritis:anunderusedtherapeuticoption.ClinJAmSoccyclophosphamideoncompleteorpartialresponseinpatientswith\nNephrol.2009;4:17541760.lupusnephritis:arandomizedclinicaltrial.JAMANetwOpen.2022;5:\ne224492. 151.MokCC,HoCT,ChanKW,etal.Outcomeandprognosticindicatorsof\ndiffuseproliferativelupusglomerulonephritistreatedwithsequential174.vanVollenhovenRF,NavarraSV,LevyRA,etal.Long-termsafetyand\noralcyclophosphamideandazathioprine.ArthritisRheum.2002;46:1003limitedorgandamageinpatientswithsystemiclupuserythematosus\n1013.treatedwithbelimumab:aphaseIIIstudyextension.Rheumatology\n(Oxford).2020;59:281291. 152.YeeCS,CrabtreeN,SkanJ,etal.Prevalenceandpredictorsoffragility\nfracturesinsystemiclupuserythematosus.AnnRheumDis.2005;64:175.WallaceDJ,GinzlerEM,MerrillJT,etal.Safetyandefcacyofbelimumab\n111113.plusstandardtherapyforuptothirteenyearsinpatientswithsystemic\nlupuserythematosus.ArthritisRheumatol.2019;71:11251134. 153.ACCESSTrialGroup.Treatmentoflupusnephritiswithabatacept:the\nﬁﬁ\nAbataceptandCyclophosphamideCombinationEfcacyandSafety176.StohlW,SchwartingA,OkadaM,etal.Efcacyandsafetyof\n–ﬁ\nStudy.ArthritisRheumatol.2014;66:30963104.subcutaneousbelimumabinsystemiclupuserythematosus:afty-\ntwo-weekrandomized,double-blind,placebo-controlledstudy.Arthritis\n154.YeeCS,GordonC,DostalC,etal.EULARrandomisedcontrolledtrialof\nRheumatol.2017;69:10161027. pulsecyclophosphamideandmethylprednisoloneversuscontinuous\ncyclophosphamideandprednisolonefollowedbyazathioprineand177.StruemperH,MurtaughT,GilbertJ,etal.Relativebioavailabilityofa\n–ﬁ\nprednisoloneinlupusnephritis.AnnRheumDis.2004;63:525529.singledoseofbelimumabadministeredsubcutaneouslybyprelled\nsyringeorautoinjectorinhealthysubjects.ClinPharmacolDrugDev. 155.CiancioG,MillerJ,GonwaTA.Reviewofmajorclinicaltrialswith\n2016;5:208215. mycophenolatemofetilinrenaltransplantation.Transplantation.",
    "page": 66,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "2005;80(2suppl):S191S200.178.YapaSW,RothD,GordonD,etal.Comparisonofintravenousand\nsubcutaneousexposuresupportingdoseselectionofsubcutaneous\n156.AlexanderS,FlemingDH,MathewBS,etal.Pharmacokineticsof\nbelimumabsystemiclupuserythematosusphase3program.Lupus. concentration-controlledmycophenolatemofetilinproliferativelupus\n2016;25:14481455. nephritis:anobservationalcohortstudy.TherDrugMonit.2014;36:\n423432.179.DyadykAI,BagriyAE,YarovayaNF,etal.Resultsoflong-term\nrandomisedstudyofimmunosuppressivetreatmentofpatientswith\n157.KittanamongkolchaiW,RukrungC,SupasiriT,etal.Therapeuticdrug\nidiopathicmembranousglomerulonephritis[abstract].NephrolDial\nmonitoringofmycophenolatemofetilforthetreatmentofseverely\nTransplant.2001;16:A64. activelupusnephritis.Lupus.2013;22:727732. 180.GrootscholtenC,LigtenbergG,HagenEC,etal.Azathioprine/\n158.LertdumronglukP,SomparnP,KittanamongkolchaiW,etal. methylprednisoloneversuscyclophosphamideinproliferativelupus\nPharmacokineticsofmycophenolicacidinseverelupusnephritis. nephritis.Arandomizedcontrolledtrial.KidneyInt.2006;70:732742. KidneyInt.2010;78:389395. 181.WangHY,CuiTG,HouFF,etal.Inductiontreatmentofproliferativelupus\n159.NeumannI,FuhrmannH,FangIF,etal.Associationbetween\nnephritiswithleunomidecombinedwithprednisone:aprospective\nmycophenolicacid12-htroughlevelsandclinicalendpointsin\nmulti-centreobservationalstudy.Lupus.2008;17:638644. patientswithautoimmunediseaseonmycophenolatemofetil.Nephrol\n–ﬂ\nDialTransplant.2008;23:35143520.182.ZhangM,QiC,ZhaY,etal.Leunomideversuscyclophosphamideinthe\ninductiontreatmentofproliferativelupusnephritisinChinesepatients:a\n160.vanGelderT,BerdenJH,BergerSP.ToTDMornottoTDMinlupusnephritis\nrandomizedtrial.ClinRheumatol.2019;38:859867. patientstreatedwithMMF?NephrolDialTransplant.2015;30:560564. 183.ClarkWF,LindsayRM,CattranDC,etal.Monthlyplasmapheresisforsystemic\n161.RovinBH,ParikhSV,HebertLA,etal.Lupusnephritis:inductiontherapy\nlupuserythematosuswithdiffuseproliferativeglomerulonephritis:apilot\ninseverelupusnephritisshouldMMFbeconsideredthedrugof\nstudy.CanMedAssocJ.1981;125:171174. choice?ClinJAmSocNephrol.2013;8:147153. KidneyInternational\nS65\n(2024)105(Suppl1S),S1–S69",
    "page": 66,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "www.kidney-international.org\n184.DoriaA,PiccoliA,VescoP,etal.Therapyoflupusnephritis.Atwo-year206.ChoiCB,WonS,BaeSC.Outcomesofmultitargettherapyusing\nprospectivestudy.AnnMedInterne(Paris).1994;145:307311.mycophenolatemofetilandtacrolimusforrefractoryorrelapsing\nlupusnephritis.Lupus.2018;27:10071011. 185.WallaceDJ,GoldngerD,PepkowitzSH,etal.Randomizedcontrolled\ntrialofpulse/synchronizationcyclophosphamide/apheresisfor207.KasitanonN,BoripatkosolP,LouthrenooW.Responsetocombinationof\nproliferativelupusnephritis.JClinApher.1998;13:163166.mycophenolatemofetil,cyclosporinAandcorticosteroidtreatmentin\nlupusnephritispatientswithpersistentproteinuria.IntJRheumDis. 186.ClarkWF,WilliamsW,CattranDC,etal.Acontrolledtrialofchronic\n2018;21:200207. plasmaexchangetherapyinS.L.E.nephritis[abstract].KidneyInt. 1984;25:161.208.KarasawaK,UchidaK,KodamaM,etal.Long-termeffectsoftacrolimus\nformaintenancetherapyoflupusnephritis:a5-yearretrospectivestudy\n187.RovinBH,vanVollenhovenRF,AranowC,etal.Amulticenter,\natasinglecenter.RheumatolInt.2018;38:22712277. randomized,double-blind,placebo-controlledstudytoevaluatethe\nefcacyandsafetyoftreatmentwithsirukumab(CNTO136)in209.YapDY,MaMK,MokMM,etal.Long-termdataontacrolimustreatment\n––\npatientswithactivelupusnephritis.ArthritisRheumatol.2016;68:2174inlupusnephritis.Rheumatology(Oxford).2014;53:22322237. 2183. 210.YumuraW,SuganumaS,UchidaK,etal.Effectsoflong-termtreatment\n188.JayneD,AppelG,ChanTM,etal.LB0003:arandomizedcontrolledstudywithmizoribineinpatientswithproliferativelupusnephritis.Clin\noflaquinimodinactivelupusnephritispatientsincombinationwithNephrol.2005;64:2834. standardofcare.AnnRheumDis.2013;72:A164. 211.ZavadaJ,SinikkaPesickovaS,RysavaR,etal.Extendedfollow-upofthe\n189.FurieR,NichollsK,ChengTT,etal.EfcacyandsafetyofabataceptinCYCLOFA-LUNEtrialcomparingtwosequentialinductionand\nlupusnephritis:atwelve-month,randomized,double-blindstudy.maintenancetreatmentregimensforproliferativelupusnephritis\nArthritisRheumatol.2014;66:379389.basedeitheroncyclophosphamideoroncyclosporineA.Lupus. 2014;23:6974. 190.GunnarssonI,SundelinB,JonsdottirT,etal.Histopathologicandclinical\noutcomeofrituximabtreatmentinpatientswithcyclophosphamide-212.MoroniG,DoriaA,MoscaM,etal.Arandomizedpilottrialcomparing\nresistantproliferativelupusnephritis.ArthritisRheum.2007;56:1263cyclosporineandazathioprineformaintenancetherapyindiffuse\n1272.lupusnephritisoverfouryears.ClinJAmSocNephrol.2006;1:925932. 191.MyslerEF,SpindlerAJ,GuzmanR,etal.Efcacyandsafetyof213.NeeR,RiveraI,LittleDJ,etal.Cost-utilityanalysisofmycophenolate\nocrelizumabinactiveproliferativelupusnephritis:resultsfromamofetilversusazathioprinebasedregimensformaintenancetherapy\nrandomized,double-blind,phaseIIIstudy.ArthritisRheum.2013;65:ofproliferativelupusnephritis.IntJNephrol.2015;2015:917567. 23682379. 214.JuliaoP,WurstK,PimentaJM,etal.Belimumabuseduringpregnancy:\n192.RovinBH,MartinezA,AnaliaA,etal.Aphase2randomizedcontrolledinterimresultsofthebelimumabpregnancyregistry.BirthDefectsRes.",
    "page": 67,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "studyofobinutuzumabwithmycophenolateandcorticosteroidsin2023;115:188204. proliferativelupusnephritis[AbstractFR-OR136.].JAmSocNephrol. 215.YapDYH,TangC,MaMKM,etal.Longtermdataondiseasearesin\n2019;30:B2. patientswithproliferativelupusnephritisinrecentyears.JRheumatol. 193.WofsyD,HillsonJL,DiamondB.Abataceptforlupusnephritis:alternative2017;44:13751383. ﬁﬂ\ndenitionsofcompleteresponsesupportconictingconclusions. 216.MathianA,PhaM,HarocheJ,etal.Withdrawaloflow-doseprednisone\nArthritisRheum.2012;64:36603665. inSLEpatientswithaclinicallyquiescentdiseaseformorethan1year:a\n194.KarimMY,PisoniCN,KhamashtaMA.Updateonimmunotherapyforrandomisedclinicaltrial.AnnRheumDis.2020;79:339346. —’’\nsystemiclupuserythematosuswhatshotandwhatsnot. 217.YapDYH,KwanLPY,MaMKM,etal.Preemptiveimmunosuppressive\nRheumatology(Oxford).2009;48:332341. treatmentforasymptomaticserologicalreactivationmayreducerenal\n195.LiEK,TamLS,ZhuTY,etal.Iscombinationrituximabwitharesinpatientswithlupusnephritis:acohortstudy.NephrolDial\ncyclophosphamidebetterthanrituximabaloneinthetreatmentofTransplant.2019;34:467473. lupusnephritis?Rheumatology(Oxford).2009;48:892898. 218.Jourde-ChicheN,Costedoat-ChalumeauN,BaumstarckK,etal.Weaning\n196.LuTY,NgKP,CambridgeG,etal.Aretrospectiveseven-yearanalysisofofmaintenanceimmunosuppressivetherapyinlupusnephritis(WIN-\ntheuseofBcelldepletiontherapyinsystemiclupuserythematosusatLupus):resultsofamulticentrerandomisedcontrolledtrial.Ann\nﬁﬁ–\nUniversityCollegeLondonHospital:therstftypatients.ArthritisRheumDis.2022;81:14201427. Rheum.2009;61:482487. 219.YapDYH,TamCH,YungS,etal.Pharmacokineticsand\n197.Ramos-CasalsM,SotoMJ,CuadradoMJ,etal.Rituximabinsystemicpharmacogenomicsofmycophenolicacidanditsclinicalcorrelations\nlupuserythematosus:asystematicreviewofoff-labelusein188cases.inmaintenanceimmunosuppressionforlupusnephritis.NephrolDial\n––\nTransplant.2018;35:810818. Lupus.2009;18:767776. 198.CondonMB,AshbyD,PepperRJ,etal.Prospectiveobservationalsingle-220.MoroniG,LonghiS,GiglioE,etal.Whathappensaftercomplete\ncentrecohortstudytoevaluatetheeffectivenessoftreatinglupuswithdrawaloftherapyinpatientswithlupusnephritis.ClinExp\nnephritiswithrituximabandmycophenolatemofetilbutnooralRheumatol.2013;31:S75S81. steroids.AnnRheumDis.2013;72:12801286. 221.AlvaradoAS,MalvarA,LococoB,etal.Thevalueofrepeatkidneybiopsy\n199.RovinBH,CasterDJ,CattranDC,etal.ManagementandtreatmentofinquiescentArgentinianlupusnephritispatients.Lupus.2014;23:840\nglomerulardiseases(part2):conclusionsfromaKidneyDisease:847. ImprovingGlobalOutcomes(KDIGO)ControversiesConference.Kidney\n222.DeRosaM,AzzatoF,ToblliJE,etal.Aprospectiveobservationalcohort\nInt.2019;95:281295. studyhighlightskidneybiopsyndingsoflupusnephritispatientsin\n200.MokCC,LauCS,WongRW.Riskfactorsforovarianfailureinpatientsremissionwhoarefollowingwithdrawalofmaintenancetherapy. withsystemiclupuserythematosusreceivingcyclophosphamideKidneyInt.2018;94:788794. therapy.ArthritisRheum.1998;41:831837.",
    "page": 67,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "223.MalvarA,AlbertonV,LococoB,etal.Kidneybiopsy-basedmanagement\n201.RadisCD,KahlLE,BakerGL,etal.Effectsofcyclophosphamideontheofmaintenanceimmunosuppressionissafeandmayameliorateare\ndevelopmentofmalignancyandonlong-termsurvivalofpatientsrateinlupusnephritis.KidneyInt.2020;97:156162. withrheumatoidarthritis.A20-yearfollowupstudy.ArthritisRheum. 224.TanakaH,WatanabeS,Aizawa-YashiroT,etal.Long-termtacrolimus-\n1995;38:11201127. basedimmunosuppressivetreatmentforyoungpatientswithlupus\n202.ContrerasG,PardoV,LeclercqB,etal.Sequentialtherapiesfornephritis:aprospectivestudyindailyclinicalpractice.NephronClin\n––\nproliferativelupusnephritis.NEnglJMed.2004;350:971980.Pract.2012;121:c165c173. 203.HoussiauFA,DCruzD,SangleS,etal.Azathioprineversus225.ChenW,LiuQ,ChenW,etal.Outcomesofmaintenancetherapywith\nmycophenolatemofetilforlong-termimmunosuppressioninlupustacrolimusversusazathioprineforactivelupusnephritis:amulticenter\nnephritis:resultsfromtheMAINTAINNephritisTrial.AnnRheumDis.randomizedclinicaltrial.Lupus.2012;21:944952. 2010;69:20832089. 226.Cortes-HernandezJ,Torres-SalidoMT,MedranoAS,etal.Long-term\n204.KaballoBG,AhmedAE,NurMM,etal.Mycophenolatemofetilversusoutcomesmycophenolatemofetiltreatmentforlupusnephritiswith\nazathioprineformaintenancetreatmentoflupusnephritis.SaudiJadditionoftacrolimusforresistantcases.NephrolDialTransplant. ––\nKidneyDisTranspl.2016;27:717725.2010;25:39393948. 205.AragonE,ResontocLP,ChanYH,etal.Long-termoutcomeswithmulti-227.TseKC,LamMF,TangSC,etal.Apilotstudyontacrolimustreatmentin\ntargetedimmunosuppressiveprotocolinchildrenwithseveremembranousorquiescentlupusnephritiswithproteinuriaresistantto\n––\nproliferativelupusnephritis.Lupus.2016;25:399406.angiotensininhibitionorblockade.Lupus.2007;16:4651. KidneyInternational\nS66\n(2024)105(Suppl1S),S1–S69",
    "page": 67,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "www.kidney-international.org\n228.UchinoA,TsukamotoH,NakashimaH,etal.Tacrolimusiseffectivefor251.Ugolini-LopesMR,SeguroLPC,CastroMXF,etal.Earlyproteinuria\nlupusnephritispatientswithpersistentproteinuria.ClinExpresponse:avalidreal-lifesituationpredictoroflong-termlupusrenal\nRheumatol.2010;28:612.outcomeinanethnicallydiversegroupwithseverebiopsy-proven\nnephritis?LupusSciMed.2017;4:e000213. 229.SugiyamaS.Long-termtherapyofmizoribineonlupusnephritisinjoint\nmulti-centerstudy.JClinTherMed.1996;12:215219.252.IoannidisJP,BokiKA,KatsoridaME,etal.Remission,relapse,andre-\nremissionofproliferativelupusnephritistreatedwith\n230.TakeuchiT,OkadaK,YoshidaH,etal.Post-marketingsurveillancestudy\ncyclophosphamide.KidneyInt.2000;57:258264. ofthelong-termuseofmizoribineforthetreatmentoflupusnephritis:\n2-yearresults.ModRheumatol.2018;28:8594.253.ToumaZ,UrowitzMB,IbanezD,etal.Timetorecoveryfromproteinuria\ninpatientswithlupusnephritisreceivingstandardtreatment. 231.FuQ,WuC,DaiM,etal.Leunomideversusazathioprinefor\nJRheumatol.2014;41:688697. maintenancetherapyoflupusnephritis:aprospective,multicentre,\n’ﬁ\nrandomisedtrialandlong-termfollow-up.AnnRheumDis.2022;81:254.DallEraM,StoneD,LevesqueV,etal.Identicationofbiomarkersthat\n15491555.predictresponsetotreatmentoflupusnephritiswithmycophenolate\nmofetilorpulsecyclophosphamide.ArthritisCareRes(Hoboken). 232.AppelGB,CohenDJ,PiraniCL,etal.Long-termfollow-upofpatients\n2011;63:351357. withlupusnephritis.AstudybasedontheclassicationoftheWorld\nHealthOrganization.AmJMed.1987;83:877885.255.BruceIN,GladmanDD,UrowitzMB.Factorsassociatedwithrefractory\nrenaldiseaseinpatientswithsystemiclupuserythematosus:therole\n233.MercadalL,MontcelST,NochyD,etal.Factorsaffectingoutcomeand\nofpatientnonadherence.ArthritisCareRes.2000;13:406408. prognosisinmembranouslupusnephropathy.NephrolDialTransplant. 2002;17:17711778.256.Costedoat-ChalumeauN,PouchotJ,Guettrot-ImbertG,etal.Adherence\ntotreatmentinsystemiclupuserythematosuspatients.BestPractRes\n234.MokCC.Membranousnephropathyinsystemiclupuserythematosus:a\nClinRheumatol.2013;27:329340. therapeuticenigma.NatRevNephrol.2009;5:212220. 257.MarengoMF,WaimannCA,deAchavalS,etal.Measuringtherapeutic\n235.MokCC,YingKY,YimCW,etal.Verylong-termoutcomeofpurelupus\nadherenceinsystemiclupuserythematosuswithelectronic\nmembranousnephropathytreatedwithglucocorticoidand\nmonitoring.Lupus.2012;21:11581165. azathioprine.Lupus.2009;18:10911095. 258.PetriM,Perez-GutthannS,LongeneckerJC,etal.Morbidityofsystemic\n236.RadhakrishnanJ,MoutzourisDA,GinzlerEM,etal.Mycophenolate\nlupuserythematosus:roleofraceandsocioeconomicstatus.AmJMed. mofetilandintravenouscyclophosphamidearesimilarasinduction\n1991;91:345353. therapyforclassVlupusnephritis.KidneyInt.2010;77:152160. 259.RiveraF,MeridaE,IllescasML,etal.Mycophenolateinrefractoryand\n237.ChanTM,LiFK,HaoWK,etal.Treatmentofmembranouslupusnephritis\nrelapsinglupusnephritis.AmJNephrol.2014;40:105112. withnephroticsyndromebysequentialimmunosuppression.Lupus. 1999;8:545551.",
    "page": 68,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "260.BangSY,LeeCK,KangYM,etal.Multicenterretrospectiveanalysisofthe\neffectivenessandsafetyofrituximabinKoreanpatientswithrefractory\n238.CramerCH2nd,MillsM,ValentiniRP,etal.Clinicalpresentationand\nsystemiclupuserythematosus.AutoimmuneDis.2012;2012:565039. outcomeinacohortofpaediatricpatientswithmembranouslupus\nnephritis.NephrolDialTransplant.2007;22:34953500. 261.ContisA,VanquaethemH,TruchetetME,etal.Analysisofthe\neffectivenessandsafetyofrituximabinpatientswithrefractorylupus\n239.BorbaEF,GuedesLK,ChristmannRB,etal.Mycophenolatemofetilis\nnephritis:achartreview.ClinRheumatol.2016;35:517522. effectiveinreducinglupusglomerulonephritisproteinuria.Rheumatol\n–ﬁ\nInt.2006;26:10781083.262.Diaz-LagaresC,CrocaS,SangleS,etal.Efcacyofrituximabin164\npatientswithbiopsy-provenlupusnephritis:pooleddatafrom\n240.SpetieDN,TangY,RovinBH,etal.MycophenolatetherapyofSLE\nEuropeancohorts.AutoimmunRev.2012;11:357364. membranousnephropathy.KidneyInt.2004;66:24112415. 263.Garcia-CarrascoM,Mendoza-PintoC,Sandoval-CruzM,etal.Anti-CD20\n241.ChenW,TangX,LiuQ,etal.Short-termoutcomesofinductiontherapy\ntherapyinpatientswithrefractorysystemiclupuserythematosus:a\nwithtacrolimusversuscyclophosphamideforactivelupusnephritis:a\nlongitudinalanalysisof52Hispanicpatients.Lupus.2010;19:213219. multicenterrandomizedclinicaltrial.AmJKidneyDis.2011;57:235244. 264.IaccarinoL,BartoloniE,CarliL,etal.Efcacyandsafetyofoff-labeluseof\n242.SzetoCC,KwanBC,LaiFM,etal.Tacrolimusforthetreatmentof\nrituximabinrefractorylupus:datafromtheItalianMulticentreRegistry. systemiclupuserythematosuswithpureclassVnephritis. ClinExpRheumatol.2015;33:449456. Rheumatology(Oxford).2008;47:16781681. 265.IwataS,SaitoK,HirataS,etal.Efcacyandsafetyofanti-CD20antibody\n243.YapDY,YuX,ChenXM,etal.Pilot24-monthstudytocompare\nrituximabforpatientswithrefractorysystemiclupuserythematosus. mycophenolatemofetilandtacrolimusinthetreatmentof\nLupus.2018;27:802811. membranouslupusnephritiswithnephroticsyndrome.Nephrology\n(Carlton).2012;17:352357.266.KoikeR,HarigaiM,AtsumiT,etal.JapanCollegeofRheumatology2009\nguidelinesfortheuseoftocilizumab,ahumanizedanti-interleukin-6\n244.ChavarotN,VerhelstD,PardonA,etal.Rituximabaloneasinduction\nreceptormonoclonalantibody,inrheumatoidarthritis.Mod\ntherapyformembranouslupusnephritis:amulticenterretrospective\nRheumatol.2009;19:351357. study.Medicine(Baltimore).2017;96:e7429. 267.KotagiriP,MartinA,HughesP,etal.Single-doserituximabinrefractory\n245.SaxenaA,CasterD,AlmaaniS,etal.Long-termuseofvoclosporinin\nlupusnephritis.InternMedJ.2016;46:899901. patientswithclassVlupusnephritis:resultsfromtheAURORA2\nContinuationStudy[abstract].ArthritisRheumatol.2022;74(suppl9).268.MelanderC,SalleeM,TrollietP,etal.Rituximabinseverelupusnephritis:\nAvailableat:AccessedMay17,2023.https://acrabstracts.org/abstract/earlyB-celldepletionaffectslong-termrenaloutcome.ClinJAmSoc\nlong-term-use-of-voclosporin-in-patients-with-class-v-lupus-nephritis-Nephrol.2009;4:579587.",
    "page": 68,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "results-from-the-aurora-2-continuation-study/\n269.TanakaY,TakeuchiT,MiyasakaN,etal.Efcacyandsafetyofrituximab\n246.HoussiauFA,VasconcelosC,DCruzD,etal.EarlyresponsetoinJapanesepatientswithsystemiclupuserythematosusandlupus\nimmunosuppressivetherapypredictsgoodrenaloutcomeinlupusnephritiswhoarerefractorytoconventionaltherapy.ModRheumatol. nephritis:lessonsfromlong-termfollowupofpatientsintheEuro-2016;26:8086. LupusNephritisTrial.ArthritisRheum.2004;50:39343940. 270.Vigna-PerezM,Hernandez-CastroB,Paredes-SaharopulosO,etal. 247.KorbetSM,LewisEJ,CollaborativeStudyGroup.Severelupusnephritis:Clinicalandimmunologicaleffectsofrituximabinpatientswithlupus\n>¼\nthepredictivevalueofa/50%reductioninproteinuriaat6months.nephritisrefractorytoconventionaltherapy:apilotstudy.ArthritisRes\nNephrolDialTransplant.2013;28:23132318.Ther.2006;8:R83. 248.KorbetSM,LewisEJ,SchwartzMM,etal.Factorspredictiveofoutcome271.WeidenbuschM,RommeleC,SchrottleA,etal.BeyondtheLUNARtrial. inseverelupusnephritis.LupusNephritisCollaborativeStudyGroup.AmEfcacyofrituximabinrefractorylupusnephritis.NephrolDial\n––\nJKidneyDis.2000;35:904914.Transplant.2013;28:106111. 249.TamirouF,DCruzD,SangleS,etal.Long-termfollow-upofthe272.AlshaikiF,ObaidE,AlmuallimA,etal.Outcomesofrituximabtherapyin\nMAINTAINNephritisTrial,comparingazathioprineandmycophenolaterefractorylupus:ameta-analysis.EurJRheumatol.2018;5:118126. mofetilasmaintenancetherapyoflupusnephritis.AnnRheumDis. 273.FeiY,WuQ,ZhangW,etal.Low-dosetacrolimusintreatinglupus\n2016;75:526531. nephritisrefractorytocyclophosphamide:aprospectivecohortstudy. 250.TamirouF,LauwerysBR,DallEraM,etal.Aproteinuriacut-offlevelof0.7ClinExpRheumatol.2013;31:6268. g/dayafter12monthsoftreatmentbestpredictslong-termrenal\n274.JesusD,RodriguesM,daSilvaJAP,etal.Multitargettherapyof\noutcomeinlupusnephritis:datafromtheMAINTAINNephritisTrial. mycophenolatemofetilandcyclosporineAforinductiontreatmentof\nLupusSciMed.2015;2:e000123. refractorylupusnephritis.Lupus.2018;27:13581362. KidneyInternational\nS67\n(2024)105(Suppl1S),S1–S69",
    "page": 68,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "www.kidney-international.org\n275.MokCC,ToCH,YuKL,etal.Combinedlow-dosemycophenolatemofetil300.BellWR,BraineHG,NessPM,etal.Improvedsurvivalinthrombotic\nandtacrolimusforlupusnephritiswithsuboptimalresponsetostandardthrombocytopenicpurpura-hemolyticuremicsyndrome.Clinical\n––\ntherapy:a12-monthprospectivestudy.Lupus.2013;22:11351141.experiencein108patients.NEnglJMed.1991;325:398403. ﬁﬁﬁ\n276.OgawaH,KamedaH,AmanoK,etal.Efcacyandsafetyofcyclosporine301.FroissartA,BuffetM,VeyradierA,etal.Efcacyandsafetyofrst-line\nAinpatientswithrefractorysystemiclupuserythematosusinadailyrituximabinsevere,acquiredthromboticthrombocytopenicpurpura\nclinicalpractice.Lupus.2010;19:162169.withasuboptimalresponsetoplasmaexchange.Experienceofthe\nFrenchThromboticMicroangiopathiesReferenceCenter.CritCareMed. 277.SheikholeslamiM,HajialiloM,RasiHashemiSS,etal.Lowdose\n2012;40:104111. cyclosporineAinthetreatmentofresistantproliferativelupus\nnephritis.ModRheumatol.2018;28:523529.302.ScullyM,CohenH,CavenaghJ,etal.Remissioninacuterefractoryand\nrelapsingthromboticthrombocytopenicpurpurafollowingrituximabis\n278.MackensenA,MullerF,MougiakakosD,etal.Anti-CD19CARTcell\nassociatedwithareductioninIgGantibodiestoADAMTS-13.BrJ\ntherapyforrefractorysystemiclupuserythematosus.NatMed.2022;28:\nHaematol.2007;136:451461. 21242132. 303.ScullyM,McDonaldV,CavenaghJ,etal.Aphase2studyofthesafety\n279.ArriensC,ChenS,KarpDR,etal.Prognosticsignicanceofrepeatbiopsy\nandefcacyofrituximabwithplasmaexchangeinacuteacquired\ninlupusnephritis:histopathologicworseningandashorttimebetween\nthromboticthrombocytopenicpurpura.Blood.2011;118:17461753. biopsiesisassociatedwithsignicantlyincreasedriskforend-stagerenal\ndiseaseanddeath.ClinImmunol.2017;185:39.304.WestwoodJP,ThomasM,AlwanF,etal.Rituximabprophylaxisto\npreventthromboticthrombocytopenicpurpurarelapse:outcomeand\n280.MoroniG,QuagliniS,GallelliB,etal.Thelong-termoutcomeof93\nevaluationofdosingregimens.BloodAdv.2017;1:11591166. patientswithproliferativelupusnephritis.NephrolDialTransplant. 2007;22:25312539.305.PeyvandiF,ScullyM,KremerHovingaJA,etal.Caplacizumabfor\nacquiredthromboticthrombocytopenicpurpura.NEnglJMed. 281.MoscaM,BencivelliW,NeriR,etal.Renalaresin91SLEpatientswith\n2016;374:511522. diffuseproliferativeglomerulonephritis.KidneyInt.2002;61:15021509. 306.ScullyM,CatalandSR,PeyvandiF,etal.Caplacizumabtreatmentfor\n282.ParikhSV,NagarajaHN,HebertL,etal.Renalareasapredictorof\nacquiredthromboticthrombocytopenicpurpura.NEnglJMed. incidentandprogressiveCKDinpatientswithlupusnephritis.ClinJ\n2019;380:335346. AmSocNephrol.2014;9:279284. 307.TektonidouMG.Antiphospholipidsyndromenephropathy:from\n283.MorrisHK,CanettaPA,AppelGB.ImpactoftheALMSandMAINTAIN\npathogenesistotreatment.FrontImmunol.2018;9:1181. trialsonthemanagementoflupusnephritis.NephrolDialTransplant.",
    "page": 69,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "2013;28:13711376.308.SciasciaS,YazdanyJ,DallEraM,etal.Anticoagulationinpatientswith\nconcomitantlupusnephritisandthromboticmicroangiopathy:a\n284.HanaokaH,IidaH,KiyokawaT,etal.Earlyachievementofdeep\nmulticentrecohortstudy.AnnRheumDis.2019;78:10041006. remissionpredictslowincidenceofrenalareinlupusnephritisclass\nIIIorIV.ArthritisResTher.2018;20:86.309.DufrostV,RisseJ,ReshetnyakT,etal.Increasedriskofthrombosisin\nantiphospholipidsyndromepatientstreatedwithdirectoral\n285.Mejia-ViletJM,ParikhSV,SongH,etal.Immunegeneexpressionin\nanticoagulants.Resultsfromaninternationalpatient-leveldatameta-\nkidneybiopsiesoflupusnephritispatientsatdiagnosisandatrenal\nﬂ–\nanalysis.AutoimmunRev.2018;17:10111021. are.NephrolDialTransplant.2019;34:11971206. 310.PengoV,DenasG,ZoppellaroG,etal.Rivaroxabanvswarfarininhigh-\n286.IoannidisJP,KatsisGE,TzioufasAG,etal.Predictorsofsustained\nriskpatientswithantiphospholipidsyndrome.Blood.2018;132:1365\namenorrheafrompulsedintravenouscyclophosphamidein\n1371. premenopausalwomenwithsystemiclupuserythematosus. JRheumatol.2002;29:21292135.311.KazzazNM,McCuneWJ,KnightJS.Treatmentofcatastrophic\nantiphospholipidsyndrome.CurrOpinRheumatol.2016;28:218227. 287.KatsisGE,TzioufasAG.Ovarianfailureinsystemiclupuserythematosus\npatientstreatedwithpulsedintravenouscyclophosphamide.Lupus.312.SchwartzJ,PadmanabhanA,AquiN,etal.Guidelinesontheuseof\n2004;13:673678.therapeuticapheresisinclinicalpractice-evidence-basedapproach\nfromtheWritingCommitteeoftheAmericanSocietyforApheresis:\n288.ParikhSV,AlvaradoA,MalvarA,etal.Thekidneybiopsyinlupus\ntheseventhspecialissue.JClinApher.2016;31:149162. nephritis:past,present,andfuture.SeminNephrol.2015;35:465477. 313.BucciarelliS,EspinosaG,CerveraR,etal.Mortalityinthecatastrophic\n289.BootsmaH,SpronkP,DerksenR,etal.Preventionofrelapsesinsystemic\nantiphospholipidsyndrome:causesofdeathandprognosticfactorsin\nlupuserythematosus.Lancet.1995;345:15951599. aseriesof250patients.ArthritisRheum.2006;54:25682576. 290.TsengCE,BuyonJP,KimM,etal.Theeffectofmoderate-dose\n314.DioszegiA,TarrT,Nagy-VinczeM,etal.Microthromboticrenal\ncorticosteroidsinpreventingseverearesinpatientswith\ninvolvementinanSLEpatientwithconcomitantcatastrophic\nserologicallyactive,butclinicallystable,systemiclupuserythematosus:\nantiphospholipidsyndrome:thebenecialeffectofrituximab\nndingsofaprospective,randomized,double-blind,placebo-\ntreatment.Lupus.2018;27:15521558. controlledtrial.ArthritisRheum.2006;54:36233632. 315.RymarzA,NiemczykS.Thecomplextreatmentincludingrituximabin\n291.GeorgeJN,NesterCM.Syndromesofthromboticmicroangiopathy. themanagementofcatastrophicantiphospholidsyndromewithrenal\nNEnglJMed.2014;371:654666. involvement.BMCNephrol.2018;19:132. 292.AhmedS,SiddiquiRK,SiddiquiAK,etal.HIVassociatedthrombotic\n316.GuillotM,RafatC,BuobD,etal.Eculizumabforcatastrophic\nmicroangiopathy.PostgradMedJ.2002;78:520525. antiphospholipidsyndromeacasereportandliteraturereview. 293.BrocklebankV,WoodKM,KavanaghD.Thromboticmicroangiopathy\nRheumatology(Oxford).2018;57:20552057.",
    "page": 69,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "andthekidney.ClinJAmSocNephrol.2018;13:300317. 317.RuffattiA,TarziaV,FedrigoM,etal.Evidenceofcomplementactivation\n294.JohnsonS,StojanovicJ,AricetaG,etal.Anauditanalysisofaguideline\ninthethromboticsmallvesselsofapatientwithcatastrophic\nfortheinvestigationandinitialtherapyofdiarrheanegative(atypical)\nantiphospholipidsyndrometreatedwitheculizumab.AutoimmunRev. hemolyticuremicsyndrome.PediatrNephrol.2014;29:19671978. 2019;18:561563. 295.LoiratC,FakhouriF,AricetaG,etal.Aninternationalconsensus\n318.TintiMG,CarnevaleV,IngleseM,etal.Eculizumabinrefractory\napproachtothemanagementofatypicalhemolyticuremicsyndrome\ncatastrophicantiphospholipidsyndrome:acasereportandsystematic\ninchildren.PediatrNephrol.2016;31:1539. reviewoftheliterature.ClinExpMed.2019;19:281288. 296.ScullyM,HuntBJ,BenjaminS,etal.Guidelinesonthediagnosisand\n319.AngioiA,FervenzaFC,SethiS,etal.Diagnosisofcomplement\nmanagementofthromboticthrombocytopenicpurpuraandother\nalternativepathwaydisorders.KidneyInt.2016;89:278288. thromboticmicroangiopathies.BrJHaematol.2012;158:323335. 320.GoodshipTH,CookHT,FakhouriF,etal.Atypicalhemolyticuremic\n297.RockGA,ShumakKH,BuskardNA,etal.Comparisonofplasmaexchange\nsyndromeandC3glomerulopathy:conclusionsfroma\"Kidney\nwithplasmainfusioninthetreatmentofthromboticthrombocytopenic\nDisease:ImprovingGlobalOutcomes\"(KDIGO)Controversies\npurpura.CanadianApheresisStudyGroup.NEnglJMed.1991;325:393\nConference.KidneyInt.2017;91:539551. 397. 321.LegendreCM,LichtC,MuusP,etal.Terminalcomplementinhibitor\n298.vonBaeyerH.Plasmapheresisinthromboticmicroangiopathy-\neculizumabinatypicalhemolytic-uremicsyndrome.NEnglJMed. associatedsyndromes:reviewofoutcomedataderivedfromclinical\n2013;368:21692181. trialsandopenstudies.TherApher.2002;6:320328. 322.LichtC,GreenbaumLA,MuusP,etal.Efcacyandsafetyofeculizumab\n299.AllfordSL,HuntBJ,RoseP,etal.Guidelinesonthediagnosisand\ninatypicalhemolyticuremicsyndromefrom2-yearextensionsofphase\nmanagementofthethromboticmicroangiopathichaemolytic\n2studies.KidneyInt.2015;87:10611073. anaemias.BrJHaematol.2003;120:556573. KidneyInternational\nS68\n(2024)105(Suppl1S),S1–S69",
    "page": 69,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 1)",
    "content": "www.kidney-international.org\n323.WijnsmaKL,DuineveldC,WetzelsJFM,etal.Eculizumabinatypical346.ChanEY,YapDY,WongWT,etal.Long-termoutcomesofchildrenand\nhemolyticuremicsyndrome:strategiestowardrestrictiveuse.Pediatradolescentswithbiopsy-provenchildhood-onsetlupusnephritis.Kidney\n––\nNephrol.2019;34:22612277.IntRep.2023;8:141150. 347.ContrerasG,PaganJ,ChokshiR,etal.ComparisonofmortalityofESRD\n324.CaveroT,RabascoC,LopezA,etal.Eculizumabinsecondaryatypical\npatientswithlupusbyinitialdialysismodality.ClinJAmSocNephrol. haemolyticuraemicsyndrome.NephrolDialTransplant.2017;32:466\n2014;9:19491956. 474. 348.LevyB,CouchoudC,RougierJP,etal.Outcomeofpatientswithsystemic\n325.CaoM,LeiteBN,FerreiroT,etal.Eculizumabmodiesoutcomesin\nlupuserythematosusonchronicdialysis:anobservationalstudyof\nadultswithatypicalhemolyticuremicsyndromewithacutekidney\nincidentpatientsoftheFrenchNationalRegistry2002-2012.Lupus. injury.AmJNephrol.2018;48:225233. 2015;24:11111121. 326.deHolandaMI,PortoLC,WagnerT,etal.Useofeculizumabina\n349.Mejia-ViletJM,Tejeda-MaldonadoJ,Correa-RotterR.Commenton\nsystemiclupuserythemathosuspatientpresentingthrombotic\nClinicalPracticeGuidelinesfortheTreatmentofSystemicLupus\nmicroangiopathyandheterozygousdeletioninCFHR1-CFHR3.Acase\nErythematosusbytheMexicanCollegeofRheumatology.Reumatol\nreportandsystematicreview.ClinRheumatol.2017;36:28592867. Clin.2018;16:433434. 327.KelloN,KhouryLE,MarderG,etal.Secondarythrombotic\n350.OShaughnessyMM,LiuS,Montez-RathME,etal.Kidneytransplantation\nmicroangiopathyinsystemiclupuserythematosusand\noutcomesacrossGNsubtypesintheUnitedStates.JAmSocNephrol. antiphospholipidsyndrome,theroleofcomplementanduseof\n2017;28:632644. eculizumab:caseseriesandreviewofliterature.SeminArthritisRheum. 351.ParkES,AhnSS,JungSM,etal.Renaloutcomeafterkidney-transplantation\n2019;49:7483. inKoreanpatientswithlupusnephritis.Lupus.2018;27:461467. 328.CaprioliJ,NorisM,BrioschiS,etal.GeneticsofHUS:theimpactofMCP,\n352.JorgeA,WallaceZS,LuN,etal.Renaltransplantationandsurvival\nCFH,andIFmutationsonclinicalpresentation,responsetotreatment,\namongpatientswithlupusnephritis:acohortstudy.AnnInternMed. andoutcome.Blood.2006;108:12671279. 2019;170:240247. 329.LoiratC,SonsinoE,HinglaisN,etal.Treatmentofthechildhood\n353.Goldfarb-RumyantzevA,HurdleJF,ScandlingJ,etal.Durationofend-\nhaemolyticuraemicsyndromewithplasma.Amulticentrerandomized\nstagerenaldiseaseandkidneytransplantoutcome.NephrolDial\ncontrolledtrial.TheFrenchSocietyofPaediatricNephrology.Pediatr\nTransplant.2005;20:167175. Nephrol.1988;2:279285. 354.PlantingaLC,PatzerRE,DrenkardC,etal.Associationoftimetokidney\n330.AricetaG,BesbasN,JohnsonS,etal.Guidelinefortheinvestigationand\ntransplantationwithgraftfailureamongU.S.patientswithend-stage\ninitialtherapyofdiarrhea-negativehemolyticuremicsyndrome.Pediatr\nrenaldiseaseduetolupusnephritis.ArthritisCareRes(Hoboken). Nephrol.2009;24:687696. 2015;67:571581.",
    "page": 70,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 2)",
    "content": "331.KaplanBS,RuebnerRL,SpinaleJM,etal.Currenttreatmentofatypical\n355.CheighJS,KimH,StenzelKH,etal.Systemiclupuserythematosusin\nhemolyticuremicsyndrome.IntractableRareDisRes.2014;3:3445. patientswithend-stagerenaldisease:long-termfollow-uponthe\n332.ReidVL,MullanA,ErwigLP.Rapidrecoveryofmembranecofactor\nprognosisofpatientsandtheevolutionoflupusactivity.AmJKidney\nprotein(MCP;CD46)associatedatypicalhaemolyticuraemicsyndrome\nDis.1990;16:189195. withplasmaexchange.BMJCaseRep.2013;2013:bcr2013200980. 356.ContrerasG,MattiazziA,GuerraG,etal.Recurrenceoflupusnephritis\n333.SengulSamanciN,AyerM,ErgenA,etal.Aneffectivetreatmentof\nafterkidneytransplantation.JAmSocNephrol.2010;21:12001207. atypicalhemolyticuremicsyndromewithplasmaexchangeand\n357.PhamPT,PhamPC.Graftlossduetorecurrentlupusnephritisinliving-\neculizumab:acasereport.TransfusApherSci.2015;52:314316. relatedkidneydonation.ClinJAmSocNephrol.2011;6:22962299. 334.BuyonJP,KimMY,GuerraMM,etal.Kidneyoutcomesandriskfactors\n358.PonticelliC,MoroniG,GlassockRJ.Recurrenceofsecondaryglomerular\nfornephritis(are/denovo)inamultiethniccohortofpregnant\ndiseaseafterrenaltransplantation.ClinJAmSocNephrol.2011;6:1214\npatientswithlupus.ClinJAmSocNephrol.2017;12:940946. 1221. 335.ClowseME,JamisonM,MyersE,etal.Anationalstudyofthe\n359.BatailleS,BurteyS,DecourtA,etal.[Antiphospholipidsantibodiesand\ncomplicationsoflupusinpregnancy.AmJObstetGynecol.2008;199:\nhemodialysis:afrequentassociationlinkedtoarteriovenousstula\n127.e16. thrombosis].NephrolTher.2015;11:2733[inFrench]. 336.AndreoliL,BertsiasGK,Agmon-LevinN,etal.EULARrecommendations\n360.MoralesJM,SerranoM,Martinez-FloresJA,etal.Antiphospholipid\nforwomenshealthandthemanagementoffamilyplanning,assisted\nsyndromeandrenalallograftthrombosis.Transplantation.2019;103:\nreproduction,pregnancyandmenopauseinpatientswithsystemic\n481486. lupuserythematosusand/orantiphospholipidsyndrome.AnnRheum\n361.WagenknechtDR,FastenauDR,TorryRJ,etal.Riskofearlyrenalallograft\nDis.2017;76:476485. failureisincreasedforpatientswithantiphospholipidantibodies.Transpl\n337.KroeseSJ,deHairMJH,LimperM,etal.Hydroxychloroquineuseinlupus\nInt.2000;(suppl1):S78S81. patientsduringpregnancyisassociatedwithlongerpregnancyduration\n362.KidneyDisease:ImprovingGlobalOutcomesGlomerularDiseasesWork\ninpretermbirths.JImmunolRes.2017;2017:2810202. Group.KDIGO2021clinicalpracticeguidelineforthemanagementof\n338.MeherS,DuleyL,HunterK,AskieL.Antiplatelettherapybeforeorafter\nglomerulardiseases.KidneyInt.2021;100:S1S276. 16weeksgestationforpreventingpreeclampsia:anindividual\n363.InstituteofMedicine(IOM).CommitteeonStandardsforDeveloping\nparticipantdatameta-analysis.AmJObstetGynecol.2017;216:121128. TrustworthyClinicalPracticeGuidelines.In:GrahamR,MancherM,\ne2. MillerWolmanD,etal.,eds.ClinicalPracticeGuidelinesWeCanTrust. 339.XuTT,ZhouF,DengCY,etal.Low-doseaspirinforpreventing\nWashington,DC:NationalAcademiesPress;2011.",
    "page": 70,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  },
  {
    "section": "references (Part 3)",
    "content": "preeclampsiaanditscomplications:ameta-analysis.JClinHypertens\n364.BrouwersMC,KhoME,BrowmanGP,etal.AGREEII:advancingguideline\n(Greenwich).2015;17:567573. development,reportingandevaluationinhealthcare.JClinEpidemiol. 340.RussellMD,DeyM,FlintJ,etal.BritishSocietyforRheumatology\n2010;63:13081311. guidelineonprescribingdrugsinpregnancyandbreastfeeding:\n365.HigginsJPT,ThomasJ,ChandlerJ,eds.CochraneHandbookfor\nimmunomodulatoryanti-rheumaticdrugsandcorticosteroids. SystematicReviewsofInterventions.Chichester,UK:Wiley;2019. Rheumatology(Oxford).2023;62:e48e88. 366.GuyattGH,OxmanAD,SchunemannHJ,etal.GRADEguidelines:anew\n341.RemmersEF,PlengeRM,LeeAT,etal.STAT4andtheriskofrheumatoid\nseriesofarticlesintheJournalofClinicalEpidemiology.JClinEpidemiol. arthritisandsystemiclupuserythematosus.NEnglJMed.2007;357:977\n2011;64:380382. 986. 367.HigginsJP,AltmanDG,GotzschePC,etal.TheCochraneCollaborations\n342.SilvaCA,AvcinT,BrunnerHI.Taxonomyforsystemiclupus\ntoolforassessingriskofbiasinrandomisedtrials.BMJ.2011;343:d5928. erythematosuswithonsetbeforeadulthood.ArthritisCareRes\n368.HigginsJP,ThompsonSG,DeeksJJ,etal.Measuringinconsistencyin\n(Hoboken).2012;64:17871793. meta-analyses.BMJ.2003;327:557560. 343.WenderferSE,RuthNM,BrunnerHI.Advancesinthecareofchildren\n369.GuyattGH,OxmanAD,KunzR,etal.GRADEguidelines6.Ratingthe\nwithlupusnephritis.PediatrRes.2017;81:406414. qualityofevidence--imprecision.JClinEpidemiol.2011;64:12831293. 344.ChandarJ,Gomez-MarinO,delPozoR,etal.Roleofroutineurinalysisin\n370.BrunettiM,ShemiltI,PregnoS,etal.GRADEguidelines:10.Considering\nasymptomaticpediatricpatients.ClinPediatr(Phila).2005;44:4348. resourceuseandratingthequalityofeconomicevidence.JClin\n345.SebestyenJF,AlonUS.Theteenagerwithasymptomaticproteinuria:\nEpidemiol.2013;66:140150. ﬁ–\nthinkorthostaticrst.ClinPediatr(Phila).2011;50:179182. KidneyInternational\nS69\n(2024)105(Suppl1S),S1–S69",
    "page": 70,
    "source": "KDIGO_2024_Lupus_Nephritis_Guideline.pdf"
  }
]